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Background: There is inadequate evidence to advise clinicians on the relative merits of swabbing versus
tissue sampling of infected diabetic foot ulcers (DFUs).
Objectives: To determine (1) concordance between culture results from wound swabs and tissue samples
from the same ulcer; (2) whether or not differences in bacterial profiles from swabs and tissue samples are
clinically relevant; (3) concordance between results from conventional culture versus polymerase chain
reaction (PCR); and (4) prognosis for patients with an infected DFU at 12 months’ follow-up.
Methods: This was a cross-sectional, multicentre study involving patients with diabetes and a foot ulcer
that was deemed to be infected by their clinician. Microbiology specimens for culture were taken
contemporaneously by swab and by tissue sampling from the same wound. In a substudy, specimens were
also processed by PCR. A virtual ‘blinded’ clinical review compared the appropriateness of patients’ initial
antibiotic regimens based on the results of swab and tissue specimens. Patients’ case notes were reviewed
at 12 months to assess prognosis.
Results: The main study recruited 400 patients, with 247 patients in the clinical review. There were
12 patients in the PCR study and 299 patients in the prognosis study. Patients’ median age was 63 years
(range 26–99 years), their diabetes duration was 15 years (range 2 weeks–57 years), and their index ulcer
duration was 1.8 months (range 3 days–12 years). Half of the ulcers were neuropathic and the remainder
were ischaemic/neuroischaemic. Tissue results reported more than one pathogen in significantly more
specimens than swabs {86.1% vs. 70.1% of patients, 15.9% difference [95% confidence interval (CI)
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11.8% to 20.1%], McNemar’s p-value < 0.0001}. The two sampling techniques reported a difference in
the identity of pathogens for 58% of patients. The number of pathogens differed in 50.4% of patients.
In the clinical review study, clinicians agreed on the need for a change in therapy for 73.3% of patients
(considering swab and tissue results separately), but significantly more tissue than swab samples required a
change in therapy. Compared with traditional culture, the PCR technique reported additional pathogens
for both swab and tissue samples in six (50%) patients and reported the same pathogens in four (33.3%)
patients and different pathogens in two (16.7%) patients. The estimated healing rate was 44.5% (95% CI
38.9% to 50.1%). At 12 months post sampling, 45 (15.1%) patients had died, 52 (17.4%) patients had a
lower-extremity ipsilateral amputation and 18 (6.0%) patients had revascularisation surgery.
Limitations: We did not investigate the potential impact of microbiological information on care.
We cannot determine if the improved information yield from tissue sampling is attributable to sample
collection, sample handling, processing or reporting.
Conclusions: Tissue sampling reported both more pathogens and more organisms overall than swabbing.
Both techniques missed some organisms, with tissue sampling missing fewer than swabbing. Results from
tissue sampling more frequently led to a (virtual) recommended change in therapy. Long-term prognosis
for patients with an infected foot ulcer was poor.
Future work: Research is needed to determine the effect of sampling/processing techniques on clinical
outcomes and antibiotic stewardship.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Plain English summary
We investigated whether or not laboratory results from infected diabetic foot ulcers depended on thetype of sample taken (a wound swab or a tissue sample of a piece of infected ulcer). Doctors
reviewed the results to see if this might have led to use of a different antibiotic. We then compared
two ways of detecting bacteria in 12 patients, namely growing them or using genetic techniques. We also
followed up patients after 1 year to see whether or not their ulcers had healed.
We enrolled 400 patients; 299 had a 12-month follow-up. On average, patients were 63 years old, had
had diabetes for 15 years and had had an ulcer for 8 weeks.
The podiatrist, nurse or doctor collected a sample from the infected ulcer using a swab and then collected
a tissue sample from the same area.
Swab results from 70% of patients reported at least one pathogen (i.e. bacteria likely to cause infection),
but significantly more tissue results reported pathogens (in 86% of patients). Doctors reported that they
would change antibiotics more often when using the tissue results than when using the swab results.
Given that we tested doctors’ clinical decisions in virtual conditions, we do not know if in actual clinical
practice the results of tissue sampling rather than swab sampling would change treatment or affect ulcer
infection or healing. Both tissue sampling and swabbing were safe overall, with few reports of pain
or bleeding.
The 1-year healing rate was 44.5%. Patients whose ulcers healed had less severe ulcers, better circulation
and a newer, single ulcer.
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Scientific summary
Background
The identification of pathogens within infected diabetic foot ulcers (DFUs) is necessary to target antibiotic
therapy. Wound swabs are commonly used, but most guidelines recommend tissue sampling. There are
few large, well-designed, prospective studies, and we lack evidence to advise clinicians on the best
technique in DFU management.
We report one ‘main study’ and three substudies:
l main study: agreement and patterns of disagreement between culture results of swab versus
tissue sampling
l substudy 1: independent clinical review of appropriateness of the empirical antimicrobial therapy given
to patients, based on swab and tissue cultures
l substudy 2: a pilot comparative study of results of standard plating and culture techniques versus
polymerase chain reaction (PCR)
l substudy 3: a follow-up study at 1 year to determine the prognosis for infected DFUs.
Objectives
The primary objective of the COncordance in DIabetic Foot Infection study was to assess agreement
(concordance) and patterns of disagreement between culture results from specimens taken by surface
swabs and by tissue sampling from patients with a DFU with suspected infection requiring
antibiotic therapy.
The secondary objectives were (1) to compare sampling-related adverse events (AEs) and costs; (2) to
evaluate whether or not differences in bacterial profiles from specimens obtained by swab versus tissue
samples were clinically relevant by asking a panel of clinicians to determine whether or not the reports
from each sample would have resulted in a change in clinical management; (3) to assess the concordance
between results from specimens with plating and culture techniques and processed by PCR techniques;
and (4) to determine the prognosis for infected DFUs by conducting a patient case-note review 12 months
after enrolment to determine the clinical outcome of patients with an infected DFU, and to explore
prognostic factors related to healing.
Methods
Design
The main study was a multicentre, cross-sectional study involving 400 patients with a DFU and suspected
infection. Consenting patients had wound specimens taken by both swab and tissue sampling for plating
and culture in order to assess agreement (concordance) and patterns of disagreement.
The secondary objectives were to:
1. Determine the appropriateness of the empirical antibiotic regimen, assessed by a blinded, ‘virtual’,
clinical panel review of the culture results from 247 patients recruited to the main study. Both inter- and
intrarater agreement were measured.
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2. Compare the results of samples processed by culture methods with those from molecular (PCR)
techniques (pilot study on 12 patients).
3. Determine the prognosis and identify risk factors for the healing of infected DFUs, using a 12-month
follow-up case-note review on a subsample of 299 patients.
Setting
All patients were enrolled in outpatient DFU clinics or inpatient wards of 25 hospital sites in England.
Patients
Participants were at least 18 years old, with diabetes mellitus and a foot ulcer that the clinician-investigator
suspected was infected and planned to treat with antibiotics. Patients were excluded from the study if the
clinician deemed it inappropriate to take a tissue or a swab sample or if the patient had previously entered
the study.
Procedures
After wound cleansing and debridement, clinicians collected a swab sample from the ulcer using a sterile
cotton-tipped swab as per Levine’s technique. The clinician then aseptically obtained a tissue sample from
the same area of the ulcer bed using sterile equipment (dermal curette or sterile scalpel blade).
Outcome measures
The primary end points for the main study were (1) the reported presence of likely pathogens and an
overall summary of pathogens per sample, (2) antimicrobial sensitivities/resistance for likely pathogens and
(3) the number of pathogens per specimen. The secondary end points were (1) sampling-related AEs
and (2) sampling cost.
The end points in the other substudies were:
l clinical panel review: the appropriateness of the empirical antibiotic therapy
l PCR pilot: the number and identity of pathogens reported by each technique
l prognosis study: (1) the clinical outcomes of patients with an infected DFU and (2) prognostic factors.
Statistical analyses
Agreement study
For pathogens with a prevalence > 8%, overall percentage prevalence, agreement and disagreement,
unadjusted kappa, prevalence- and bias-adjusted kappa (PABAK) and McNemar’s test for differences
are presented. Multinomial regression was used to determine whether or not the overall summary of
agreement was influenced by any of baseline factors, and ordinal regression modelling was used to assess
the influence of baseline factors on the number of pathogens reported. In both regression analyses, centre
was included as a random effect and multiple imputation (MI) was used to impute missing baseline factors.
Clinical panel review substudy
McNemar’s test was used to identify if one sample identified significantly more patients requiring a
change/initiation in therapy. Multinomial regression analysis was conducted to evaluate the association
between baseline factors on agreement for the requirement for a change/initiation of therapy; reviewer
was included in each model as a random effect and MI was used to impute missing baseline data.
Polymerase chain reaction substudy
Overall summaries of the pathogens reported using plating/culture and PCR for swab and tissue samples
independently, as well as the pathogens reported using PCR techniques by swab and tissue sample
are produced.
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Prognosis diabetic foot ulcer infection substudy
A competing risk analysis using cumulative incidence functions was conducted to estimate the cumulative
incidence of healing at 12 months, adjusted for lower extremity amputation and death. Exploratory
analysis was conducted to model the relationship of baseline factors with the cumulative incidence of
healing, using the proportional subdistribution hazards model for competing risks data. MI was used to
impute the time of healing for patients whose index ulcer was known to have healed but whose date of
healing was unknown, and for patients for whom at least one baseline covariate was missing.
Results
Agreement study
A total of 400 patients consented and were recruited, mostly from outpatient clinics (79.8%). Participants
had a median age of 63 years (range 26–99 years), a median duration of diabetes of 15 years (range
2 weeks–57 years), and median duration of the index ulcer of 1.8 months (range 3 days–12 years). Before
sampling, 60.3% of patients had been treated with an antimicrobial dressing or agent and 46.8% had
received systemic antibiotics. Ulcer grades were (as per the Wagner scale), 34% at grade 1, 33.5% at
grade 2 and 32.5% at grade 3 or above. In total, 50.5% of ulcers were neuropathic and 49% were
ischaemic/neuroischaemic.
There were 395 evaluable patients (i.e. results were available from both swab and tissue culture). At least
one pathogen was reported from swabs in 277 (70.1%) patients and from tissue in 340 (86.1%) patients;
this difference of 15.9% [95% confidence interval (CI) 11.8% to 20.1%] was statistically significant
(p-value < 0.0001, McNemar’s test).
The most frequently reported pathogen groups were Gram-positive cocci (70.6%), Gram-negative bacilli
(36.7%), Enterobacteriaceae including coliforms (26.6%), obligate anaerobes (23.8%), Gram-positive
bacilli (11.1%). The most frequently reported organisms were Staphylococcus aureus [excluding
meticillin-resistant S. aureus (MRSA)] (35.7%), Streptococcus (16.7%), Enterococcus (14.9%),
coagulase-negative staphylococci (CNS) (12.2%), Corynebacterium (9.4%), Pseudomonas (8.6%) and
MRSA (8.1%).
For the majority of pathogens, the reported prevalence was higher from the tissue than from the swab
samples (McNemar’s p-value < 0.01), with the exception of S. aureus, MRSA and Pseudomonas.
Disagreement between the results of the two specimen types for S. aureus and Pseudomonas was
symmetrical (i.e. pathogen was reported in one sample but not the other equally). The reported prevalence
of MRSA was non-significantly higher in the tissue than in the swab sample 1.0% (95% CI –0.2% to
2.8%; p-value= 0.2188).
Overall, there was a difference in the pathogens reported from the two sampling techniques for 58% of
patients: swabs reported additional pathogens over tissue samples in 8.1% of patients; tissue samples
reported additional pathogens over swabs in 36.7% of patients; and tissue samples and swabs reported
additional or different pathogens in 13.2% of patients.
The number of reported pathogens ranged from 0 to 4 in the swab sample and 0 to 6 in the tissue
sample. The mean number of reported pathogens in the swab and tissue samples was 1 and 1.5,
respectively.
In half (49.6%) of patients, the same number of pathogens were reported for the tissue and swab
samples; for 41.5% of patients, the tissue sample reported at least one more pathogen than the swab,
and for 8.9% of patients the swab sample reported at least one more pathogen than the tissue sample.
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There was no evidence of an association regarding agreement of swab and tissue results with ulcer type,
Wagner grade, pre-sampling antibiotic therapy or antimicrobial dressing or agent. However, patients
whose ulcers had been present for > 56 days had reduced odds of the tissue sampling reporting more
pathogens than the swab sample (odds ratio 0.64, 95% CI 0.43 to 0.95; p-value= 0.024).
Bleeding of concern was reported in 30 (7.6%) patients and was attributed to swab sampling in 6 (1.5%)
patients and to tissue sampling in 27 (6.8%) patients. Different levels of pain after swab and tissue
sampling were reported in 42 (10.5%) patients: 5 (1.3%) patients reported worse pain after swabbing
compared with tissue sampling, and 37 (9.3%) patients reported worse pain after tissue sampling
versus swabbing.
Clinical panel review substudy
Thirteen study clinician-investigators reviewed results from 247 patients. A total of 30 cases were used to
measure inter-rater agreement and 30 more to measure intrarater agreement.
There was 73.3% overall agreement on the requirement for a change in (including initiation of) therapy
between swab and tissue samples, with a kappa value of 0.45 (95% CI 0.34 to 0.56) representing
moderate agreement. The PABAK of 0.47 similarly represents moderate agreement. There was significant
evidence that more tissue than swab samples reported a requirement for a change/initiation in therapy
[increase of 8.9% (95% CI 2.65% to 15.3%)].
There was no evidence of an association between patient or ulcer characteristics on the agreement
between samples on the requirement for a change in therapy.
Polymerase chain reaction substudy
This study included samples from 14 patients from four centres, of which 12 pairs of samples were
evaluated by molecular analysis. For six (50%) patients, the PCR technique reported additional pathogens
compared with plating and culture for both swab and tissue samples. In four patients (33.3%), the
molecular and traditional culture techniques reported the same pathogens, whereas in the remaining two
(16.7%) patients, different pathogens were reported using PCR versus traditional culture reports (with or
without overlap). There were no samples in which additional pathogens were reported from the traditional
culture compared with the PCR results.
Prognosis substudy
We obtained follow-up information on 299 (74.8%) patients, from case notes, at 12 months after baseline
sampling. The index ulcer was reported as having healed in 136 (45.5%) patients; in 13 (9.6%) patients,
the index ulcer reoccurred before 12 months. A total of 45 (15.1%) patients died within the 12-month
follow-up period, 52 (17.4%) patients had a lower-extremity amputation on the same limb on which the
index ulcer was found, and 18 (6.0%) patients had revascularisation surgery. The estimated healing rate
was 44.5% (95% CI 38.9% to 50.1%) at 12 months.
The median time to healing of those healed was 4.5 months (range 0.5–12.9 months). Of 13 patients
whose ulcers were reported to have reoccurred, the median time to reoccurrence was 1.7 months
(range 0.3–10.7 months). Median time to death was 5.6 months (range 0.6–11.5 months), and median
time to an ipsilateral amputation was 2 months (range 0.0–10.6 months). Median time to revascularisation
surgery was 3.0 months (range 0.1–9.5 months). The estimated healing rate was 44.5% (95% CI 38.9%
to 50.1%) at 12 months.
Of the 163 (54.5%) patients whose index ulcer had not healed, 93 (57.1%) were known to be alive and
without amputation at 12 months, and were censored at the earliest of their case-note review or at the
12-month follow-up. Amputation occurred for 33 (20.2%) patients alive, and seven (4.3%) patients
who had died, by 12-month follow-up, resulting in a competing event at patients’ date of amputation.
A further 30 (18.4%) patients died (without amputation) before 12 months and thus had a competing
event at their date of death.
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Multivariable regression analysis with competing risk for amputation or death found the following to have
a significant direct association with the cumulative incidence of healing as follows (with a HR > 1
indicating a higher likelihood of healing):
l Patients with a perfusion grade ≥ 2 had a lower incidence of healing compared with a grade 1-to-hazard
ratio (HR) of 0.37 (95% CI 0.25 to 0.55).
l Patients with older ulcers (≥ 56 days vs. < 56 days) had a lower incidence of healing: HR 0.55 (95% CI
0.39 to 0.77).
l Patients with a single ulcer had an increased incidence of healing compared with those with more than
one ulcer on their index foot: HR 1.90 (95% CI 1.18 to 3.06).
l Older patients had an increased incidence of healing with each year of age: HR 1.02 (95% CI 1.01 to
1.04); however, this is suspected to be a spurious relationship.
l Patients whose wound contained CNS at baseline had an increased incidence of healing: HR 1.53
(95% CI 0.98 to 2.40).
Conclusions
Culture of specimens by tissue sampling rather than by swabbing had a higher yield overall. As tissue
samples missed some organisms identified by swabbing, the techniques provide somewhat different,
potentially complementary, information. The differences in wound microbiology reported from the
two types of specimens appeared to be clinically relevant, as the clinical review panel recommended a
change in antibiotic therapy more often when presented with tissue results than when presented with swab
results (for paired samples from the same wound). As the relationship between microbiology results and the
selected antimicrobial therapy, or its effectiveness, is not fully understood, we cannot conclude that the
higher yield from tissue sampling would lead to more appropriate therapy or better patient outcomes.
These results may be attributable to the death of the organisms collected during sampling and hence
changes to either transport media or specimen collection practices could potentially increase the yield from
swabs when processed for culture. For molecular analysis techniques, swabbing appeared to have a higher
yield than tissue, potentially owing to the larger sampling area. Furthermore, specimens obtained by
swabbing and tissue sampling are likely to be processed and reported differently by many microbiology
laboratories. Given that tissue sampling is associated with higher cost and a slightly higher risk of pain and
bleeding, the trade-off between sampling techniques needs to be determined by further research to
estimate the impact of various sampling regimens on patient outcomes and antibiotic stewardship practices.
The small substudy of PCR techniques found that they identified more organisms than traditional culture,
with the difference being greater for swabs than for tissue sampling (based on arbitrary cut-off levels for
PCR reporting). Further research is needed to determine the clinical significance of these additional isolates
and appropriate cut-off points for clinical practice.
The 1-year prognosis for patients with an infected DFU was poor in this population, and we confirmed the
adverse prognostic effect of the presence of ischaemia, higher ulcer grade and longer ulcer duration.
Patients with a single foot ulcer are more likely to experience wound healing than those with multiple
ulcers. It remains to be determined the extent to which more rapid or complete characterisation of the
infected ulcer flora might lead to earlier, more specific and more effective antibiotic therapy.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
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Chapter 1 Background
Diabetes: prevalence and complications
Worldwide prevalence of diabetes mellitus was estimated at around 2.8% in 20001 and this is predicted to
increase to 7.7% (affecting 439 million adults) by 2030,2 largely as a result of the obesity epidemic.3,4 In
the USA, the prevalence of diabetes was 8.3% in 2012, which is a sharp increase (more than doubling)
compared with the prevalence in 1990, which was 3.5%.5 Estimates from the USA predict that Americans
born in 2000 will have a one in three lifetime risk of developing type 2 diabetes.6 In the UK, the prevalence
of diabetes is 6.0% (3.2 million people),7 and Diabetes UK estimates that there are around 630,000 people
with diabetes who have not yet been diagnosed.8 Treatment of diabetes in the UK cost approximately
£23.7B in 2010/11, accounting for approximately 10% of the total health resource expenditure.
Both type 1 and type 2 diabetes can lead to serious health problems.9 Complications of diabetes, especially
in patients with poorly controlled blood sugar levels, include damage to the eyes, kidneys, nerves and
arteries. In the feet, diabetes-related peripheral neuropathy leads to changes to foot architecture (hence
increasing pressure on plantar surfaces, including those unaccustomed to load-bearing),10,11 reduced
sweating (hence dry, cracking skin), poor sensation (hence susceptibility to trauma) and accelerated
atherosclerotic disease, which leads to reduced circulation, with consequent problems with healing
wounds and fighting infection. These peripheral neuropathic and vascular changes, either alone or in
combination, predispose the foot to ulceration and its sequalae.12,13
Diabetic ulcer infection: epidemiology and aetiology
It is estimated that the proportion of people with diabetes in the UK who have ever had a foot ulcer is
around 6%,14 and that lifetime risk of ulceration is 15–25%.15,16 Diabetic foot ulcers (DFUs) can take many
weeks or often months to heal and have a negative impact on patients’ functional ability and quality of
life. Foot ulceration in diabetic individuals also has a wider societal impact, such as reduced work
productivity, high health-care costs and financial loss.17–21 An open wound related to foot ulceration,
combined with various immunological perturbations caused by diabetes, frequently results in infection.
Prospective studies have found that about half of recent-onset DFUs are clinically infected at
presentation.22 Diabetic foot infection is thought to be the most common cause of diabetes-related
hospital admissions and precedes approximately 80% of non-traumatic lower limb amputations.15,23–27
Foot infections in people with diabetes can be hard to manage because of the associated impaired arterial
supply to the legs, as well as impaired function of the immune system (especially those related to
defects in polymorphonuclear leucocytes). This leads to an increased risk of progression of infection with
contiguous spread to deeper tissues (including bone), and proximal extension up the foot and leg, as well
as systemic spread into the blood stream. Therefore, many diabetic foot infections require some level of
lower extremity amputation as a limb-sacrificing, but potentially life-saving, measure.14,28,29
The incidence of lower extremity amputations is 10–30% higher in people with diabetes than in the
general population,28,29 and about 85% of these amputations are preceded by a foot ulcer
infection.23,24,26,30–33 Limb amputation is associated with major consequences, as it dramatically reduces
health-related quality of life, is expensive for both the patient and the health-care system and is associated
with a 5-year mortality of over 50%.15 To reduce the risk of foot ulceration, accelerate the healing of open
ulcers and identify and treat infection promptly, many health-care systems have deployed multidisciplinary
foot teams to co-ordinate foot care. The prevention of foot ulceration and amputation involves optimising
glycaemic control and foot care. This may include supplying pressure-relieving shoes or insoles,
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undertaking surgical interventions promptly and optimally treating any infection. Providing this care
involves input from the specialties of general practice, diabetology, nursing, dietetics, podiatry, orthotics,
vascular surgery and infectious diseases/clinical microbiology.
Wound infection: definition, identification and characterisation
All chronic wounds, including DFUs, have bacteria on their surface that may originate from the
surrounding normal skin flora, as well as opportunistic bacteria, such as gut flora. Therefore, the presence
of bacteria in a wound does not indicate the presence of infection. When the host tissues show no
inflammatory response or incur no damage associated with the bacterial growth, then the wound is
described as ‘colonised,’ rather than infected. At this stage, there is typically thought to be a ‘balance’
between the growth of the several species of bacteria and no single organism usually dominates. When a
critical density or high virulence of colonising organisms causes damage to host tissues, the wound is
deemed to be ‘infected’. Therefore, infection of chronic wounds is usually a clinical diagnosis based on
signs and symptoms of host tissue inflammation, such as pyrexia, purulent secretions, pain or tenderness,
erythema, warmth and induration.34–38 Although some investigators and clinicians also describe a
quantitative diagnostic criterion for the presence of infection (e.g. a bacterial load of > 105 colony-forming
units per gram of tissue), there is no agreement on this.39 In chronic wounds, a single cut-off point for
bacteria has been found to be insufficient for defining infection; other factors, such as the number or
virulence of the bacterial groups and the presence of biofilm, are also important.40
When a wound infection is diagnosed, the therapeutic approach depends on the whole clinical situation.
Because in infected diabetic foot wounds the consequences of delayed antibiotic treatment can be
profound, empiric antibiotic therapy should usually be initiated immediately. The antimicrobial regimen is
usually selected in accordance with departmental protocols that are based on the probable causative
organisms and their susceptibility patterns. Concurrently, samples for microbiological analysis are taken to
identify the infecting organisms within the wound and their susceptibility to a range of antimicrobials.
The resulting microbiological information guides subsequent modifications of the empiric antibiotic therapy
required should the infection not improve and resistant organisms be isolated.34–38,41,42 The culture and
sensitivity results also allow a change from broad- to narrow-spectrum antibiotic agents, thus following the
principles of antibiotic stewardship.34–38,41
The microbiological analysis of specimens from the ulcer is useful only if the specimen is properly collected
and processed and reported accurately and promptly. The aim is to acquire a wound sample that identifies
all pathogens while avoiding colonising flora. First, the ulcer must be cleaned, which may involve
debridement to remove necrotic material or callus and undermining tissues. Second, a specimen is taken
from the site of infection, using one of a number of specimen-acquisition techniques, such as wound
swabbing, fluid sampling using a fine-needle aspiration, or tissue sampling (by biopsy or curettage).36,37,42
Taking a tissue sample either uses a tool to extract a ‘punch biopsy’ or scrapes the base of a wound with a
sharp-edged dermal curette or scalpel blade to obtain ulcer tissue from the debrided ulcer bed.43
It is important that the culture of the sample obtained reflects an accurate profile of the bacterial
environment in the ulcer. Either failing to identify a true pathogen or identifying a coloniser as a pathogen
can lead to inappropriate treatment of an infected wound. Therefore, it is important that health-care
staff use a technique that will give a specimen that provides an accurate account of the bacteria present,
including their number and sensitivity to antibiotics. Most published guidelines recommend obtaining a
tissue specimen rather than a swab, in order to increase the likelihood of accurately reflecting the
organisms associated with clinical infection at initial presentation.34,36,37,42
In clinical practice, however, samples from wounds are often taken with a cotton swab.44–47 The
advantages of a wound swab include the almost universal availability of the equipment, the relative ease
of the technique, the low cost of the swab and the fact that little training is needed to perform this
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correctly, which means that it can be done by non-clinician staff.45 Furthermore, there is little risk of harm
using a swab to collect a tissue sample. The disadvantages of a swab include the concerns that it may
not collect those bacteria responsible for the infection deep within the tissues (e.g. as happens if an
appropriate technique is used), that it will collect the colonising bacteria on the wound surface, or that it
will fail to provide an environment conducive to growth of obligate anaerobes and other fastidious
organisms (i.e. those that may be present in the wound but die in a swab device that does not provide an
adequate medium for their survival). To counter these problems, advocates of wound swabbing have
specified how to prepare the ulcer bed (i.e. removing dead tissue that may contain non-pathogenic
bacterial groups) and how to obtain a sample from deep in the ulcer (by pressing to collect fluid from deep
in the subcutaneous tissues, as described by Levine et al.48 in 1976), as well as the optimal storage and
transport procedures (use of charcoal swab, transport medium and swift delivery to the laboratory to
maintain the viability of fastidious organisms).48
In contrast, the reported advantage of tissue sampling is that the specimen is likely to contain the
pathogens responsible for tissue destruction and infection. However, tissue-sampling techniques require
disruption or cutting of the ulcer bed to obtain a specimen and this may lead to bleeding or pain (although
most DFUs are complicated by neuropathy, which reduces the ability to perceive pain). Some clinical staff
may need additional training to be able to take these samples safely and they also require some basic
equipment: sharp sterile blades (scalpel), dermal curettes or a biopsy cutter. Using appropriate storage and
transport procedures (transport medium and swift delivery to laboratory to maintain the viability of
fastidious organisms) is still required.
Processing method
Accurate characterisation of the bacterial flora depends on both the sample collection method and the
processing method. Standard culture and plating techniques involve the multiplication of the bacteria in a
medium, by growing them on various types of culture plates, identifying the organisms and assessing their
sensitivity to antimicrobial agents. It is thought that some organisms do not survive collection and transport
and, hence, a swab (or occasionally tissue sample) does not fully reflect the organisms causing the wound
infection. These ‘fastidious’ organisms remain undetected in the laboratory but may be important
pathogens.49 As these uncultured organisms cannot be identified by standard microbiological methods,
appropriate antibiotic selection is problematic. This may partly account for the fact that approximately
10–20% of diabetic foot wounds fail to respond to initial antibiotic treatment. There is, therefore, some
question over whether or not alternative techniques to identify bacteria within a sample, either instead of
or in addition to sample plating and culture, may provide a more accurate picture of the wound flora.
Modern molecular (or genotypic) techniques, such as polymerase chain reaction (PCR), have been
proposed for this as the equipment for these tests become more readily available in hospitals.50 It is not
yet clear, however, how the results of these molecular tests, which generally identify more pathogens,
should be interpreted.51
The full report of culture results can take 4 or 5 days to be returned to the clinician. This delay in
reporting, combined with the effects of antibiotic treatment given in the intervening period, means that
the laboratory result may be out of date and that the wound flora may have changed. Therefore, a
clinician reviewing an ulcer that has not improved with treatment cannot presume that the bacteria
described in the microbiologists report are the same pathogens responsible for an infected ulcer 5 days
later. Quicker techniques for microbiological analyses, such as genetic fingerprinting, that take 1 day or
less, may help to address this delay.52
These newer microbiological analysis techniques multiply the genetic material of the bacteria rather than
grow them in culture. Genetic fingerprint techniques are then used to identify the bacteria group from its
deoxyribonucleic acid (DNA)/ribonucleic acid (RNA) signature.52 Culture-based methodology may not
identify minor, although possibly important, components of a mixed bacterial population, whereas genetic
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fingerprinting techniques can.53 Therefore, we also conducted a small substudy to compare identification
of ulcer pathogens using conventional culture versus PCR techniques. This enabled us to determine the
agreement between analysis techniques, that is, how does the quicker molecular technique reflect the
bacterial load captured by swabs and tissues samples in the foot ulcer compared with swab and curettage
specimens (e.g. for those organism not identified via plating and culture).
Diabetic foot ulcer guideline recommendations for infection
(diagnosis/identification and characterisation and treatment)
Several guidelines and consensus documents aimed at improving the care for people with DFUs have been
published over the past decade.9,15,34–37,41,42,54,55 In this report, we have focused on three guidelines: (1) the
UK National Institute for Health and Care Excellence (NICE) guidance on inpatient management of diabetic
foot problems;37 (2) the Infectious Diseases Society of America (IDSA) guidelines for the diagnosis and
treatment of diabetic foot infections;1,2,36 and (3) the International Working Group on the Diabetic Foot
(IWGDF) guidelines on the management and prevention of the diabetic foot.42,56 IDSA guidelines were first
published in 200434,35 and are widely used. The IWGDF guidelines were published in 200842 and the latest
NICE guidance in 2011.37 The IDSA guidelines have recently been updated and provide details on the
strength of the recommendations and the quality of the supporting evidence,36 making them the most
current and comprehensive guidelines for the diagnosis and management of DFUs.
National Institute for Health and Care Excellence guidance37 recommends that clinicians should evaluate
a diabetic patient presenting with a foot wound at three levels: the patient as a whole, the affected
foot or limb and the infected wound. For infected wounds, an appropriately obtained specimen for culture
is recommended prior to starting empiric antibiotic therapy, if possible. NICE guidance37 recommends
sending a specimen for culture that is from deep tissue, obtained by biopsy or curettage and after the
wound has been cleansed and debrided. The guidance advises against taking swab specimens, especially
of inadequately debrided wounds, as they are likely to provide less accurate results. The IWGDF
guidelines have the same message about obtaining the specimen but also mention the value of
obtaining a Gram-stained smear of the wound in addition to culture.42 For infected wounds, the IDSA
guidelines34–36 recommend sending a specimen for culture that is from deep tissue, obtained by biopsy
or curettage after the wound has been cleansed and debrided. The guidelines also advise against
obtaining for culture by swabbing the wound or wound drainage.36 In summary, all the clinical
guidelines34–37,42 agree on their preference of tissue sample (obtained by biopsy, curettage or aspiration)
to wound swab specimens.
The need for research
Although clinicians commonly use swab samples to provide information on the bacteria in a clinically
infected wound, the current major guidelines all recommend tissue specimens over swab samples.34–38
This is mainly because swabs can be contaminated with colonising flora, can miss deep pathogens and
may be less likely to grow anaerobic and some fastidious aerobic organisms. However, the strength of this
recommendation was specified only in IDSA guidelines,36 where it was ‘moderate’ (i.e. further definitive
research is likely to have an important impact on future recommendations).57
Three primary studies of culture techniques informing the guidelines were those conducted by Pellizzer
et al.,58 Slater et al.59 and Bill et al.60 Pellizzer et al.58 assessed the reliability of results of ulcer swabbing
versus deep tissue biopsy in 29 diabetic patients with a limb-threatening foot infection, who were neither
recently treated with antibiotics nor hospitalised. This selected population does not reflect many of the
patients with foot infections seen in outpatient clinics, who have often had recent antibiotic therapy.
The study did not report on the agreement between swab and tissue samples, but, rather, simply on the
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number of bacterial colonies in each. Their conclusion that tissue samples are better than swab samples
was based on a comparison of the numbers of isolates in only 21 participants remaining in the study at
30 days. Their finding may be due to chance as they performed 20 comparisons without adjustment for
multiple testing. Furthermore, a method that identifies more colonies may be collecting more colonising
bacteria and, therefore, is not necessarily ‘better’. The unpaired analysis presented means that we cannot
readily compare the two techniques using appropriate statistical methods.
Slater et al.59 aimed to evaluate the accuracy of swab compared with deep tissue (obtained via needle
aspiration) cultures in diabetic wounds of varying depth and severity. Their study, however, included only
30 people with ulcers (in a sample of 60, in which the other patients had deep abscesses, etc.) and it is
not clear if the results were heterogeneous across types of wounds or apply to tissue samples collected
using scalpel or curette. In 62% of the samples, there was a similar profile of organisms isolated from the
swab and the deep tissue sample, whereas in 20% of samples the swab identified more organisms and in
18% the deeper tissue sample picked up more organisms. These data were not stratified by the presence
or absence of an ulcer or by ulcer type (i.e. neuropathic or ischaemic). This study identified that there can
be two forms of disagreement between swabbing and sampling, with swabs identifying more organisms
or tissue samples identifying more organisms; hence, they did not consider either technique to be a
gold standard.
In a 2006 systematic review of the diagnosis and management of infection in DFUs,61 only one study that
evaluated sample acquisition and reported agreement in sufficient detail to allow appropriate analysis was
identified. This study by Bill et al.60 included 18 patients with a pressure ulcer, 10 with a DFU, 5 with a
venous leg ulcer, and 5 with an arterial ulcer. In this study, quantitative analysis of bacterial growth from
a punch biopsy taken from the centre of the wound was compared with that of a wound swab. Using a
definition of infection of a bacterial load of > 106 bacteria per gram of tissue in the punch biopsy, the
authors reported a sensitivity for wound swabbing of 79%, meaning that the swab failed to detect
approximately one in five wound infections as defined by punch biopsy. The derived likelihood ratios
suggested that the wound swab was not a useful method of identifying infection in chronic wounds.
Interpretation of this study’s findings is impeded by its small size and heterogeneity in the ulcer population.
We cannot be sure that these data are directly transferable to the population of interest here, namely
people with a DFU and a clinically diagnosed ulcer infection (there is no reason to sample uninfected ulcers
and inclusion of people with uninfected foot ulcers may reduce the external validity of the study). In
addition, there were potential sources of bias, such as no description of blind test verification and lack of
clarity over whether or not the same clinical data were available when test results were interpreted as
would be available when the test is used in practice.
Two studies62,63 have been published since the IDSA, NICE and IWGDF guidelines. Mutluoglu et al.62
assessed the reliability of cultures of superficial swabs by comparing them with cultures of concomitantly
obtained deep tissue specimens in patients with DFUs. They retrospectively reviewed the notes from
54 patients from whom there were 89 pairs of samples, one a superficial swab and the other deep tissue.
The results showed a 73% concordance between swab cultures and deep tissue biopsies, which dropped
to 69.2% when sterile pairs of cultures were excluded. Compared with deep tissue specimens, in 11.2%
of cases swabs detected additional species, in 9.0% of cases swabs detected fewer species and in 6.7%
the two techniques identified totally different organisms. The study concluded that superficial swab
cultures are not sufficiently accurate to identify the causative organisms in patients with an infected DFU.
They described three forms of disagreement: swabs identified more organisms, tissue samples identified
more organisms and the techniques found different organisms.
Demetriou et al.63 assessed the diagnostic performance of swabs versus tissue cultures in 50 consecutive
diabetic patients with a foot ulcer, 28 of which were neuropathic and 22 of which were neuroischaemic.
The authors stated that 36 (72%) wounds were infected, based on ‘the presence of at least 2 of the
following criteria: local swelling or induration, erythema greater than 0.5 cm in any direction around the
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ulcer, local tenderness or pain, local increase of temperature, and purulent discharge’. Overall, the results
showed that swabs reported significantly more isolates than tissue cultures, this difference being more
evident in neuropathic than in neuroischaemic ulcers. They defined the tissue sample as the ‘gold
standard’ for the diagnosis of infection, and reported swab culture sensitivity of 100% and negative
predictive value of 100%, but the specificity was only 14.3% in neuropathic and 18.2% in neuroischaemic
ulcers. They concluded that swabs are useful only to rule out infection. Given that guidelines do not
recommend sampling/swabbing uninfected ulcers, the inclusion of 14 people in this study with uninfected
ulcers reduces its external validity.
In summary, we concluded that the existing evidence regarding the results of cultures of specimens
obtained by swabbing versus tissue sampling was derived from small, heterogeneous and, often,
methodologically poor studies. Thus, there is a lack of robust evidence on the most appropriate method to
use in routine clinical practice.
The question addressed in this study was not how to diagnose infection in a DFU, but rather what was
the best way to collect a sample to characterise the bacterial flora. We therefore set out to describe the
patterns of agreement and disagreement between swab and tissue samples. To help advise clinicians on
the best technique to identify pathogens and to avoid colonising organisms in DFUs, we conducted a
series of studies. The first was the ‘main study’, followed by three substudies:
l main study: cross-sectional study to determine the patterns of agreement between culture results of
contemporaneously collected swab versus tissue samples
l substudy 1: independent ‘virtual’ clinical review of the appropriateness of empirical antimicrobial
therapy based on the results of swabs compared with tissue samples to describe the potential clinical
relevance of any differences in sampling results from swabs and tissue
l substudy 2: a pilot comparative study of results of standard plating and culture techniques versus the
molecular technique of PCR
l substudy 3: a study of the prognosis of diabetic foot infection.
The main study was the first large, cross-sectional, multicentre study to examine agreement and
disagreement of culture results between swab and tissue sampling techniques taken at the same time in
a large group of patients with a clinically infected DFU.64 Each of the studies is described in detail in
Chapters 2–5.
Study aims
The primary aim of the main study (patterns of agreement between swab sampling and tissue sampling)
was to evaluate concordance between culture results from wound swabs and tissue samples from the
same patient (see Chapter 2).
The aim of the clinical panel review study was to evaluate whether or not any differences in bacterial
profiles from specimens obtained from swabs and tissue samples are clinically relevant. This was done by
ascertaining from a panel of clinicians whether or not the reports from a swab or tissue sample would
have resulted in a change in clinical management (see Chapter 3).
The aim of the pilot comparative study of standard plating and culture techniques versus PCR was to
assess the concordance between results from specimens taken by conventional culture techniques and by
molecular techniques (see Chapter 4).
The aim of the prognosis of foot infection study was to determine the outcome of patients with an
infected DFU at 12 months post registration and to explore prognostic factors that may be related to time
to wound healing (see Chapter 5).
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Patient and public involvement
In this study, patient and public involvement was achieved by using our links with diabetes organisations at
the national (Diabetes UK), regional (North West Diabetes Local Research Network) and local (School of
Healthcare Service User Group) levels.
As this work was commissioned by the NHS Health Technology Assessment (HTA) programme, then there
had been patient and public involvement engagement at the prioritisation stage, and this informed the
commissioners as regards the importance and relevance of the clinical question.
During the study we were fortunate to recruit a patient representative, Mrs Christine Thomas, as a
member of the Study Steering Committee (SSC). She played a key part in the SSC meetings and advised
the study team at different stages, including at the writing of patient and public-facing information.
She also had an important role in shaping all aspects of the communications with patients as regards
consent, particularly when moving to verbal consent. Furthermore, Mrs Thomas advised the study team
about the dissemination of the initial results to participants at the end of the study and reviewed
draft communications.
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Chapter 2 Patterns of agreement between swab
sampling and tissue sampling
Introduction
For infected DFUs, the accurate identification of pathogens, rather than colonising bacteria, is a
prerequisite for selecting targeted antibiotic therapy to ensure optimal patient outcomes and avoid the
acquisition of antibiotic resistance. Currently available evidence from the main diabetic foot infection
guidelines (NICE,37 IDSA1,2,36 and the IWGDF42,56) and other studies62,63 is not sufficiently robust to advise
clinicians on the best technique to identify pathogens in DFUs.
Objectives
The primary objective of the COncordance in DIabetic Foot Infection (CODIFI) main agreement study was
to assess the level of agreement and patterns of disagreement between culture results from specimens
taken by both surface swabs and tissue sampling from DFUs with suspected infection. We were interested
in comparing three major microbiological parameters:
1. reported presence of isolates likely to be pathogens
2. the number of bacterial pathogens reported
3. the presence of antimicrobial resistance among likely pathogens.
Secondary objectives of the main agreement study were to compare rates of sampling-related adverse
events (AEs) and the costs of sampling using each of the two techniques.
Methods
Study design
A multicentre, cross-sectional study involving 400 patients with a DFU with suspected infection requiring
antibiotic therapy was conducted (Figure 1). Consenting patients had both a swab and tissue sample taken
from their suspected infected DFU for conventional plating and culture.
Eligibility
All patients at least 18 years of age with a DFU that the attending clinician suspected was either a new
case of infection or a chronic infection were screened for enrolment against the eligibility criteria below.
A DFU was considered to be any open wound on the foot (below the malleoli/ankle) in a patient with a
diagnosis of diabetes mellitus. Each patient underwent an eligibility screen by a member of the research
team, prior to entry, and an anonymised log was used to capture patient demographics along with reasons
for not entering the study.
Inclusion criteria
l Patient had a diagnosis of diabetes mellitus (type 1 or type 2).
l Patient had a suspected foot ulcer infection, with or without bone involvement, based on clinical signs
and symptoms using IDSA/IWGDF36,42 criteria and the judgement of the investigator.
l The clinical plan was to treat the patient with antibiotics for their infected ulcer.
l Patient was at least 18 years of age at the time of signing the consent form.
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Exclusion criteria
l The clinician deemed it inappropriate to take a tissue sample or a swab sample for any reason.
l The patient had already been recruited to the study.
Infection suspected and
antibiotic therapy
indicated/initiated
Swab and tissue sample collection
Register patient
• Provide full verbal explanation of study
• Provide second patient information leaflet
• Obtain written informed consent
• Eligibility confirmed
Existing and newly referred
patients in foot 
ulcer/diabetic clinics
Provide verbal details about
the study and a patient
information leaflet
Identify potential patients
Existing and newly referred
in-patients in hospital wards
under care of local PI/Co-I
Patient makes decision to
participate within same
clinic appointment
Patient makes decision to 
participate on same day
Posters and inserts to
patient letters
Provide verbal details about
the study, the introductory
letter and a patient
information leafllet
Foot ulcer/diabetic clinic Hospital ward
FIGURE 1 Study flow diagram. Adapted from Nelson EA, Backhouse MR, Bhogal MS, Wright-Hughes A, Lipsky BA,
Nixon J, et al. Concordance in diabetic foot ulcer infection. BMJ Open 2013;3:e002370. Used under Creative
Commons Attribution-Non Commercial 2.0 licence. Co-I, co-ordinator; PI, principal investigator.
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Recruitment and registration
The study was approved by the Sheffield Research Ethics Committee (reference 11/YH/0078) and had
central and local NHS permissions at each participating centre prior to data collection.
Patients were recruited from multidisciplinary primary and secondary care-based foot ulcer/diabetic clinics
and hospital wards, by a member of the research team (usually a clinical research nurse). Potential patients
were provided with a patient information leaflet outlining all aspects of the study and given the chance
to read it and to ask any questions they may have about the study. Written informed consent was
documented by the patient and member of the local team. Informed written consent was obtained from
all patients prior to entering the study.
Patients were registered via a 24-hour automated telephone registration system that automatically sent
confirmation of successful registration through to the site.
Assessments
Sample acquisition
Clinicians in the participating sites participated in a study information session to instruct them on
techniques for swab and tissue sample acquisition. An e-learning package was also developed and issued
to all sites, detailing study procedures, including video footage of the correct use of both
sampling techniques.
After wound cleansing (using sterile saline and gauze) and debridement (removal of necrotic tissue, foreign
material, callus, undermining, usually with sharp instruments), a physician or podiatrist obtained specimens
from the wound for cultures in one of the following ways:
l Rubbing a sterile, cotton-tipped swab over the wound surface to sample superficial wound fluid and
tissue debris. The swab was pressed with sufficient pressure on the wound bed to capture expressed
wound fluid and was positioned deep in the ulcer to collect from likely infected areas. This is the
wound swabbing technique described by Levine et al.48
l Immediately after the cotton swab had been collected, a tissue sample was removed from the same
area of the ulcer bed. This procedure was performed using sterile equipment and aseptic technique,
involved removal of a small piece of wound tissue at the base of the wound by scraping or scooping
using a dermal curette or sterile scalpel blade.
Sample transport and processing
Each sample was placed individually in the standard transport medium used at the site and delivered to the
local medical microbiology laboratory in accordance with routine clinical practice. A UK national standard
method was used for collecting and processing samples.65,66 Both samples from each patient were
processed in the same local laboratory as routine clinical samples. Neither sample was labelled as having
been taken as part of a clinical study. Our goal was to ensure that, as far as possible, the reports reflected
current sample processing methods in each laboratory, rather than these samples having received special
attention or processing.
Clinical assessments
A member of the research team used a case report form (see Appendix 5) to record patient demographics,
diabetes status and foot health history, including current or proposed antibiotic treatment and wound
dressings. Details of the index ulcer were recorded using each of the Perfusion, Extent/Size, Depth/Tissue
loss, Infection, Sensation (PEDIS),67 Wagner grade,68 and Clinical Signs and Symptoms Classification for
Infection69 schemes. The research team also filled out other study-related documentation, which was
forwarded to the study co-ordinating centre at the University of Leeds.
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Centre differences questionnaire
A ‘centre differences questionnaire’ aimed to capture, from each centre and laboratory processing samples,
details relating to the clinical acquisition of samples, specimen transport, sample analysis, methods of
reporting results of samples by the laboratory and local antibiotic protocols for infected DFUs.
End points
Coprimary end points
In order to assess agreement and patterns of disagreement between results from the swab and tissue
samples, three coprimary end points were defined.
Reported presence of likely pathogens
The first coprimary end point was originally defined as the reported presence or not of the following
likely pathogens, identified by the UK Health Protection Agency (HPA) as likely pathogens from
limb-threatening DFUs:65,66
l Staphylococcus aureus Rosenbach 1884 (categorised by the presence or absence of meticillin
resistance)
l Streptococcus species Rosenbach 1884
l Enterobacter aerogenes Hormaeche and Edwards 1960
l Escherichia coli (Migula 1895) Castellani and Chalmers 1919
l Pseudomonas species Migula 1984
l Corynebacterium species Lehmann and Neumann 1896
l anaerobic cocci (i.e. mixed anaerobes)
l Fusobacterium species Knorr 1922
l Bacteroides fragilis (Veillon and Zuber 1898) Castellani and Chalmers 1919
l Prevotella bivia (Holdeman and Johnson 1977) Shah and Collins 1990.
A revised definition was implemented to include the most prevalent pathogens, defined as those reported
in ≥ 10% of patients (in either swab or tissue samples). This overall prevalence rate was determined based
on statistical justification of the sample size calculation; we also used clinical discretion to determine
whether or not the end point would include pathogens with an overall prevalence below 10%.
An overall summary of pathogens reported59 allowed for the comparison of all pathogens reported within each
sample and an assessment of whether or not agreement was influenced by any of a number of covariates.
Antimicrobial resistance
Presence or absence of resistance to antibiotics to which the specific species is ordinarily susceptible among
likely pathogens, as reported by standard techniques for:
l meticillin-resistant S. aureus (MRSA)
l meticillin-resistant coagulase-negative staphylococci (CNS)
l vancomycin-resistant Enterococcus species.
Number of pathogens
Number of pathogens reported per specimen.
Secondary end points
Adverse events
The secondary end point relating to AEs was the number of patients with a study-related event categorised
as an expected AE, defined as bleeding of concern attributable to the sampling method or patient-reported
pain before and after each sampling technique, or as a related unexpected serious adverse event (RUSAE).
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Costs
A full economic evaluation was beyond the scope of this study. The cost data collected were the laboratory
costs, including all components used in processing and reporting of swab and tissue samples. Costs of
these procedures were requested from the microbiologists at study centres.
Derivation involving reported pathogens
Microbiology laboratories reported pathogens at a range of taxonomic levels (species, genus, family and
group); therefore, the end points for the prevalence, overall summary and number of pathogens
required derivation in order to allow for comparison of pathogens reported within each sample at a
meaningful level.
Staphylococcus aureus is used in reference to non-MRSA, whereas MRSA is used to describe S. aureus that
is meticillin resistant.
The majority of pathogens were included at the genus level, with the exception of S. aureus (identified at
the species level) and vancomycin-resistant and non-resistant Enterococcus spp. (included separately by
vancomycin resistance). The following groups of pathogens were also included as part of the first
coprimary end point for reported presence or absence: Gram-positive cocci, Gram-negative cocci,
Gram-positive bacilli, Gram-negative bacilli, anaerobes (where possible as anaerobic cocci or anaerobic
rods), CNS and Enterobactereaceae (including coliforms).
Furthermore, the following isolate designations were considered unlikely to represent pathogenic
organisms in a sample from a DFU and were not included in the end points: yeasts, skin flora, normal
flora, mixed flora, skin organisms, bacterial flora, enteric flora and faecal flora.
Statistical methods
Sample size
The sample size calculation was based on the primary outcome of reported ‘presence or absence of a
pathogen’ for the whole sample overall.
To be confident that swabs adequately sampled wound flora, it was assumed that the chance corrected
agreement between swab and tissue samples needed to be at least ‘good’ (usually defined as a κ-statistic
> 0.6).70 Of course, the κ-statistic alone does not convey the distribution of disagreement between swabs
and tissue samples. Good overall agreement, with balanced disagreement, would be clinically important
if tests were to be regarded as interchangeable. Therefore, the total sample size was based on there
being good agreement and reasonably balanced disagreement for clinically important and less
prevalent pathogens.
Using a two-sided McNemar’s test at the 5% level of significance, a sample size of 399 patients would
provide 80% power to detect a difference of ≥ 3% in the reported presence of a pathogen, assuming an
overall prevalence of the pathogen of 10% and 5% disagreement between the swab and tissue samples.
This amount of agreement would also result in a κ-statistic of ≈ 0.7, and the calculation was based on the
expected prevalence of less common pathogens, such as Pseudomonas (present in 10% of samples in
Pellizer et al.58). It was, therefore, planned that a total of 400 patients would be recruited. Further details
of the sample size calculation are provided in Appendix 1.
Analysis methods
All data analyses and summaries were performed using SAS® version 9.2 (SAS Institute Inc., Cary, NC,
USA),71 with the exception of exact confidence intervals (CIs) only, which were calculated within R version
3.0 (The R Foundation for Statistical Computing, Vienna, Austria).72 All significance tests were two-sided
and conducted at the 5% level of significance, with p-values and 95% CI provided where appropriate.
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Patient populations
The full analysis set consisted of all patients registered and consented to take part in the study, regardless
of their adherence to the study protocol or eligibility violation.
The evaluable population consisted of all registered and consented patients with evaluable swab and tissue
samples. Patients for whom the swab or tissue samples were not successfully collected or were lost, or for
whom the sample results were lost, were excluded from this evaluable population.
The per-protocol (PP) population consisted of all registered and consented patients for whom there were
no protocol violations. Patients who did not satisfy the eligibility criteria, or those for whom a protocol
deviation in the collection or processing of either sample had occurred, were excluded from the
PP population.
Coprimary end point analysis
Reported presence of likely pathogens
The first coprimary end point was defined for each patient as the reported presence or absence of each
likely pathogen reported from the result of culture of the swab and tissue sample. Patients for whom
either the swab or tissue sample result was not available were excluded from the primary end point, with
analysis conducted on the evaluable population.
For each likely pathogen, cross-tabulations of reported presence were generated to investigate agreement
and the pattern of disagreement. For each pathogen, the following statistics are presented:
l overall percentage prevalence, calculated as the proportion of patients with the pathogen reported
from either the swab or tissue sample results
l the percentage of patients for whom the swab and tissue sample results agreed or disagreed in the
reported presence of the pathogen
l the unadjusted κ-statistic (with 95% CIs) and the prevalence- and bias-adjusted kappa (PABAK), which
evaluates chance corrected agreement between swab and tissue samples. Strength of agreement
according to the κ-statistic was categorised as shown in Table 1
l the difference in percentage prevalence between the swab and tissue samples (tissue percentage minus
swab percentage) with 95% CIs (accounting for paired samples)
l McNemar’s test of the difference between the swab and tissue samples in the percentage of samples
reporting the pathogen accounting for paired samples.
When the proportion of disagreement was low, leading to cell counts in the cross-tabulations of < 5, a
small-sample binomial version of McNemar’s test was used to provide an exact p-value73 and the exact
95% CI for the difference in percentage prevalence was calculated using an inductive method.74
TABLE 1 The κ-statistic70
Strength of agreement Value of kappa (κ)
Poor < 0.0
Slight 0.0–0.2
Fair 0.21–0.4
Moderate 0.41–0.6
Substantial 0.61–0.8
Almost perfect 0.81–1.0
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Cross-tabulations on the semiquantitative extent of bacterial growth (none, + to +++) and weighted
κ-statistics by type of DFU (neuropathic, ischaemic, without inferential statistics) were also generated.
An overall summary of the pathogens reported was further generated,59 with each patient’s pair of results
(swab and tissue sample) coded as follows: swab and tissue sample report the same pathogens; swab
reports same pathogens as tissue sample plus extra pathogens; tissue sample reports same pathogens as
swab plus extra pathogens; both tissue sample and swab report different pathogens (with or without
overlap in pathogen). Multinomial logistic regression analysis was used to model the proportion of patients
in each category, compared with the reference category ‘swab and tissue sample report the same
pathogens’ on pre-specified baseline factors to investigate their relevance in determining agreement
between sample results. These factors included type of ulcer (ischaemic or neuroischaemic vs. neuropathic);
Wagner ulcer grade (1 to 5); recent (on the day of sampling) systemic or topical antimicrobial therapy; or
dressing and wound duration (< 56 days vs. ≥ 56 days, and continuous on the log-scale). The centre from
which the patient was enrolled was included in each model as a random effect in order to allow for
additional variability in outcome by centre and estimates of the effect of baseline factors without directly
requiring the estimation of individual centre effects. Estimates of odds ratios for each covariate are
presented along with 95% CIs and p-values (based on the change in –2 log-likelihood).
Reported presence of antimicrobial resistance among likely pathogens
Meticillin-resistant S. aureus, meticillin-resistant CNS and vancomycin-resistant Enterococcus were the
three antimicrobial-resistant pathogens identified for exploration. For each of these resistant pathogens,
cross-tabulations were created (reported presence or absence of resistant pathogen) and the following
statistics presented: PABAK, unadjusted κ-statistic and overall percentage agreement. McNemar’s test was
used to test for a difference between swab and tissue sampling techniques in the proportion of samples in
which the specified resistant pathogen was reported.
For each resistant pathogen the following codes were also created: resistant pathogen reported by swab
not tissue sample; resistant pathogen reported by tissue sample not swab; swab and tissue sample results
agree. To determine if agreement is influenced by specified covariates, multinomial regression modelling
was planned to model these categories on type of ulcer (predominantly neuropathic or ischaemic), ulcer
grade, pre-sampling antibiotic therapy, pre-sampling antimicrobial dressing, wound duration and centre.
Number of pathogens reported
Summaries (including cross-tabulations) on the number of pathogens reported per specimen were
generated for swab versus tissue samples. Samples were further coded as follows: tissue sample had two
or more extra pathogens reported; tissue sample had one extra pathogen reported; tissue sample and
swab had the same number of pathogens reported; swab had one extra pathogen reported; swab had
two or more extra pathogens reported.
Ordinal logistic regression analysis, based on the proportional odds model,75 was used to model the
number of pathogens reported per specimen on pre-specified baseline factors to investigate their relevance
in determining agreement between sample results. These factors included type of ulcer (ischaemic or
neuroischaemic vs. neuropathic); Wagner ulcer grade (1–5); recent systemic or topical antimicrobial therapy
or dressing; and wound duration (< 56 days vs. ≥ 56 days, and continuous on the log-scale). Centre was
included in each model as a random effect in order to allow for additional variability in outcome by centre
and estimates of the effect of baseline factors without directly requiring the estimation of individual
centre effects. Estimates of odds ratios for each covariate are presented along with 95% CIs and p-values
(based on the change in –2 log-likelihood).
Analysis population
Patients for whom both swab and tissue sample results were available were included in the coprimary end
points, with analysis conducted on the evaluable population.
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Missing data
As part of the study design, efforts were made to collect complete data; however, where data remained
missing, this was assumed to be missing at random, and multiple imputation (MI)76 was used to impute
missing baseline covariates, thereby allowing inclusion of the 28 (7.1%) patients with missing data for
at least one candidate baseline factor. The pattern and prevalence of missing data among covariates
considered within the regression analysis of the coprimary end points are presented in Appendix 1,
Table 81.
The outcome and all baseline covariates (including type of ulcer, Wagner ulcer grade, recent systemic or
topical antimicrobial therapy or dressing, wound duration) to be considered in each regression analyses
were included in the MI models alongside centre. A total of 10 imputations were conducted using
the Markov chain Monte Carlo (MCMC) method77 with multiple chains, initial values from the
expectation–maximisation (EM) algorithm, 200 burn-in iterations, and the assumption of normality for
factors with missing data (thus, imputations were made on a continuous scale).71 For dichotomous factors,
imputations were not restricted for ‘implausible values’ and thus continuous imputations were rounded to
plausible values for the dichotomous factor (with a small proportion of missing data the bias introduced as
a result of this method is minimal).78 This method was used as the pattern of missing data was arbitrary
and non-monotone.
For the 10 imputed data sets, the odds ratios generated through the regression analyses were combined
using Rubin’s rules;79 therefore, reported estimates reflect the average of estimates across the imputed
data sets, and estimated standard errors include variability across the imputed sets as well as the usual
uncertainty in parameter estimates. The mean change in –2 log-likelihood was used to calculate the
overall p-value.
Derivation
Semi-quantitative extent of bacterial growth A number of common scales were used to quantify the
extent of growth of a pathogen, specific to each recruiting site. In order of severity of growth within a
scale, these were: +/++/+++; +/++/+++/++++; scanty/light/moderate/heavy; scanty/+/++/+++; light,
moderate, heavy. The reported growth for each pathogen was derived onto one 3-point scale reported as
+/++/+++ (Table 2).
Weighted κ-statistic for cross-tabulations on the extent of growth κ-statistic weights were selected
to reflect the ordinal nature of extent of growth, in which the difference between a sample with an extent
of growth of + and ++ is far smaller than the difference between ++ and +++, owing to the increase in
dilution factors used to determine the extent of growth (10-fold increase). To account for this relationship,
TABLE 2 Derivation of extent of growth
Scale
Derived level of growth
1: + 2: ++ 3: +++
Scanty/light/moderate/heavy Scanty/light Moderate Heavy
+/++/+++/++++ + ++ +++/++++
+/++/+++ + ++ +++
Scanty/+/++/+++ Scanty/+ ++ +++
Light/moderate/heavy Light Moderate Heavy
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while allowing greater differentiation between the highest level of growth (+++), the following
exponential values were assigned to each level of growth, from which linear Cicchetti–Allison agreement
weights were derived:80 pathogen not reported (= 1), + (= 2.7), ++ (= 7.4), +++ (= 20.1).
As the choice of values for each level of growth was somewhat arbitrary, a sensitivity analysis assessed the
impact of these weights, in which levels of growth were assigned the following linear values: pathogen
not reported – 0, + – 1, ++ – 2, +++ – 3.
Summary of pathogens To account for pathogens reported at various taxonomic ranks and to
determine whether or not swab and tissue results reported the same pathogens, pathogens were
compared according to pre-defined groups set out in Appendix 1 [i.e. largely at the genus level, and at
the higher group level where further detail was not reported from the laboratory result (e.g. Gram-positive
cocci rather than S. aureus)]. For example, where a pathogen was reported at the species level it was
compared with the corresponding alternative sample at the genus level (e.g. E. coli belongs to the
Escherichia genus). If, however, one sample reported the pathogen at a taxonomic rank higher than
the genus level, such as ‘Gram-negative bacilli’ with the corresponding alternative sample reporting the
pathogen in more detail (in this scenario ‘Escherichia’), then we did not class the patient’s results as
reporting the same pathogens. This was based on clinical relevance of pathogens and overcame
discrepancies in the level of reporting.
Summary and number of pathogens The summary and number of pathogens reported per specimen
was calculated independently for both the swab and tissue samples.
Samples were identified where more than one strain or species of pathogen (in which we were interested
in the genus level or higher) was reported. In these samples, a single pathogen at the level of interest was
retained for comparison with the corresponding swab or tissue sample in the summary of pathogens and
with the count of the number of pathogens within the sample.
Samples from which results of a Gram-stained smear had been reported in addition to those from the
culture were identified by the reporting of the following groups of pathogens: Gram-positive bacilli,
Gram-negative bacilli, Gram-positive cocci, Gram-positive cocco-bacillus and Gram-negative cocci.
Gram stain results were then compared with pathogens reported within the corresponding culture result,
and pathogens belonging to the group of pathogens reported by the Gram stain were further identified.
Where a pathogen belonged to the same group as that reported by the Gram stain, it was considered
likely that both referred to the same pathogen and the corresponding Gram stain result was excluded from
the summary and number of pathogens reported from the swab or tissue sample. For example, where
both Gram-positive cocci and S. aureus were reported, because S. aureus is a type of Gram-positive cocci,
only S. aureus was retained in the summary and number of pathogens. Conversely, where the results of a
Gram stain were provided and no pathogens identified by the culture belonged to the group identified by
the Gram stain, all pathogens were included. Details of all samples for which this derivation was applied
are in Appendix 1.
Secondary end point analysis
Adverse events
Safety analyses presents summaries of all expected AEs (bleeding of concern that is attributable to either of
the sampling methods, pain as reported by the patient before and immediately after acquisition of each
sample) and RUSAEs. The number of events and number of patients with events are also summarised.
Results
Sample size
In total, 680 patients were screened for recruitment into CODIFI and 401 patients were enrolled between
November 2011 and May 2013. One patient was excluded as the written informed consent was lost.
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Of 27 centres, 25 recruited patients into the study; Figure 2 shows the number of patients recruited and
screened per centre, and Figure 3 shows the overall, monthly and cumulative recruitment of patients to the
study together with our original target. See Appendix 1 for full centre names.
Analysis populations
The numbers of patients recruited to CODIFI and included in the full analysis set, the evaluable population
and the PP population are each summarised in Table 3.
Full analysis set
No patient withdrew consent for the samples to be used for research purposes and hence only the one
patient without informed consent was excluded from the full analysis set.
Evaluable population
The evaluable population consisted of the 395 (98.8%) patients who had both swab and tissue sample
results available. Patients with a protocol deviation involving the loss of one or both samples or results
were excluded. The number of patients excluded from the evaluable population and the reasons are
summarised in Table 4.
Per-protocol population
The PP population consisted of the 386 (96.5%) patients without an eligibility violation or protocol
deviation. The number of patients excluded from the PP population and the reasons are summarised in
0
Bi
rm
in
gh
am
Ja
m
es
 C
oo
k
N
ew
 C
ro
ss
N
or
fo
lk
 a
nd
 N
or
w
ic
h
Pi
nd
er
fie
ld
s
So
ut
h 
Ty
ne
sid
e
SJ
U
H
Br
ad
fo
rd
H
ar
ro
ga
te
H
ud
de
rs
fie
ld
M
an
ch
es
te
r
La
nc
as
te
r
Ki
ng
’s 
Ly
nn
Sc
ar
bo
ro
ug
h
Le
w
ish
am
N
or
th
 M
an
ch
es
te
r
W
es
to
n 
G
en
er
al
N
or
th
 T
ee
s
Fa
irfi
el
d
Ta
m
es
id
e 
G
en
er
al
Ro
ya
l O
ld
ha
m
Co
ve
nt
ry
 a
nd
 W
ar
w
ic
k
N
or
th
 S
ta
ff
or
ds
hi
re
Be
ns
ha
m
Ch
or
le
y 
an
d 
So
ut
h 
Ri
bb
le
M
in
er
va
 C
en
tr
e
M
iss
in
g
10
20
Centre
30
40
50
60
70
80
90
100
N
u
m
b
e
r 
o
f 
p
a
ti
e
n
ts
Screened
Recruited
FIGURE 2 Screening and recruitment by centre. SJUH, St James’s University Hospital.
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Table 4. Given that only an additional nine patients were excluded from the PP population compared with
the evaluable population, no analyses were repeated for the PP population.
Study conduct
Figure 4 presents a flow diagram depicting the study conduct and analysis population.
Baseline characteristics
Tables 5–13 summarise the baseline characteristics, including patient demographics, information about
diabetes, clinical details, ulcer characteristics, PEDIS classification, clinical signs and symptoms, and antibiotic
regimens immediately pre and post sampling. Because the evaluable population was very similar to the
full analysis set with respect to baseline characteristics, characteristics of the full sample only are
detailed below.
Tables 5 and 6 summarise patient demographics and diabetes details, respectively. The median age of
patients was 63 years (range 26–99 years); 79% of patients were male; and the majority of patients
(94.3%) were of white ethnic origin. Recruitment of patients was from outpatient clinics for 79.8%
of patients, hospital wards for 13.3% and community clinics for 7%. The median duration of diabetes
TABLE 3 Number of patients in each analysis population
Analysis population Total (N= 400), n (%)
Full analysis set 400 (100.0%)
Evaluable population 395 (98.8%)
PP population 386 (96.5%)
TABLE 4 Reasons for exclusion from the evaluable and PP populations
Exclusions and reasons for exclusion Total (N= 400), n (%)
Excluded from the evaluable population 5 (1.3)
Protocol deviation: swab not processed by laboratory 2 (40.0)
Swab sample used for other purpose: MRSA screen 1 (20.0)
Swab and curettage samples were lost 1 (20.0)
Swab sample was lost 1 (20.0)
Excluded from the PP population 14 (3.5)
Eligibility violation: clinical plan not to treat with antibiotics 3 (21.4)
Clinical plan not to treat with antibiotics and no suspected infection 2 (14.3)
Protocol deviation: tissue sample taken before the swab sample 3 (21.4)
Swab not processed by laboratory 2 (14.3)
Swab sample used for other purpose: MRSA screen 1 (7.1)
Swab and tissue sample was lost 1 (7.1)
Swab sample was lost 1 (7.1)
Second swab sample taken after the tissue sample 1 (7.1)
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in enrolled patients was 15 years (range 2 weeks–57 years); 14.5% and 85.5% of patients had type 1 or
type 2 diabetes, respectively; and the vast majority of patients (96.3%) were receiving treatment for
their diabetes.
Assessed for eligibility
(n = 680)
Ineligible n = 230 (33.8%)
• Not diagnosed with diabetes, n = 10
• No suspected ulcer infection, n = 72
• Clinical plan not to treat with antibiotics, n = 34
• Unable to give written informed consent, n = 15
• Clinician deemed inappropriate to take tissue 
   or swab sample, n = 77
• Previously registered into CODIFI, n = 11
• Other, n = 10
• Missing, n = 1
Eligible 
n = 450 (66.2%)
Not consented n = 45 (10.0%)
• Refused without reason, n = 7
• Does not want to be involved in research, n = 7
• Feels poorly or unwell, n = 6
• Does not want to provide a tissue sample, n = 10
• Other, n = 14
• Missing, n = 1
Consented
n = 405 (90.0%)
Not registered n = 4 (1.0%)
• No longer eligible, n = 1
• Patient no longer wishes to participate, n = 1
• Unable to obtain tissue sample, n = 1
• Misplaced consent, n = 1
Registered
(n = 401)
Full analysis set (n = 400)
• Full written informed consent not received, n = 1
Analysed: evaluation population (n = 395)
• Swab not processed by laboratory, n = 2
• Swab sample used for other purpose: MRSA screen, n = 1
• Swab and curettage sample was lost, n = 1
• Swab sample was lost, n = 1
FIGURE 4 Patient flow diagram.
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Tables 7 and 8 summarise patients’ ulcer characteristics. The total number of DFUs ranged from one to
seven per patient, with one ulcer observed for 67.0% of patients, two ulcers for 19.5%, and three or
more ulcers for 13.6% of patients. The anatomic site of the index ulcer, from which both the swab and
tissue samples were obtained, was most commonly the plantar surface (43.0%), the digital surface
(22.5%), the dorsum (14.0%) or the apex (i.e. tip of toe, 11.8%). The duration of the index ulcer varied to
a large degree, with a median of 1.84 months (range 3 days–12 years). A total of 72.0% of patients’ index
ulcers were incident as opposed to recurrent. Only 3.5% of ulcers were solely ischaemic, 50.5% of ulcers
were neuropathic only, and 45.5% of ulcers were both ischaemic and neuropathic.
Tables 9–11 summarise ulcer characterisation according to the PEDIS criteria, clinical signs and symptoms,
and Wagner scale. Almost all patients (98%) had a grade 1 or 2 perfusion rating (no critical limb
ischaemia); approximately equal proportions of patients had a grade 1–3 depth/tissue loss rating; the
majority of patients (93.3%) had grade 2 sensation (loss of protective sensation); and the majority of
patients had an infection of either grade 2 (inflammation of skin/subcutaneous tissue only, 37.3%) or
grade 3 (extensive erythema deeper than skin/subcutaneous tissue, 59.3%). The majority of patients had
an ulcer debridement undertaken at the baseline visit (87.8%), with the median area measuring 1.77 cm2
(range 0.01–138.2 cm2). The clinical signs and symptoms classification of patients’ index ulcers revealed
that 31.8% of patients had a foul wound odour; 42.5% had pocketing in the wound; 56.3% had
discoloured granulation tissue; 51.0% had friable granulation tissue; 31.3% had a recent increase in pain,
as opposed to the 2.3% who had a recent decrease in pain; 61.5% had a recent increase in wound size;
and 31.5% had a breakdown of epithelium. Furthermore, of all index ulcers, 34.0% were classified as
TABLE 5 Baseline patient demographics and type of recruiting site
Patient demographics Full analysis set (N= 400) Evaluable population (N= 395)
Age (years)
Mean (SD) 63.1 (13.3) 63.1 (13.4)
Median (range) 63.0 (26–99) 63.0 (26–99)
Missing 0 0
Sex, n (%)
Male 316 (79.0) 311 (78.7)
Female 84 (21.0) 84 (21.3)
Ethnicity, n (%)
White 377 (94.3) 372 (94.2)
Other mixed background 1 (0.3) 1 (0.3)
Asian: Indian 3 (0.8) 3 (0.8)
Asian: Pakistani 11 (2.8) 11 (2.8)
Other Asian background 2 (0.5) 2 (0.5)
Black: Caribbean 3 (0.8) 3 (0.8)
Black: African 1 (0.3) 1 (0.3)
Other ethnic group 2 (0.5) 2 (0.5)
Site of recruitment, n (%)
Hospital ward 53 (13.3) 53 (13.4)
Outpatient clinic 319 (79.8) 314 (79.5)
Community clinic 28 (7.0) 28 (7.1)
SD, standard deviation.
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TABLE 7 Ulcer characteristics
Ulcer characteristics Full analysis set (N= 400) Evaluable population (N= 395)
Location of ulcer(s), n (%)
Ulcers on both right and left foot 60 (15.0) 59 (14.9)
Ulcer(s) on right foot only 173 (43.3) 169 (42.8)
Ulcer(s) on left foot only 167 (41.8) 167 (42.3)
Total number of ulcers, n (%)
1 268 (67.0) 264 (66.8)
2 78 (19.5) 78 (19.7)
3 43 (10.8) 43 (10.9)
4 6 (1.5) 6 (1.5)
5 1 (0.3) 1 (0.3)
6 3 (0.8) 2 (0.5)
7 1 (0.3) 1 (0.3)
Mean (SD) 1.5 (0.9) 1.5 (0.9)
Median (range) 1.0 (1–7) 1.0 (1–7)
Missing 0 0
SD, standard deviation.
TABLE 6 Baseline diabetes details
Diabetes details Full analysis set (N= 400) Evaluable population (N= 395)
Diabetes type, n (%)
Type 1 58 (14.5) 58 (14.7)
Type 2 342 (85.5) 337 (85.3)
Duration of diabetes (years)
Mean (SD) 16.8 (11.0) 16.9 (11.0)
Median (range) 15.0 (0.04–57) 15.0 (0.04–57)
Missing 3 3
HbA1C (%)
Mean (SD) 8.72 (2.29) 8.71 (2.29)
Median (range) 8.10 (4.6–17.2) 8.10 (4.6–17.2)
Missing 6 6
Current diabetes treatment, n (%)
Yes 385 (96.3) 381 (96.5)
No 15 (3.8) 14 (3.5)
Diabetes treatment details, n (%)
Oral hypoglycaemic agent 107 (27.8) 106 (27.8)
Insulin 168 (43.6) 166 (43.6)
Both oral hypoglycaemic agent and insulin 109 (28.3) 108 (28.3)
Oral hypoglycaemic agent and exenatide 1 (0.3) 1 (0.3)
HbA1c, glycated haemoglobin; SD, standard deviation.
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grade 1 (superficial diabetic ulcer); 33.5% were classified as grade 2 (ulcer extension to ligament, tendon,
joint capsule or deep fascia without abscess or osteomyelitis); 30.5% were classified as grade 3 (deep ulcer
with abscess, osteomyelitis or joint sepsis); 1.8% were classified as grade 4 (gangrene localised to a
portion of forefoot or heel); and 0.3% were classified as grade 5 (extensive gangrenous involvement of the
entire foot).
Tables 12 and 13 and Figure 5 summarise the antibiotic regimens patients were prescribed immediately
pre and post sampling. Prior to sampling, 60.3% of patients had been treated with an antimicrobial
TABLE 8 Index ulcer characteristics
Index ulcer characteristics Full analysis set (N= 400) Evaluable population (N= 395)
Foot containing index ulcer, n (%)
Right foot 205 (51.3) 201 (50.9)
Left foot 195 (48.8) 194 (49.1)
Index ulcer location, n (%)a
Apex 47 (11.8) 45 (11.4)
Interdigital 25 (6.3) 25 (6.3)
Plantar 172 (43.0) 170 (43.0)
Dorsum 56 (14.0) 56 (14.2)
Digital 90 (22.5) 89 (22.5)
Other 8 (2.0) 8 (2.0)
Missing 2 (0.5) 2 (0.5)
Duration of index ulcer (months)
Mean (SD) 5.58 (12.28) 5.52 (12.17)
Median (range) 1.84 (0.1–144.0) 1.84 (0.1–144.0)
Missing 4 4
First or recurrent index ulcer, n (%)
Incident 288 (72.0) 283 (71.6)
Recurrent 110 (27.5) 110 (27.8)
Missing 2 (0.5) 2 (0.5)
Aetiology of index ulcer, n (%)
Ischaemic 14 (3.5) 14 (3.5)
Neuropathic 202 (50.5) 199 (50.4)
Both ischaemic and neuropathic 182 (45.5) 180 (45.6)
Missing 2 (0.5) 2 (0.5)
Antimicrobial dressing on the ulcer, n (%)
Yes 241 (60.3) 238 (60.3)
No 154 (38.5) 152 (38.5)
Missing 5 (1.3) 5 (1.3)
SD, standard deviation.
a The other locations of index ulcer are the dorsum and digital for two patients and the apex interdigital space plantar
surface, lateral surface, lateral outer aspect of foot, left lateral malleolus, medial surface and medial malleolus for the
remaining patients.
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TABLE 9 Perfusion, Extent/Size, Depth/Tissue loss, Infection, Sensation classification and ulcer debridement
PEDIS classification and ulcer debridement Full analysis set (N= 400) Evaluable population (N= 395)
Perfusion, n (%)
Grade 1: no symptoms/signs of PAD 200 (50.0) 197 (49.9)
Grade 2: symptoms or signs of PAD, but no CLI 192 (48.0) 190 (48.1)
Grade 3: CLI 8 (2.0) 8 (2.0)
aExtent/size: estimated index ulcer area, cm2
Mean (SD) 6.76 (15.16) 6.60 (14.85)
Median (range) 1.77 (0.01–138.2) 1.77 (0.01–138.2)
Missing 3 3
Depth/tissue loss, n (%)
Grade 1: superficial full-thickness ulcer 131 (32.8) 130 (32.9)
Grade 2: ulcer penetrating below dermis to skin
structures
134 (33.5) 132 (33.4)
Grade 3: all subsequent layers of foot, including
bone/joint
135 (33.8) 133 (33.7)
Infection, n (%)
Grade 1: no symptoms/signs of inflammation 2 (0.5) 2 (0.5)
Grade 2: inflammation of skin/subcutaneous tissue
only
149 (37.3) 148 (37.5)
Grade 3: extensive erythema deeper than
skin/subcutaneous tissue
237 (59.3) 234 (59.2)
Grade 4: systemic inflammatory response syndrome 12 (3.0) 11 (2.8)
Sensation, n (%)
Grade 1: no loss of protective sensation 27 (6.8) 27 (6.8)
Grade 2: loss of protective sensation 373 (93.3) 368 (93.2)
Ulcer debridement undertaken, n (%)
Yes 351 (87.8) 347 (87.8)
No 49 (12.3) 48 (12.2)
CLI, critical limb ischaemia; PAD, peripheral arterial disease; SD, standard deviation.
a Calculated using Kundin:81 length ×width × 0.785.
TABLE 10 Clinical signs and symptoms classification
Presence of clinical signs and symptoms
Full analysis set (N= 400),
n (%)
Evaluable population (N= 395),
n (%)
Wound odour 127 (31.8) 126 (31.9)
Pocketing in wound 170 (42.5) 168 (42.5)
Discoloured granulation tissue 225 (56.3) 220 (55.7)
Friable granulation tissue 204 (51.0) 202 (51.1)
Recent increase in paina 125 (31.3) 123 (31.1)
Recent decrease in paina 9 (2.3) 9 (2.3)
Recent increase in wound sizea 246 (61.5) 241 (61.0)
Breakdown of epitheliuma 126 (31.5) 124 (31.4)
a Missing data were present for recent increase in pain, recent increase in wound size and breakdown of epithelium for
one patient for each and for recent decrease in pain for three patients.
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TABLE 11 Wagner grade
Wagner grade
Full analysis set
(N= 400), n (%)
Evaluable population
(N= 395), n (%)
Grade 1: superficial diabetic ulcer (partial or full thickness) 136 (34.0) 135 (34.2)
Grade 2: ulcer extension ligament, tendon, joint capsule or deep fascia
without abscess or osteomyelitis
134 (33.5) 132 (33.4)
Grade 3: deep ulcer with abscess, osteomyelitis or joint sepsis 122 (30.5) 120 (30.4)
Grade 4: gangrene localised to portion of forefoot or heel 7 (1.8) 7 (1.8)
Grade 5: extensive gangrenous involvement of the entire foot 1 (0.3) 1 (0.3)
TABLE 12 Antibiotic therapy: pre and post sampling
Antibiotic therapy
Full analysis set
(N= 400)
Evaluable population
(N= 395)
Patient on a pre-sampling antibiotic therapy regimen, n (%)
Yes 187 (46.8) 186 (47.1)
None prescribed 194 (48.5) 190 (48.1)
Missing 19 (4.8) 19 (4.8)
Days spent on pre-sampling antibiotic therapy
Mean (SD) 14.6 (21.9) 14.7 (21.9)
Median (range) 7.0 (1–145) 7.0 (1–145)
Missing 1 1
Change to antibiotic therapy: immediately post sampling, n (%)
Yes 248 (62.0) 244 (61.8)
No 133 (33.3) 132 (33.4)
Missing 19 (4.8) 19 (4.8)
SD, standard deviation.
TABLE 13 Summary of patients’ baseline antibiotic regimen (pre sampling) and proposed new antibiotic regimen
(immediately post sampling)
Antibiotic regimen
Full analysis set
(N= 400), n (%)
Evaluable population
(N= 395), n (%)
No pre-sampling antibiotic but initiation immediately post sampling 168 (42.0) 164 (41.5)
No pre-sampling antibiotic and no initiation immediately post
sampling
26 (6.5) 26 (6.6)
On a pre-sampling antibiotic with or without a change immediately
post sampling
187 (46.8) 186 (47.1)
Unknown whether or not there was a pre-sampling antibiotic but
initiation/change immediately post sampling
19 (4.8) 19 (4.8)
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dressing or agent on the infected ulcer. Furthermore, 46.8% of patients were on a systemic antibiotic
regimen, with the most frequently prescribed antibiotics being flucloxacillin (31.1%), clindamycin (18.3%),
co-amoxiclav (13.1%), ciprofloxacin (13.1%) and metronidazole (7.2%). The patient’s antibiotic regimen
was changed following clinical assessment and specimen sampling, but before microbiology results were
available, in 62.0% of patients. Among the 42.0% of patients who were not on an antibiotic regimen
prior to sampling, treatment was initiated immediately post sampling. Finally, 6.5% of patients were not
on an antibiotic regimen prior to sampling and did not have an antibiotic regimen initiated immediately
post sampling.
Microbiology results
Microbiology reports of culture results for swab and tissue samples produced a total of 79 different
microbial isolates from the 395 evaluable patients.
Table 14 presents the number of patients with at least one pathogen reported. At least one pathogenic
isolate was reported from swab results in 277 (70.1%) patients and from tissue results in 340 (86.1%)
patients. On swab sample results, only isolates not likely to be pathogenic (defined as mixed skin flora,
normal flora, enteric flora, yeast, faecal flora) were reported for 39 (9.9%) patients, and no isolates were
reported at all for 79 (20.0%) patients. Based on tissue results, only isolates not likely to be pathogenic
were reported for 15 (3.8%) patients and no isolates were reported at all for 40 (10.1%) patients.
Table 15 presents the pathogens most frequently reported, following their grouping at a range of
taxonomic levels. The most frequently reported groups of pathogens from at least one of the patient’s swab
or tissue sample were Gram-positive cocci (70.6%), Gram-negative bacilli (36.7%), Enterobacteriaceae
including coliforms (26.6%), anaerobes (23.8%) and Gram-positive bacilli (11.1%). The most frequently
reported genus- and species-level pathogens were S. aureus (35.7%), Streptococcus (16.7%), Enterococcus
(14.9%), CNS (12.2%), Corynebacterium (9.4%), Pseudomonas (8.6%) and MRSA (8.1%). The prevalence
of additional genus- and species-level pathogens were all < 6%.
Coprimary end points
Coprimary end point: reported presence of likely pathogens
Most prevalent pathogens
Table 16 presents full cross-tabulations of the reported presence of the most prevalent pathogens (those
with prevalence > 8%), Figure 6 depicts this information and Table 17 presents statistics relating to the
agreement and differences in reporting of these pathogens.
Overall, there was evidence of a significant difference [15.9% (95% CI 11.8% to 20.1%); p-value
< 0.0001] between the swab and tissue samples in the percentage reporting at least one pathogen
(86.1% of patients with tissue sample vs. 70.1% of patients with swab sample) (see Table 17).
Among the most prevalent pathogens, overall agreement between swab and tissue sample results was at
least 79%. The κ-values for the chance corrected agreement suggested:
l almost perfect agreement for MRSA [κ= 0.89 (95% CI 0.80 to 0.98)] and S. aureus [κ= 0.81 (95% CI
0.75 to 0.87)]
l substantial agreement for Streptococcus [κ= 0.76 (95% CI 0.66 to 0.85)], Pseudomonas [κ= 0.67
(95% CI 0.52 to 0.82)] and Gram-negative bacilli [κ= 0.63 (95% CI 0.55 to 0.71)]
l moderate agreement for Enterobactereaceae (including coliforms) [κ= 0.60 (95% CI 0.50 to 0.70)],
Gram-positive cocci [κ= 0.57 (95% CI 0.50 to 0.65)] and Enterococcus [κ= 0.44 (95% CI 0.30 to 0.58)]
l fair agreement for overall anaerobes [κ= 0.38 (95% CI 0.26 to 0.50)] and CNS [κ= 0.26 (95% CI
0.11 to 0.41)]
l slight agreement for Corynebacterium [κ= 0.13 (95% CI –0.01 to 0.28)] and Gram-positive bacilli
[κ= 0.11 (95% CI –0.01 to 0.23)].
PATTERNS OF AGREEMENT BETWEEN SWAB SAMPLING AND TISSUE SAMPLING
NIHR Journals Library www.journalslibrary.nihr.ac.uk
28
TABLE 14 Summary of the reporting of pathogens from results of patients’ swab and tissue samples
Reporting of pathogens
Specimen type
Swab (N= 395), n (%) Tissue (N= 395), n (%)
No pathogens reported 118 (29.9) 55 (13.9)
No isolates reported at all 79 (20.0) 40 (10.1)
Only isolates not likely to be pathogenic reporteda 39 (9.9) 15 (3.8)
At least one pathogen reported 277 (70.1) 340 (86.1)
a Includes isolates not likely to represent pathogenic organisms such as mixed skin/normal flora, enteric flora, yeast and
faecal flora.
TABLE 15 Overall prevalence of grouped pathogens
Pathogensa Swab (N= 395) Tissue (N= 395) Overall (N= 395)
Groups of pathogens, n (%)
Gram-positive cocci 211 (53.4) 265 (67.1) 279 (70.6)
Gram-negative bacilli 96 (24.3) 133 (33.7) 145 (36.7)
Enterobacteriaceae (including coliforms) 68 (17.2) 91 (23.0) 105 (26.6)
Overall anaerobes 48 (12.2) 75 (19.0) 94 (23.8)
Anaerobes (type not reported) 42 (10.6) 64 (16.2) 83 (21.0)
Anaerobic cocci 3 (0.8) 6 (1.5) 6 (1.5)
Anaerobic rods 3 (0.8) 5 (1.3) 5 (1.3)
Gram-positive bacilli 4 (1.0) 43 (10.9) 44 (11.1)
Gram-negative cocci 0 (0.0) 1 (0.3) 1 (0.3)
Genus-level pathogens, n (%)
Streptococcus 48 (12.2) 61 (15.4) 66 (16.7)
Enterococcus (excluding vancomycin resistant) 25 (6.3) 53 (13.4) 59 (14.9)
CNS 9 (2.3) 47 (11.9) 48 (12.2)
Corynebacterium 4 (1.0) 36 (9.1) 37 (9.4)
Pseudomonas 26 (6.6) 26 (6.6) 34 (8.6)
Proteus 14 (3.5) 20 (5.1) 23 (5.8)
Enterobacter 4 (1.0) 11 (2.8) 11 (2.8)
Klebsiella 3 (0.8) 8 (2.0) 10 (2.5)
Candida 5 (1.3) 5 (1.3) 9 (2.3)
Acinetobacter 3 (0.8) 5 (1.3) 6 (1.5)
Citrobacter 2 (0.5) 4 (1.0) 4 (1.0)
Bacteroides 1 (0.3) 2 (0.5) 2 (0.5)
Prevotella 1 (0.3) 2 (0.5) 2 (0.5)
Enterococcus (vancomycin resistant) 1 (0.3) 1 (0.3) 1 (0.3)
continued
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TABLE 15 Overall prevalence of grouped pathogens (continued )
Pathogensa Swab (N= 395) Tissue (N= 395) Overall (N= 395)
Species-level pathogens, n (%)
S. aureus 125 (31.6) 125 (31.6) 141 (35.7)
MRSA 27 (6.8) 31 (7.8) 32 (8.1)
E. coli 6 (1.5) 13 (3.3) 15 (3.8)
Morganella morganii 2 (0.5) 5 (1.3) 6 (1.5)
Serratia marcescens 1 (0.3) 5 (1.3) 5 (1.3)
Stenotrophomonas maltophilia 1 (0.3) 3 (0.8) 3 (0.8)
Peptoniphilus asaccharolyticus 1 (0.3) 1 (0.3) 1 (0.3)
Raoultella planticola 1 (0.3) 1 (0.3) 1 (0.3)
a The following pathogens were also reported, each in a single patient’s tissue sample only: Neisseria, Pediococcus,
Achromobacter denitrificans (Rüger and Tan 1983) Coenye et al. 2003, Alcaligenes faecalis Castellani and Chalmers
1919, Gemella morbillorum (Prévot 1933) Kilpper-Bälz and Schleifer 1988, and Helcococcus kunzii Collins et al. 1993.
TABLE 16 Cross-tabulations of reported presence of at least one pathogen and most prevalent pathogens in order
of taxonomic rank and prevalence
Pathogen (overall prevalence) Swab results, n (%) Tissue results, n (%)
At least one pathogen (88.1%) Not reported Reported Total
Swab Not reported 47 (11.9) 71 (18.0) 118 (29.9)
Reported 8 (2.0) 269 (68.1) 277 (70.1)
Total 55 (13.9) 340 (86.1) 395 (100.0)
Gram-positive cocci (70.6%) Not reported Reported Total
Swab Not reported 116 (29.4) 68 (17.2) 184 (46.6)
Reported 14 (3.5) 197 (49.9) 211 (53.4)
Total 130 (32.9) 265 (67.1) 395 (100.0)
Gram-negative bacilli (36.7%) Not reported Reported Total
Swab Not reported 250 (63.3) 49 (12.4) 299 (75.7)
Reported 12 (3.0) 84 (21.3) 96 (24.3)
Total 262 (63.3) 133 (33.7) 395 (100.0)
Enterobacteriaceae (26.6%) Not reported Reported Total
Swab Not reported 290 (73.4) 37 (9.4) 327 (82.8)
Reported 14 (3.5) 54 (13.7) 68 (17.2)
Total 304 (77.0) 91 (23.0) 395 (100.0)
Overall anaerobes (23.8%) Not reported Reported Total
Swab Not reported 301 (76.2) 46 (11.6) 347 (87.8)
Reported 19 (4.8) 29 (7.3) 48 (12.2)
Total 320 (81.0) 75 (19.0) 395 (100.0)
Gram-positive bacilli (11.1%) Not reported Reported Total
Swab Not Reported 351 (88.9) 40 (10.1) 391 (99.0)
Reported 1 (0.3) 3 (0.8) 4 (1.0)
Total 352 (89.1) 43 (10.9) 395 (100.0)
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The PABAK for the majority of pathogens showed a considerably higher estimate of agreement after
accounting for the low prevalence of the majority of pathogens.
For the majority of pathogens, there was evidence of a significant difference (McNemar’s p-value < 0.01),
with reported prevalence higher in the tissue sample results than the swab results, with the exception
for S. aureus, MRSA and Pseudomonas. Symmetrical disagreement was observed for S. aureus and
Pseudomonas, with the pathogen reported in one sample but not the other an equal number of times for
the two samples. The reported prevalence of MRSA was non-statistically higher in tissue samples than
swab samples.
TABLE 16 Cross-tabulations of reported presence of at least one pathogen and most prevalent pathogens in order
of taxonomic rank and prevalence (continued )
Pathogen (overall prevalence) Swab results, n (%) Tissue results, n (%)
Streptococcus (16.7%) Not reported Reported Total
Swab Not reported 329 (83.3) 18 (4.6) 347 (87.8)
Reported 5 (1.3) 43 (10.9) 48 (12.2)
Total 334 (84.6) 61 (15.4) 395 (100.0)
Enterococcus (excluding vancomycin resistant) (14.9%) Not reported Reported Total
Swab Not reported 336 (85.1) 34 (8.6) 370 (93.7)
Reported 6 (1.5) 19 (4.8) 25 (6.3)
Total 342 (86.6) 53 (13.4) 395 (100.0)
CNS (12.2%) Not reported Reported Total
Swab Not reported 347 (87.8) 39 (9.9) 386 (97.7)
Reported 1 (0.3) 8 (2.0) 9 (2.3)
Total 348 (88.1) 47 (11.9) 395 (100.0)
Corynebacterium (9.4%) Not reported Reported Total
Swab Not reported 358 (90.6) 33 (8.4) 391 (99.0)
Reported 1 (0.3) 3 (0.8) 4 (1.0)
Total 359 (90.9) 36 (9.1) 395 (100.0)
Pseudomonas (8.6%) Not reported Reported Total
Swab Not reported 361 (91.4) 8 (2.0) 369 (93.4)
Reported 8 (2.0) 18 (4.6) 26 (6.6)
Total 369 (93.4) 26 (6.6) 395 (100.0)
S. aureus (35.7%) Not reported Reported Total
Swab Not reported 254 (64.3) 16 (4.1) 270 (68.4)
Reported 16 (4.1) 109 (27.6) 125 (31.6)
Total 270 (68.4) 125 (31.6) 395 (100.0)
MRSA (8.1%) Not reported Reported Total
Swab Not reported 363 (91.9) 5 (1.3) 368 (93.2)
Reported 1 (0.3) 26 (6.6) 27 (6.8)
Total 364 (92.2) 31 (7.8) 395 (100.0)
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FIGURE 6 Reported presence of at least one pathogen and most prevalent pathogens. VRE, vanconycin-resistant Enterococcus.
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Semi-quantitative extent of bacterial growth
Table 18 presents cross-tabulations of the level of growth of each of the most prevalent pathogens, by
swab and tissue samples, and the associated κ-values. The overall κ-value does not account for the ordinal
levels of growth, whereas the weighted κ-value quantifies the relative difference between levels of growth.
κ-values were calculated after excluding patients with a missing level of growth for either the swab or
tissue sample.
Agreement on the level of growth (according to the primary weighting) was somewhat skewed owing to
the prevalence of each pathogen and the proportion of patients with discordant results where a pathogen
was reported in one sample and not the other. Therefore, the level of growth in one sample was often in
comparison with the lack of presence of the pathogen rather than a corresponding level of growth. The
range for agreement was substantial for Streptococcus, Pseudomonas, S. aureus and MRSA; moderate
for Gram-positive cocci, Gram-negative bacilli, Enterobacteriaceae and Enterococcus; fair for CNS and
Corynebacterium; and slight for Gram-positive bacilli.
TABLE 17 Summary of agreement and disagreement statistics for most prevalent pathogens and the report of
at least one pathogen
Pathogens
Overall
prevalence,
%
Disagreement,
%
Difference,
% (95% CI)a
McNemar’s
p-value
Agreement,
% κ (95% CI) PABAK
≥ 1 pathogen 88.1 20.0 15.9
(11.8 to 20.1)
< 0.0001 80.0 0.44
(0.34 to 0.53)
0.60
Gram-positive
cocci
70.6 20.8 13.7
(9.4 to 18.0)
< 0.0001 79.2 0.57
(0.50 to 0.65)
0.58
Gram-negative
bacilli
36.7 15.4 9.4
(5.6 to 13.1)
< 0.0001 84.6 0.63
(0.55 to 0.71)
0.69
Enterobactereaceae
(including coliforms)
26.6 12.9 5.8
(2.3 to 9.3)
0.0013 87.1 0.60
(0.50 to 0.70)
0.74
Overall anaerobes 23.8 16.5 6.8
(2.9 to 10.8)
0.0008 83.5 0.38
(0.26 to 0.50)
0.67
Gram-positive
bacilli
11.1 10.4 9.9
(6.9 to 13.5)
< 0.0001b 89.6 0.11
(–0.01 to 0.23)
0.79
Streptococcus 16.7 5.8 3.3
(0.9 to 5.6)
0.0067 94.2 0.76
(0.66 to 0.85)
0.88
Enterococcus
(excluding
vancomycin resistant)
14.9 10.1 7.1
(4.0 to 10.1)
< 0.0001 89.9 0.44
(0.30 to 0.58)
0.80
CNS 12.2 10.1 9.6
(6.7 to 12.9)
< 0.0001b 89.9 0.26
(0.11 to 0.41)
0.80
Corynebacterium 9.4 8.6 8.1
(5.4 to 11.2)
< 0.0001b 91.4 0.13
(–0.01 to 0.28)
0.83
Pseudomonas 8.6 4.1 0.0
(–2.0 to 2.0)
1.0000 95.9 0.67
(0.52 to 0.82)
0.92
S. aureus 35.7 8.1 0.0
(–2.8 to 2.8)
1.0000 91.9 0.81
(0.75 to 0.87)
0.84
MRSA 8.1 1.5 1.0
(–0.2 to 2.8)
0.2188b 98.5 0.89
(0.80 to 0.98)
0.97
a Tissue minus swab.
b Exact p-value/CI.
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TABLE 18 Cross-tabulations on the semiquantitative extent of bacterial growth and κ-statistics
Tissue results: level of growth
Total, n (%) κ-valuea κ 95% CINot reported Reported: no growth + ++ +++
Gram-positive cocci
Swab results, n (%) (n= 340)
Not reported 116 (29.4) 13 (3.3) 25 (6.3) 14 (3.5) 16 (4.1) 184 (46.6) Overall 0.49 0.42 to 0.55
Reported: no growth 3 (0.8) 33 (8.4) 1 (0.3) 0 (0.0) 1 (0.3) 38 (9.6) Weighted 1 0.58 0.51 to 0.66
+ 4 (1.0) 1 (0.3) 22 (5.6) 3 (0.8) 0 (0.0) 30 (7.6) Weighted 2 0.60 0.54 to 0.67
++ 3 (0.8) 0 (0.0) 13 (3.3) 15 (3.8) 10 (2.5) 41 (10.4)
+++ 4 (1.0) 3 (0.8) 9 (2.3) 21 (5.3) 65 (16.5) 102 (25.8)
Total 130 (32.9) 50 (12.7) 70 (17.7) 53 (13.4) 92 (23.3) n= 395
Gram-negative bacilli
Swab results, n (%) (n= 354)
Not reported 250 (63.3) 5 (1.3) 14 (3.5) 12 (3.0) 18 (4.6) 299 (75.7) Overall 0.48 0.39 to 0.57
Reported: no growth 4 (1.0) 18 (4.6) 2 (0.5) 3 (0.8) 5 (1.3) 32 (8.1) Weighted 1 0.49 0.38 to 0.61
+ 2 (0.5) 1 (0.3) 6 (1.5) 0 (0.0) 2 (0.5) 11 (2.8) Weighted 2 0.53 0.43 to 0.63
++ 3 (0.8) 2 (0.5) 4 (1.0) 10 (2.5) 2 (0.5) 21 (5.3)
+++ 3 (0.8) 1 (0.3) 5 (1.3) 5 (1.3) 18 (4.6) 32 (8.1)
Total 262 (66.3) 27 (6.8) 31 (7.8) 30 (7.6) 45 (11.4) n= 395
Enterobacteriaceae (including coliforms)
Swab results, n (%) (n= 359)
Not reported 290 (73.4) 6 (1.5) 12 (3.0) 5 (1.3) 14 (3.5) 327 (82.8) Overall 0.45 0.33 to 0.56
Reported: no growth 4 (1.0) 17 (4.3) 2 (0.5) 1 (0.3) 3 (0.8) 27 (6.8) Weighted 1 0.50 0.35 to 0.64
+ 2 (0.5) 1 (0.3) 2 (0.5) 0 (0.0) 0 (0.0) 5 (1.3) Weighted 2 0.51 0.38 to 0.64
++ 3 (0.8) 1 (0.3) 3 (0.8) 5 (1.3) 0 (0.0) 12 (3.0)
+++ 5 (1.3) 1 (0.3) 2 (0.5) 3 (0.8) 13 (3.3) 24 (6.1)
Total 304 (77.0) 26 (6.6) 21 (5.3) 14 (3.5) 30 (7.6) n= 395
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Tissue results: level of growth
Total, n (%) κ-valuea κ 95% CINot reported Reported: no growth + ++ +++
Overall anaerobes
Swab results, n (%) (n= 377)
Not reported 301 (76.2) 9 (2.3) 12 (3.0) 14 (3.5) 11 (2.8) 347 (87.8) Overall 0.32 0.21 to 0.43
Reported: no growth 4 (1.0) 4 (1.0) 0 (0.0) 0 (0.0) 0 (0.0) 8 (2.0) Weighted 1 0.43 0.29 to 0.57
+ 7 (1.8) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.3) 8 (2.0) Weighted 2 0.44 0.31 to 0.56
++ 1 (0.3) 1 (0.3) 1 (0.3) 4 (1.0) 6 (1.5) 13 (3.3)
+++ 7 (1.8) 0 (0.0) 0 (0.0) 2 (0.5) 10 (2.5) 19 (4.8)
Total 320 (81.0) 14 (3.5) 13 (3.3) 20 (5.1) 28 (7.1) n= 395
Gram-positive bacilli
Swab results, n (%) (n= 389)
Not reported 351 (88.9) 6 (1.5) 15 (3.8) 10 (2.5) 9 (2.3) 391 (99.0) Overall 0.06 –0.00 to 0.13
+ 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) Weighted 1 0.07 –0.01 to 0.16
++ 1 (0.3) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.3) 2 (0.5) Weighted 2 0.11 –0.01 to 0.24
+++ 0 (0.0) 0 (0.0) 1 (0.3) 1 (0.3) 0 (0.0) 2 (0.5)
Total 352 (89.1) 6 (1.5) 16 (4.1) 11 (2.8) 10 (2.5) n= 395
Streptococcus
Swab results, n (%) (n= 384)
Not reported 329 (83.3) 6 (1.5) 5 (1.3) 1 (0.3) 6 (1.5) 347 (87.8) Overall 0.65 0.55 to 0.75
Reported: no growth 0 (0.0) 4 (1.0) 0 (0.0) 0 (0.0) 1 (0.3) 5 (1.3) Weighted 1 0.68 0.56 to 0.80
+ 2 (0.5) 0 (0.0) 5 (1.3) 1 (0.3) 0 (0.0) 8 (2.0) Weighted 2 0.74 0.65 to 0.84
++ 1 (0.3) 0 (0.0) 1 (0.3) 4 (1.0) 2 (0.5) 8 (2.0)
+++ 2 (0.5) 0 (0.0) 2 (0.5) 7 (1.8) 16 (4.1) 27 (6.8)
Total 334 (84.6) 10 (2.5) 13 (3.3) 13 (3.3) 25 (6.3) n= 395
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D
O
I:
1
0
.3
3
1
0
/h
ta
2
0
8
2
0
H
E
A
LT
H
T
E
C
H
N
O
LO
G
Y
A
S
S
E
S
S
M
E
N
T
2
0
1
6
V
O
L.
2
0
N
O
.
8
2
©
Q
u
e
e
n
’s
P
rin
te
r
a
n
d
C
o
n
tro
lle
r
o
f
H
M
S
O
2
0
1
6
.
T
h
is
w
o
rk
w
a
s
p
ro
d
u
ce
d
b
y
N
e
lso
n
e
t
a
l.
u
n
d
e
r
th
e
te
rm
s
o
f
a
co
m
m
issio
n
in
g
co
n
tra
ct
issu
e
d
b
y
th
e
S
e
cre
ta
ry
o
f
S
ta
te
fo
r
H
e
a
lth
.
T
h
is
issu
e
m
a
y
b
e
fre
e
ly
re
p
ro
d
u
ce
d
fo
r
th
e
p
u
rp
o
se
s
o
f
p
riva
te
re
se
a
rch
a
n
d
stu
d
y
a
n
d
e
xtra
cts
(o
r
in
d
e
e
d
,
th
e
fu
ll
re
p
o
rt)
m
a
y
b
e
in
clu
d
e
d
in
p
ro
fe
ssio
n
a
l
jo
u
rn
a
ls
p
ro
vid
e
d
th
a
t
su
ita
b
le
a
ck
n
o
w
le
d
g
e
m
e
n
t
is
m
a
d
e
a
n
d
th
e
re
p
ro
d
u
ctio
n
is
n
o
t
a
sso
cia
te
d
w
ith
a
n
y
fo
rm
o
f
a
d
ve
rtisin
g
.
A
p
p
lica
tio
n
s
fo
r
co
m
m
e
rcia
l
re
p
ro
d
u
ctio
n
sh
o
u
ld
b
e
a
d
d
re
sse
d
to
:
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry,
N
a
tio
n
a
l
In
stitu
te
fo
r
H
e
a
lth
R
e
se
a
rch
,
E
va
lu
a
tio
n
,
T
ria
ls
a
n
d
S
tu
d
ie
s
C
o
o
rd
in
a
tin
g
C
e
n
tre
,
A
lp
h
a
H
o
u
se
,
U
n
ive
rsity
o
f
S
o
u
th
a
m
p
to
n
S
cie
n
ce
P
a
rk
,
S
o
u
th
a
m
p
to
n
S
O
1
6
7
N
S
,
U
K
.
3
5
TABLE 18 Cross-tabulations on the semiquantitative extent of bacterial growth and κ-statistics (continued )
Tissue results: level of growth
Total, n (%) κ-valuea κ 95% CINot reported Reported: no growth + ++ +++
Enterococcus (excluding vancomycin resistant)
Swab results, n (%) (n= 384)
Not reported 336 (85.1) 6 (1.5) 9 (2.3) 12 (3.0) 7 (1.8) 370 (93.7) Overall 0.39 0.24 to 0.54
Reported – no growth 0 (0.0) 4 (1.0) 0 (0.0) 0 (0.0) 0 (0.0) 4 (1.0) Weighted 1 0.52 0.34 to 0.70
+ 2 (0.5) 0 (0.0) 1 (0.3) 0 (0.0) 0 (0.0) 3 (0.8) Weighted 2 0.47 0.31 to 0.64
++ 1 (0.3) 1 (0.3) 0 (0.0) 3 (0.8) 1 (0.3) 6 (1.5)
+++ 3 (0.8) 0 (0.0) 0 (0.0) 1 (0.3) 8 (2.0) 12 (3.0)
Total 342 (86.6) 11 (2.8) 10 (2.5) 16 (4.1) 16 (4.1) n= 395
CNS
Swab results, n (%) (n= 389)
Not reported 347 (87.8) 5 (1.3) 22 (5.6) 7 (1.8) 5 (1.3) 386 (97.7) Overall 0.23 0.08 to 0.37
+ 0 (0.0) 0 (0.0) 2 (0.5) 0 (0.0) 0 (0.0) 2 (0.5) Weighted 1 0.34 0.11 to 0.57
++ 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.3) 2 (0.5) 3 (0.8) Weighted 2 0.31 0.13 to 0.50
+++ 1 (0.3) 1 (0.3) 0 (0.0) 0 (0.0) 2 (0.5) 4 (1.0)
Total 348 (88.1) 6 (1.5) 24 (6.1) 8 (2.0) 9 (2.3) n= 395
Corynebacterium
Swab results, n (%) (n= 390)
Not reported 358 (90.6) 5 (1.3) 10 (2.5) 10 (2.5) 8 (2.0) 391 (99.0) Overall 0.07 –0.00 to 0.15
++ 1 (0.3) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.3) 2 (0.5) Weighted 1 0.08 –0.01 to 0.17
+++ 0 (0.0) 0 (0.0) 1 (0.3) 1 (0.3) 0 (0.0) 2 (0.5) Weighted 2 0.13 –0.01 to 0.27
Total 359 (90.9) 5 (1.3) 11 (2.8) 11 (2.8) 9 (2.3) n= 395
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Tissue results: level of growth
Total, n (%) κ-valuea κ 95% CINot reported Reported: no growth + ++ +++
Pseudomonas
Swab results, n (%) (n= 391)
Not reported 361 (91.4) 1 (0.3) 1 (0.3) 3 (0.8) 3 (0.8) 369 (93.4) Overall 0.58 0.42 to 0.75
Reported: no growth 0 (0.0) 2 (0.5) 0 (0.0) 0 (0.0) 1 (0.3) 3 (0.8) Weighted 1 0.61 0.40 to 0.82
+ 4 (1.0) 0 (0.0) 3 (0.8) 0 (0.0) 1 (0.3) 8 (2.0) Weighted 2 0.61 0.44 to 0.79
++ 2 (0.5) 0 (0.0) 1 (0.3) 3 (0.8) 0 (0.0) 6 (1.5)
+++ 2 (0.5) 0 (0.0) 1 (0.3) 0 (0.0) 6 (1.5) 9 (2.3)
Total 369 (93.4) 3 (0.8) 6 (1.5) 6 (1.5) 11 (2.8) n= 395
S. aureus
Swab results, n (%) (n= 363)
Not reported 254 (64.3) 1 (0.3) 11 (2.8) 3 (0.8) 1 (0.3) 270 (68.4) Overall 0.64 0.57 to 0.71
Reported: no growth 4 (1.0) 25 (6.3) 0 (0.0) 0 (0.0) 0 (0.0) 29 (7.3) Weighted 1 0.7 0.62 to 0.79
+ 3 (0.8) 1 (0.3) 14 (3.5) 1 (0.3) 0 (0.0) 19 (4.8) Weighted 2 0.74 0.68 to 0.81
++ 6 (1.5) 0 (0.0) 8 (2.0) 8 (2.0) 2 (0.5) 24 (6.1)
+++ 3 (0.8) 1 (0.3) 9 (2.3) 10 (2.5) 30 (7.6) 53 (13.4)
Total 270 (68.4) 28 (7.1) 42 (10.6) 22 (5.6) 33 (8.4) n= 395
MRSA
Swab results, n (%) (n= 391)
Not reported 363 (91.9) 0 (0.0) 1 (0.3) 2 (0.5) 2 (0.5) 368 (93.2) Overall 0.73 0.61 to 0.85
Reported: no growth 0 (0.0) 4 (1.0) 0 (0.0) 0 (0.0) 0 (0.0) 4 (1.0) Weighted 1 0.79 0.67 to 0.91
+ 1 (0.3) 0 (0.0) 3 (0.8) 0 (0.0) 0 (0.0) 4 (1.0) Weighted 2 0.83 0.73 to 0.93
++ 0 (0.0) 0 (0.0) 2 (0.5) 1 (0.3) 2 (0.5) 5 (1.3)
+++ 0 (0.0) 0 (0.0) 0 (0.0) 3 (0.8) 11 (2.8) 14 (3.5)
Total 364 (92.2) 4 (1.0) 6 (1.5) 6 (1.5) 15 (3.8) n= 395
a Weighted 1, exponential values; weighted 2, linear values (sensitivity analysis).
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Summary of pathogens
Table 19 presents the overall summary of all pathogens reported by specimen type for the evaluable
population and by baseline characteristics. Figure 7 presents the overall summary by centre. Overall, there
is a difference in the pathogens reported by the two techniques for 58.0% of patients. Findings among
the 395 patient pairs of results were swab and tissue results reported the same pathogens in 42.0% of
patients; swab results reported additional pathogens to those in the tissue in 8.1% of patients; tissue
reported additional pathogens to those in the swab in 36.7% of patients; and the tissue sample and swab
specimens reported different pathogens, with or without overlap, in 13.2% of patients.
TABLE 19 Overall summary of pathogens by baseline characteristics
Baseline
characteristics
Swab and tissue
report the same
pathogens, n (%)
Swab reports
additional pathogens
to the tissue, n (%)
Tissue reports
additional pathogens
to the swab, n (%)
Swab and tissue
report different
pathogens,d n (%)
Total (n= 395) 166 (42.0)a 32 (8.1)b 145 (36.7)c 52 (13.2)
Type of ulcer
Any ischaemia
(± neuropathy)
(n= 194)
87 (44.8) 17 (8.8) 68 (35.1) 22 (11.3)
Neuropathic only
(n= 199)
79 (39.7) 15 (7.5) 76 (38.2) 29 (14.6)
Missing (n= 2) 0 (0.0) 0 (0.0) 1 (50.0) 1 (50.0)
Grade of ulcer
Grade 1 (n= 135) 60 (44.4) 12 (8.9) 47 (34.8) 16 (11.9)
Grade 2 (n= 132) 59 (44.7) 8 (6.1) 48 (36.4) 17 (12.9)
Grade 3, 4 or 5
(n= 128)
47 (36.7) 12 (9.4) 50 (39.1) 19 (14.8)
Pre-sampling antibiotic therapy
Yes (n= 186) 78 (41.9) 12 (6.5) 71 (38.2) 25 (13.4)
No (n= 190) 80 (42.1) 15 (7.9) 70 (36.8) 25 (13.2)
Missing (n= 19) 8 (42.1) 5 (26.3) 4 (21.1) 2 (10.5)
Presence of antimicrobial dressing or agent
Yes (n= 238) 101 (42.4) 20 (8.4) 82 (34.5) 35 (14.7)
No (n= 152) 61 (40.1) 11 (7.2) 63 (41.4) 17 (11.2)
Missing (n= 5) 4 (80.0) 1 (20.0) 0 (0.0) 0 (0.0)
Wound duration (by median)
< 56 days (n= 189) 72 (38.1) 13 (6.9) 81 (42.9) 23 (12.2)
≥ 56 days (n= 202) 94 (46.5) 18 (8.9) 62 (30.7) 28 (13.9)
Missing (n= 4) 0 (0.0) 1 (25.0) 2 (50.0) 1 (25.0)
a The swab and tissue samples reported the same pathogens for 47 (11.9%) patients as no pathogens were reported for
either sample.
b The swab sample reported additional pathogens for 8 (2.0%) patients as no pathogens were reported from the tissue
sample only.
c The tissue sample reported additional pathogens for 71 (18.0%) patients as no pathogens were reported from the
swab only.
d With or without overlap.
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Multinomial regression analyses
Multinomial regression modelling with a random effect for centre (and MIs to allow for missing data) was
used to assess whether or not agreement, based on the overall summary of pathogens, was influenced by
the pre-specified baseline covariates (Table 20).
None of the baseline factors [ulcer type (any ischaemia/neuropathic only), ulcer grade (Wagner grade 1/
grade 2/grade 3, 4 or 5), pre-sampling antibiotic therapy (yes/no), antimicrobial dressing or agent
(yes/no), wound duration (considered dichotomously as < 56 days/≥ 56 days and continuously on the
log-scale)] was found to have a significant overall impact on agreement. However, comparison of the
individual outcomes did suggest that patients with a wound duration ≥ 56 days had significantly reduced
odds of their tissue sample reporting additional pathogens to the swab sample, as opposed to their
swab and tissue reporting the same pathogens, with an odds ratio of 0.57 (95% CI 0.35 to 0.93). This
finding was not, however, supported on the continuous scale for wound duration.
Coprimary end point 2: reported presence of antimicrobial resistance among
likely pathogens
Likely pathogens
Of the three pathogens of interest, no meticillin-resistant CNS was reported and vancomycin-resistant
Enterococcus was reported for just one patient in both their swab and tissue sample results (Table 21).
Meticillin-resistant S. aureus was reported in 32 (8.1%) patients overall, with overall agreement of 98.5%
between swab and tissue samples. In 5 (1.3%) patients, the pathogen was reported in the tissue results
but not the swab, and in 1 (0.3%) patient, the pathogen was reported in the swab but not the tissue
results (see Table 16). As such, a difference of 1.0% (exact 95% CI –0.2% to 2.8%) was reported, with
McNemar’s test suggesting that this was not a significant difference (exact p-value= 0.2188) (see
Table 17).
To evaluate whether or not agreement was influenced by pre-specified covariates, multinomial regression
modelling had been proposed based on the outcomes of reported MRSA: by swab not tissue, by tissue not
swab, swab and tissue results agree. However, given the small number of patients whose swab and tissue
sample results did not agree [6 (1.6%)], this analysis was not appropriate and was not performed.
Additional sensitivities and resistances
In addition to the three pathogens of interest, resistance and sensitivity to antibiotics were collected where
reported for all pathogens within a patient’s swab or tissue sample.
Patients’ swab or tissue sample results were reported to contain pathogens with a resistance to a
maximum of eight different antibiotics and sensitivity to a maximum of 10 different antibiotic agents, of
any of the antibiotics for which samples were tested (Table 22). There were 123 (31.1%) patients whose
swab sample reported pathogen(s) with resistance to at least one antibiotic agent, whereas 165 (41.8%)
patients’ tissue samples reported pathogen(s) with resistance to at least one resistant antibiotic agent.
Overall, from either the swab or tissue sample results there were 185 (46.8%) patients for whom
resistance to at least one antibiotic agent was reported. A greater proportion of patients’ sample results
reported at least one antibiotic to which pathogens were sensitive. There were 221 (55.9%) patients
whose swab samples reported pathogen(s) with sensitivity to at least one antibiotic agent, 268 (67.8%)
patients whose tissue sample reported pathogen(s) with sensitivity to at least one antibiotic agent and
284 (71.9%) patients for whom the swab or tissue sample reported pathogen(s) with sensitivity to at least
one antibiotic agent.
The most frequently reported antibiotic agent to which at least one pathogen isolated from a patient’s
swab or tissue sample was resistant was penicillin, with a resistance observed in either the swab or tissue
sample results for 72 (18.2%) patients; that is, 47 (11.9%) patients’ swab samples and 63 (15.9%)
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TABLE 21 Reported presence of antimicrobial resistance among likely pathogens
Antimicrobial resistance Swab (N= 395), n (%) Tissue (N= 395), n (%) Overall prevalence (N= 395), n (%)
MRSA 27 (6.8) 31 (7.8) 32 (8.1)
Vancomycin-resistant
Enterococcus
1 (0.3) 1 (0.3) 1 (0.3)
Meticillin-resistant CNS 0 (0) 0 (0) 0 (0)
TABLE 20 Multinomial regression analyses for individually fitted baseline factors on the overall summary of
pathogens with random-centre effect
Multinomial
regression
analyses
Summary of pathogens (reference: both
swab and tissue report the same pathogens)
Odds ratioa
(95% CI) AICb df p-valuec
Null model 941.29
Ulcer type: any ischaemia (± neuropathy) vs. neuropathic only 945.72 3 0.6663
Swab reports additional pathogens to the tissue 1.03 (0.48 to 2.20)
Tissue reports additional pathogens to the swab 0.86 (0.53 to 1.40)
Both swab and tissue report different pathogens 0.68 (0.35 to 1.31)
Ulcer grade 949.16 6 0.6598
Grade 2 vs. grade 1 Swab reports additional pathogens to the tissue 0.68 (0.26 to 1.78)
Tissue reports additional pathogens to the swab 1.08 (0.60 to 1.93)
Both swab and tissue report different pathogens 1.14 (0.51 to 2.54)
Grade 3/4/5 vs. grade 1 Swab reports additional pathogens to the tissue 1.28 (0.52 to 3.11)
Tissue reports additional pathogens to the swab 1.60 (0.87 to 2.95)
Both swab and tissue report different pathogens 1.55 (0.69 to 3.45)
Pre-sampling antibiotic therapy: yes vs. no 946.28 3 0.8001
Swab reports additional pathogens to the tissue 0.80 (0.36 to 1.80)
Tissue reports additional pathogens to the swab 1.14 (0.69 to 1.89)
Both swab and tissue report different pathogens 1.10 (0.56 to 2.16)
Antimicrobial dressing: yes vs. no 943.44 3 0.2782
Swab reports additional pathogens to the tissue 1.13 (0.51 to 2.51)
Tissue reports additional pathogens to the swab 0.69 (0.40 to 1.19)
Both swab and tissue report different pathogens 1.38 (0.66 to 2.89)
Wound duration (median split): ≥ 56 days vs. < 56 days 941.48 3 0.1216
Swab reports additional pathogens to the tissue 1.06 (0.49 to 2.32)
Tissue reports additional pathogens to the swab 0.57 (0.35 to 0.93)
Both swab and tissue report different pathogens 0.88 (0.46 to 1.70)
Log-wound duration (continuous) 944.97 3 0.5091
Swab reports additional pathogens to the tissue 0.95 (0.72 to 1.25)
Tissue reports additional pathogens to the swab 0.88 (0.74 to 1.04)
Both swab and tissue report different pathogens 0.93 (0.74 to 1.18)
AIC, Akaike information criterion; df, degrees of freedom.
a An odds ratio of > 1.0 indicates an increase in the odds of the specified outcome compared with the outcome reference
(both swab and tissue report the same pathogens) for the specified factor compared with its reference group (listed after
vs. in the table).
b Smaller is better.
c Based on the reduction in –2 log-likelihood from null model.
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patients’ tissue samples. Figure 8 presents all reported antibiotics to which pathogens were found to be
resistant within patients’ samples. A similar pattern is observed across all reported antibiotic agents with
each reported more often in the tissue sample than in the swab.
The most frequently reported antibiotic agent to which at least one pathogen isolated from a patient’s
swab or tissue sample was sensitive was flucloxacillin, with a sensitivity observed in either the swab or
tissue sample results for 144 (36.5%) patients; that is, 126 (31.9%) patients’ swab samples and
126 (31.9%) patients’ tissue samples. Figure 9 presents all reported antibiotics to which pathogens were
found to be resistant within patients’ samples, with a similar pattern observed across the majority of
reported antibiotic agents, with all agents but erythromycin reported in the same or a greater percentage
of patients in the tissue sample than the swab sample.
Coprimary end point 3: number of pathogens reported per specimen
The third coprimary end point evaluated agreement between the two specimen collection methods for
microbiological characterisation determined by the number of pathogens reported per specimen.
Tables 23 and 24 present the cross-tabulation and summary statistics of the number of pathogens reported
from each sample. A median of 1 pathogen was reported in both samples, and the mean number of
pathogens reported in the swab and tissue samples was 1 and 1.5, respectively, with a slightly higher level
of variation observed in the tissue samples. The number of pathogens ranged from 0 to 4 in the swab
sample and 0 to 6 in the tissue sample. A greater proportion of swab results reported no pathogens
compared with tissue results (29.9% vs. 13.9%), whereas similar proportions of samples reported just one
TABLE 22 Summary of the number of different antibiotic agents for which pathogens within swab and tissue
sample results were found to be resistant or sensitive
Number of
antibiotics
Antibiotic resistance Antibiotic sensitivity
Swab
(N= 395)
Tissue
(N= 395)
Overall
(N= 395)
Swab
(N= 395)
Tissue
(N= 395)
Overall
(N= 395)
Number of antibiotics
Mean (SD) 0.6 (1.16) 0.9 (1.35) 1.0 (1.45) 1.6 (1.80) 2.1 (1.98) 2.5 (2.14)
Median (range) 0.0 (0–6) 0.0 (0–8) 0.0 (0–8) 1.0 (0–9) 2.0 (0–9) 2.0 (0–10)
IQR (0.0–1.0) (0.0–1.0) (0.0–2.0) (0.0–3.0) (0.0–3.0) (0.0–4.0)
Missing 0 0 0 0 0 0
Number of antibiotics, n (%)
0 272 (68.9) 230 (58.2) 210 (53.2) 174 (44.1) 127 (32.2) 111 (28.1)
1 62 (15.7) 77 (19.5) 81 (20.5) 38 (9.6) 39 (9.9) 27 (6.8)
2 31 (7.8) 41 (10.4) 51 (12.9) 63 (15.9) 69 (17.5) 64 (16.2)
3 10 (2.5) 21 (5.3) 19 (4.8) 56 (14.2) 68 (17.2) 68 (17.2)
4 14 (3.5) 17 (4.3) 21 (5.3) 35 (8.9) 50 (12.7) 58 (14.7)
5 3 (0.8) 4 (1.0) 6 (1.5) 16 (4.1) 14 (3.5) 28 (7.1)
6 3 (0.8) 4 (1.0) 5 (1.3) 10 (2.5) 18 (4.6) 23 (5.8)
7 0 (0.0) 0 (0.0) 1 (0.3) 2 (0.5) 5 (1.3) 10 (2.5)
8 0 (0.0) 1 (0.3) 1 (0.3) 0 (0.0) 4 (1.0) 4 (1.0)
9 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.3) 1 (0.3) 1 (0.3)
10 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.3)
IQR, interquartile range; SD, standard deviation.
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pathogen (45.1% and 40.8%). Where more than one pathogen was reported, there was consistently a
greater frequency of patients with more pathogens in the tissue sample than the swab sample results.
A summary of the number of pathogens by baseline characteristics, presented in Table 25, shows that for
approximately half (49.6%) of all patients the same number of pathogens were reported for the tissue and
swab sample; for 41.5% of patients the tissue sample reported at least one more pathogen than the
swab; and for 8.9% of patients the swab sample reported at least one more pathogen than the tissue.
Figure 10 presents the summary of the number of pathogens by centre.
Ordinal regression analyses
Ordinal regression modelling with a random effect for centre (and MIs to allow for missing data) was used
to assess whether or not agreement, based on the summary of the number of pathogens, was influenced
by the pre-specified baseline covariates. The results are presented in Table 26.
TABLE 23 Cross-tabulation of the number of pathogens reported per specimen
Swab results
Tissue results, n (%)
Total0 1 2 3 4 or more
0 47 (11.9) 44 (11.1) 16 (4.1) 10 (2.5) 1 (0.3) 118 (29.9)
1 7 (1.8) 96 (24.3) 50 (12.7) 17 (4.3) 8 (2.0) 178 (45.1)
2 1 (0.3) 20 (5.1) 43 (10.9) 13 (3.3) 4 (1.0) 81 (20.5)
3 0 (0.0) 1 (0.3) 6 (1.5) 8 (2.0) 1 (0.3) 16 (4.1)
4 or more 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.5) 2 (0.5)
Total 55 (13.9) 161 (40.8) 115 (29.1) 48 (12.2) 16 (4.1) 395 (100.0)
Green text indicates agreement.
TABLE 24 Summary statistics of the number of pathogens reported per specimen
Number of pathogens reported per specimen Swab (N= 395) Tissue (N= 395)
Mean (SD) 1.0 (0.84) 1.5 (1.04)
Median (range) 1.0 (0–4) 1.0 (0–6)
Range 0–4 0–6
Number of pathogens: frequency, n (%)
0 118 (29.9) 55 (13.9)
1 178 (45.1) 161 (40.8)
2 81 (20.5) 115 (29.1)
3 16 (4.1) 48 (12.2)
4 2 (0.5) 13 (3.3)
5 0 (0.0) 2 (0.5)
6 0 (0.0) 1 (0.3)
SD, standard deviation.
DOI: 10.3310/hta20820 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 82
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Nelson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
45
Of the baseline factors [ulcer type (any ischaemia/neuropathic only), ulcer grade (Wagner grade 1/grade 2/
grade 3, 4 or 5), pre-sampling antibiotic therapy (yes/no), antimicrobial dressing or agent (yes/no),
wound duration (considered dichotomously as < 56 days/≥ 56 days and continuously on the log-scale)],
only wound duration (< 56 days/≥ 56 days) was found to have a statistically significant association
(p-value= 0.0240). The associated odds ratio of 0.64 (95% CI 0.43 to 0.95) suggests that patients whose
ulcer has been present for 56 days or more had significantly reduced odds of having a higher outcome
(i.e. in the direction that the tissue sampling had two or more extra pathogens) than those whose ulcer
has been present for fewer than 56 days.
TABLE 25 Summary of the number of pathogens by baseline characteristics
Baseline
characteristics
1: swab sampling
had ≥ 2 extra
pathogens
reported
2: swab sampling
had 1 extra
pathogen
reported
3: tissue and
swab sampling
had the same
number of
pathogens
reported
4: tissue
sampling had
1 extra
pathogen
reported
5: tissue
sampling had
≥ 2 extra
pathogens
reported
Total (N= 395),
n (%)
2 (0.5) 33 (8.4) 196 (49.6) 108 (27.3) 56 (14.2)
Type of ulcer, n (%)
Any ischaemia
(± neuropathy)
(n= 194)
0 (0.0) 18 (9.3) 101 (52.1) 50 (25.8) 25 (12.9)
Neuropathic only
(n= 199)
2 (1.0) 15 (7.5) 94 (47.2) 57 (28.6) 31 (15.6)
Missing (n= 2) 0 (0.0) 0 (0.0) 1 (50.0) 1 (50.0) 0 (0.0)
Grade of ulcer, n (%)
Grade 1 (n= 135) 1 (0.7) 13 (9.6) 69 (51.1) 33 (24.4) 19 (14.1)
Grade 2 (n= 132) 0 (0.0) 8 (6.1) 68 (51.5) 35 (26.5) 21 (15.9)
Grade 3, 4 or 5
(n= 128)
1 (0.8) 12 (9.4) 59 (46.1) 40 (31.3) 16 (12.5)
Pre-sampling antibiotic therapy, n (%)
Yes (n= 186) 0 (0.0) 15 (8.1) 92 (49.5) 51 (27.4) 28 (15.1)
No (n= 190) 2 (1.1) 13 (6.8) 94 (49.5) 54 (28.4) 27 (14.2)
Missing (n= 19) 0 (0.0) 5 (26.3) 10 (52.6) 3 (15.8) 1 (5.3)
Presence of antimicrobial dressing or agent, n (%)
Yes (n= 238) 0 (0.0) 23 (9.7) 123 (51.7) 58 (24.4) 34 (14.3)
No (n= 152) 2 (1.3) 9 (5.9) 69 (45.4) 50 (32.9) 22 (14.5)
Missing (n= 5) 0 (0.0) 1 (20.0) 4 (80.0) 0 (0.0) 0 (0.0)
Wound duration, n (%)
< 56 days (n= 189) 1 (0.5) 13 (6.9) 85 (45.0) 57 (30.2) 33 (17.5)
≥ 56 days (n= 202) 1 (0.5) 19 (9.4) 110 (54.5) 49 (24.3) 23 (11.4)
Missing (n= 4) 0 (0.0) 1 (25.0) 1 (25.0) 2 (50.0) 0 (0.0)
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Owing to the significance of wound duration, a forward selection model building approach was used to
determine if further covariates had an influential effect on outcome in the model containing wound duration
and centre random effect. Table 27 presents the results of the model building. There was no further significant
improvement in the fit of the model on the addition of any additional baseline factors, and so the final model
contained wound duration and random-centre effect and is presented in Table 28 and Figure 11.
Graphical plots were used to assess the proportional odds assumption for each baseline factor and can be
found in Appendix 1. The proportional odds assumption was supported for all factors with the exception
of centre, which was, however, fitted as a random effect negating the need for proportional odds.
The figure presents the ranked predicted random-centre effect on the parameter estimate of wound
duration of –0.4501 (see Table 28). The parameter estimate relates to the odds of a higher outcome
(i.e. tissue sample finds two or more pathogens), with a negative value reducing these odds, and a positive
TABLE 26 Ordinal regression analyses for individually fitted baseline factors on the summary of the number of
pathogens with random-centre effect
Baseline characteristics Odds ratioa (95% CI) AICb df p-valuec
Null model 917.72
Ulcer type: any ischaemia (± neuropathy) vs. neuropathic only 0.90 (0.61 to 1.33) 919.45 1 0.6030
Ulcer grade 920.16 2 0.4587
Grade 2 vs. grade 1 1.33 (0.82 to 2.15)
Grade 3, 4 or 5 vs. grade 1 1.27 (0.78 to 2.07)
Pre-sampling antibiotic therapy: yes vs. no 1.25 (0.81 to 1.91) 918.56 1 0.2828
Antimicrobial dressing: yes vs. no 0.76 (0.49 to 1.18) 918.16 1 0.2127
Wound duration (median split): ≥ 56 days vs. < 56 days 0.64 (0.43 to 0.95) 914.62 1 0.0240d
Log-wound duration (continuous) 0.92 (0.80 to 1.05) 918.15 1 0.2101
AIC, Akaike information criterion; df, degrees of freedom.
a An odds ratio of > 1.0 indicating a positive relationship with outcome compared with the variable reference group (those
listed after ‘vs.’ in the table). For example, an odds ratio > 1.0 indicates a tendency towards higher levels of the ordinal
outcome (i.e. in the direction that the tissue sample finds 2 or more pathogens) compared with the variable
reference group.
b Smaller is better.
c Based on the reduction in –2 log-likelihood from null model.
d Significant at the 5% level.
TABLE 27 Sequential chi-squared tests for the reduction in –2 log-likelihood: wound duration fixed effect
(1 degree of freedom) and centre random effect (1 degree of freedom)
Additional baseline characteristic Reduction in df AICa Reduction in –2log-likelihood p-valueb
Wound duration (median split) 914.62
+ Ulcer type 1 916.53 0.086 0.7688
+ Ulcer grade 2 916.69 1.925 0.3820
+ Pre-sampling antibiotic therapy 1 915.94 0.674 0.4115
+ Antimicrobial dressing 1 915.60 1.019 0.3128
AIC, Akaike information criterion; df, degrees of freedom.
a Smaller is better.
b Based on the reduction in –2 log-likelihood from the model containing wound duration and centre random effect.
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increasing the odds. The presented predicted centre effects vary considerably, across both positive and
negative values, and therefore impact on the likely odds of a higher outcome and variability around the
estimate across centres.
Secondary end points
Adverse events
During the collection of swab and tissue samples, AEs consisting of bleeding of concern were reported for
30 (7.5%) patients: for 3 (0.8%) patients this was attributable to swab sampling; for 24 (6.0%) patients it
was attributable to tissue sampling; and for 3 (0.8%) patients it was attributable to both swab and tissue
sampling (Table 29).
TABLE 28 Final ordinal logistic regression model containing random-centre effect and fixed effect for
wound duration
Fixed effect
Odds ratio
(95% CI)
Estimates of fixed effect Random-centre effect
Parameter
estimate
Standard
error p-value
Parameter
estimate
Standard
error
Test of H0:
random
intercept
variance= 0
Wound duration:
≥ 56 days vs.
< 56 days
0.64
(0.43 to 0.95)
–0.4501 0.2008 0.0250 0.4689 0.2065 < 0.0001
H0, null hypothesis.
2
1
P
re
d
ic
te
d
 c
e
n
tr
e
 e
ff
e
ct
0
–1
–2
Ro
ya
l O
ld
ha
m
Ch
or
le
y 
an
d 
So
ut
h 
Ri
bb
le
Br
ad
fo
rd
Ta
m
es
id
e 
G
en
er
al
N
or
fo
lk
 a
nd
 N
or
w
ic
h
Pi
nd
er
fie
ld
s
La
nc
as
te
r
Bi
rm
in
gh
am
SJ
U
H
N
or
th
 M
an
ch
es
te
r
Co
ve
nt
ry
 a
nd
 W
ar
w
ic
k
M
an
ch
es
te
r
N
or
th
 T
ee
s
H
ud
de
rs
fie
ld
Fa
irfi
el
d
W
es
to
n 
G
en
er
al
Be
ns
ha
m
N
or
th
 S
ta
ff
or
ds
hi
re
M
in
er
va
 C
en
tr
e
Centre
N
ew
 C
ro
ss
So
ut
h 
Ty
ne
sid
e
H
ar
ro
ga
te
Ja
m
es
 C
oo
k
Ki
ng
’s 
Ly
nn
Le
w
ish
am
FIGURE 11 Plot of predicted random-centre effect in the model with fixed effect for wound duration (median
split). SJUH, St James’s University Hospital.
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Patient-reported pain, collected before sampling and immediately following both swab and tissue
sampling, is summarised in Tables 30 and 31. At baseline, prior to sampling, 74% of patients reported no
pain, 15% reported mild pain, 8% reported moderate pain and 3% reported severe pain. Comparing pain
ratings after swab and tissue sampling, 5 (1.3%) patients reported an increased pain score immediately
after swab sampling compared with tissue sampling, 37 (9.3%) patients reported an increased pain score
immediately after tissue sampling compared with swab sampling, and 358 (89.5%) patients reported the
same pain score immediately after swab and tissue sampling. Patient-rated pain is also presented according
to patients’ type of ulcer: ischaemic, neuropathic or neuroischaemic ulcers (Table 32).
No unexpected serious AEs related to the specimen collections were reported.
Sampling costs
Sampling costs were provided by only one CODIFI study site, but information was also provided from an
additional non-study site by a microbiologist. At the study site, the quoted swab cost was £15.55, whereas
the cost for a tissue sample was £16.53. At the non-study site, the swab cost was quoted as £3.91 and
the tissue sample as £5.85. These costs do not include sampling equipment, transport or staff costs. It was
not possible to obtain full economic costs within the confines of the study. Many sites considered this
information as commercially sensitive.
TABLE 31 Cross-tabulation of patient-rated pain after swab and tissue sampling
Pain score after swab sampling
Pain score after tissue sampling, n (%)
TotalNo pain Mild pain Moderate pain Severe pain
No pain 279 (69.8) 17 (4.3) 2 (0.5) 1 (0.3) 299 (74.8)
Mild pain 1 (0.3) 35 (8.8) 13 (3.3) 1 (0.3) 50 (12.5)
Moderate pain 1 (0.3) 2 (0.5) 36 (9.0) 3 (0.8) 42 (10.5)
Severe pain 0 (0.0) 1 (0.3) 0 (0.0) 8 (2.0) 9 (2.3)
Total 281 (70.3) 55 (13.8) 51 (12.8) 13 (3.3) 400 (100.0)
Green text indicates agreement.
TABLE 30 Verbal rating scale pain summary
Verbal rating scale
pain score, n (%)
Before sampling
(n= 400)
Immediately after swab
sampling (n= 400)
Immediately after tissue
sampling (n= 400)
No pain 296 (74.0) 299 (74.8) 281 (70.3)
Mild pain 60 (15.0) 50 (12.5) 55 (13.8)
Moderate pain 32 (8.0) 42 (10.5) 51 (12.8)
Severe pain 12 (3.0) 9 (2.3) 13 (3.3)
TABLE 29 Cross-tabulation of patients with bleeding of concern attributable to sampling
Swab sampling
Tissue sampling, n (%)
Yes No Total
Yes 3 (0.8) 3 (0.8) 6 (1.5)
No 24 (6.0) 370 (92.5) 394 (98.5)
Total 27 (6.8) 373 (93.3) 400 (100.0)
Shaded cells indicate agreement between swab sampling and tissue sampling.
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Centre differences
Completed site difference questionnaires were received from 22 of the 25 participating sites. For full
details and tables summarising the responses, see Appendix 3.
Tissue samples were collected using a scalpel at 20 of these sites and a dermal curette and one site.
There were no differences in the time taken for swab and tissue samples to reach the laboratory. The
majority of laboratories reported no clear differences in the time taken from receipt of swab and tissue
samples to commencement of processing, with just 4 of 17 reporting slightly more urgent/quicker time to
processing for tissue samples. There were, however, clear differences in the transport media used for the
two sampling techniques. Swabs were all transported with an Amies nutritional growth medium, whereas
the vast majority of tissue samples were either transported in a dry container (11/17) or a dry container
with saline (3/17). The remaining three tissue samples were transported using nutritional media
(Amies= 2, Stuarts= 1).
Further differences were identified in the analysis and reporting of samples. Only 3 out of 19 laboratories
reported performing a Gram-stained smear on both swab and tissue samples, whereas 9 out of 19
laboratories performed these on tissue samples only, the remaining 6 out of 19 never performed one, with
1 out of 19 performing them only on request.
A variety of systems were used to report amount of bacterial growth, with 8 out of 18 using combinations
of scanty/light/moderate/heavy, 4 out of 18 using combinations of +/++/+++/++++, and 4 out of 18 not
reporting amount of growth.
TABLE 32 Verbal rating scale pain summary: by aetiology of patients’ ulcer
Ulcer aetiologya
Verbal rating scale pain score, n (%)
Before sampling Immediately after swab sampling Immediately after tissue sampling
Ischaemic (n = 14)
No pain 5 (35.7) 4 (28.6) 3 (21.4)
Mild pain 2 (14.3) 2 (14.3) 2 (14.3)
Moderate pain 5 (35.7) 5 (35.7) 5 (35.7)
Severe pain 2 (14.3) 3 (21.4) 4 (28.6)
Neuropathic (n = 202)
No pain 154 (76.2) 156 (77.2) 145 (71.8)
Mild pain 29 (14.4) 24 (11.9) 28 (13.9)
Moderate pain 14 (6.9) 18 (8.9) 22 (10.9)
Severe pain 5 (2.5) 4 (2.0) 7 (3.5)
Both ischaemic and neuropathic (n = 182)
No pain 136 (74.7) 138 (75.8) 132 (72.5)
Mild pain 29 (15.9) 24 (13.2) 25 (13.7)
Moderate pain 12 (6.6) 18 (9.9) 23 (12.6)
Severe pain 5 (2.7) 2 (1.1) 2 (1.1)
a Ulcer aetiology was unknown for two patients, the first of whom reported ‘no pain’ and the second of whom reported
‘moderate pain’, each for all three time points.
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Isolates were reported to a variety of taxonomic ranks, ranging from species, genus and other. It is reported
that 16 out of 18 laboratories report to the same level for swab and tissue samples, whereas 1 out of 18
reported that all tissue isolates are provided to the species level and only significant organisms are provided
in such detail for the swab. However, differences are more apparent when considering whether or not all
recovered isolates are reported to the clinician. Only 8 out of 18 laboratories reported that the same isolates
are reported from swab and tissue samples. In contrast, the remaining 10 out of 18 laboratories report that
all are reported from a tissue sample, whereas reporting of those from a swab sample depends on a mix of
clinical details, clinical significance, whether or not there is heavy pure growth and whether or not they are
clinically significant pathogens; those that are not are reported as enteric or skin flora. In 16 out of 19
laboratories it was reported that their standard procedures allow identification of the same isolates;
however, 3 out of 16 laboratories said that their standard procedures would not allow this, and one of
these reported that the tissue samples are also put into a broth.
A total of 12 out of 13 laboratories reported that the same antibacterial agents were tested in swab and
tissue samples, with one laboratory reporting additional agents for the tissue sample.
Discussion
This study is a cross-sectional multicentre study to examine agreement and disagreement between swab
and tissue sampling techniques in patients with a suspected DFU infection. The conclusions drawn from
this study will help to determine if the extra effort and cost of sampling tissue is potentially worthwhile.
Furthermore, if there is disagreement, we aimed to determine whether one method provided additional
information or different information.
The key results were that a significant proportion of wounds suspected to be infected had microbiology
reports that indicated no growth, and a further proportion indicated no pathogens. There was a higher
proportion of swab samples than tissue samples that had no reported pathogens. There are a number of
possible explanations why the culture results may report no pathogens, such as the clinical diagnosis being
incorrect (e.g. inflammation was mistaken for infection). Given the lack of validated tools for diagnosing
the presence of wound infection and the acknowledged risk of missing infection in diabetic foot
ulceration, it is understandable that clinical diagnosis might prioritise sensitivity over specificity (accepting
practice that misclassifies people as having an infected ulcer when it is not, but not missing anyone with
an infected ulcer). Furthermore, it may be that sampling technique as currently practised in these centres
may not have adequately captured wound flora. For example, if there was inadequate wound ulcer
debridement, then swabbing or taking a tissue sample from a sloughy ulcer area will be likely to collect
surface contaminants, with or without wound tissue bacteria. Last, the lack of any organisms identified
from a sample may be attributable to them not having survived the transport to the microbiology
laboratory. Our information from sites indicated a range of transport media, and in some centres dry tissue
samples were transported, which may not adequately support fastidious organisms or anaerobes. Although
the sites were practising to HPA standards, there was considerable variation in collection and microbiology
practice and this heterogeneity may be important. As part of this study, we attempted to ensure that all
centres practised appropriate sample collection by developing and delivering to them a training package in
person or remotely, and we updated staff when turnover occurred.
In almost two-thirds of patients (58%), there was a difference in the described biome from the
microbiology culture results depending on whether swab or tissue sampling was used. Furthermore, in half
of the patients (50.4%), there was a difference in the number of pathogens reported. However, this was
not invariably that tissue samples had a greater yield (i.e. they reported the information contained in the
paired swab sample) and additional organisms (although this was the case for 36.7% of patients). In a
minority of cases (8.1%), the swab sample had a greater yield than the tissue sample, that is, it reported
additional information over the tissue samples. This variation in yield may be attributable to variation in the
bacterial profile across a wound surface. Therefore, a swab taken from an area of a tissue subsequently
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removed for tissue sampling would be a closer comparison, able to account of the spread of bacteria,
although the area of tissue removal would preclude this practice in many wounds, as it would potentially
impact healing.
A greater proportion of tissue sample results detailed at least one antibiotic to which pathogens within the
sample were resistant (41.8% vs. 31.1%) and sensitive (67.8% vs. 55.9%); however, it was not always
the case that the tissue samples reported all the information contained in the paired swab sample.
The fact that a tissue sample is able to collect bacteria from deep within the wound bed and that a swab
relies on the capture of bacteria from the fluid expressed by pressing the wound (as per Levine et al.’s48
technique) means that one might expect a tissue sample to collect additional deep bacteria. We found that
tissue samples provide information on more pathogens, but it is not clear from this study if the added
information might have an effect on clinical decision-making. Wound microbiology results are only one
aspect of the clinical assessment, with direct assessment of the wound progress during treatment likely
to be an important cue for determining progress or deterioration in a wound and guiding treatment.
If clinicians currently default to swabbing wounds, then it is uncertain if a move to tissue sampling
is warranted.
It is clear that more patients experienced a higher degree of pain with tissue sampling than swabbing,
regardless of the ulcer type. In addition, post-sampling bleeding was noted more often after tissue
sampling than swabbing – bleeding of concern was attributable to tissue sampling in 24 (6.0%) patients,
attributable to swab sampling in 3 (0.8%) patients and attributable to both swab and tissue sampling in
3 (0.8%) patients. The limited information indicates that there is a small difference in costs for tissue
sampling and swab sampling and, hence, the question remains as to the added clinical value of tissue
sampling over swabbing.
One of the strengths of our study is that we recruited a large study population with a single aetiology, all
clinically suspected to be infected and intended to be treated on antibiotics. As the question we sought to
address (i.e. is the selection of sampling by swab or tissue collection best) arises in the management of
infected foot ulcers, we have studied this group rather than a consecutive series of ulcers or a unselected
sample. This is because bacterial sampling in chronic wounds is not used to diagnose infection; if it were,
then a study sample that included both infected and uninfected wounds would be essential. One should
not usually collect microbiology from a clinically uninfected wound and, therefore, only patients with
clinically infected wounds were recruited. The study was pragmatic in that it allowed clinicians to diagnose
infection according to their current clinical practice. This means that our study is relevant to contemporary
practice in a range of settings and not just specialist centres. The processing of samples using current NHS
laboratory practice is also a strength, as results are thus applicable to regular clinical settings.
Given the lack of a gold standard, our study did not consider diagnostic accuracy, but rather agreement;
hence, we used appropriate statistical methods to summarise and analyse our data. Most previous studies
asking a similar question have presumed that a tissue sample was the criterion standard against which swab
specimens are judged as providing true- and false-positive results. We believe that this is not appropriate,
as it presupposes that there is a criterion standard assumed to be the tissue sample, whereas there is
evidence from studies that have found swabs to report additional isolates in 11% (Mutluoglu et al.62) and
8.1% of samples (CODIFI), and different isolates in 6.7% (Mutluoglu et al.62) and 13.2% (CODIFI).
Our study was also significantly larger than previous investigations in the area.
Overall, the results indicate that the results of tissue and swab cultures are different in a substantial
minority of cases, with tissue sampling usually providing reports with higher numbers of pathogens. This is
potentially attributable to the less detailed reporting by some microbiology laboratories for the swab
specimens. These factors favouring tissue samples must be weighed against the slightly more complex
process of collecting tissue specimens, the slightly greater pain and bleeding, and the possibly slightly
higher cost.
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Chapter 3 Independent clinical review of the
appropriateness of empirical antimicrobial therapy
based on swab and tissue sampling information
Introduction
In the main study (see Chapter 2), the extent of agreement and pattern of disagreement on presence and
number of pathogens reported was investigated, and we concluded that tissue samples more often
reported additional information than swab samples. At the outset of the study, however, we were aware
that if one method of sampling did provide more information as assessed by the number of pathogens
identified, this did not necessarily mean that the additional microbiology information would be considered
‘more informative’ by clinicians. We therefore wished to investigate the clinician’s perspective on the
microbiology reports. In order to determine whether or not a microbiology report from tissue sampling was
‘more informative’ than a swab report, we presented paired reports (a swab report and a tissue report
from the same patient) to clinicians to assess the microbiology information within a patient vignette, and
we analysed how the clinician would have responded to the available information. Therefore, this clinical
panel review study investigated the clinical usefulness of the information provided by tissue versus swab
samples, using an expert clinical panel blinded to the type of specimen to interpret the results. We
assumed that a more informative culture report would allow a more appropriate decision regarding the
choice of an empiric antibiotic regimen.
The best available test of the clinical utility of whether either swab or tissue information was better would
be a trial in which clinicians were provided with results from one or the other sample, but this was not
possible within the remit of this commissioned study.
If the method of sampling makes no difference to ongoing treatment decisions, then the sampling method
that is the quickest, cheapest and best tolerated by patients would be the recommended method for
clinical practice. However, if the choice of sampling method does affect subsequent treatment choice, then
there is a trade-off between clinical usefulness and cost, specimen collection-related pain or bleeding and
clinician time and skill in taking the sample.
Objectives
The main objective of this substudy was to compare the proportion of patients for whom the empirical
antibiotic regimen (initially prescribed by the attending medical team immediately following swab and
tissue sampling) was ‘appropriate,’ based on culture and sensitivity results of swab or tissue samples. This
was assessed by a review of the microbiology data by a blinded clinical panel (with a record of empirical
antimicrobial regimen prescribed).
A further objective of this substudy was to assess whether or not the appropriateness of the selected
empirical antibiotic regimen based on the swab versus the tissue culture results was influenced by the
clinical characteristics of the patient and of the infected ulcer.
A further exploratory objective was to evaluate the inter- and intrarater reliability for reviewers involved in
the clinical review.
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Methods
Study design
Main substudy
Appropriateness of the empirical antibiotic regimen was assessed by a blinded ‘virtual’ clinical panel,
conducted on a subsample of 250 patients recruited to the main CODIFI study whose sample results were
sent for review. Further subsamples of 30 patients from these 250 patients were additionally assessed by
reviewers to allow us to ascertain the degree of agreement between different reviewers (inter-rater
reliability) as well as consistency of reviewers from one time point to another (intrarater reliability).
Reviewers were provided with anonymised patient vignettes comprising (1) key baseline clinical information
including, age, sex and baseline clinical assessment (PEDIS); (2) the microbiology laboratory results
(including antibiotic sensitivities and resistance of pathogens identified); and (3) the patient’s empirical
antibiotic regimen [none, or name(s) of antibiotic(s)], that is, the antibiotic regimen patients were initially
prescribed immediately following swab and tissue sampling based only on clinical (not microbiological)
knowledge acquired during the visit. Vignettes were provided with only a reference code to blind reviewers
to the source of the vignette for both patient study number and sample type (swab or tissue).
To conduct the review, patient vignettes were randomly assigned to reviewers. Each reviewer received both
the swab and tissue vignette (i.e. paired vignettes) for a number of patients; however, reviewers were not
informed that they would receive paired vignettes. Paired vignettes were provided in separate rounds to
avoid bias via the matching of vignettes based on patients’ baseline clinical and demographic information.
Each round contained a mixture of results from swab and tissue samples, and the second round of vignettes
(containing vignettes based on the same patients as in the first round but for the corresponding swab or
tissue sample) were sent only when the first had been completed and returned, approximately 2 weeks
later. Reviews from both the first and second round of vignettes were required to ensure that the same
reviewer reviewed the vignettes generated from the same patient’s swab and tissue sample results.
This process was repeated in two batches. The first batch consisted of patient vignettes for the first
200 patients recruited to the study. Following the review of vignettes from the first batch, a second batch
of vignettes were generated and sent for review to increase the number of patients included in the clinical
review to 250 and to allow the assessment of inter- and intrarater reliability.
Inter- and intrarater reliability substudy
To assess the inter-rater reliability for reviewers involved in the clinical review, vignettes from 30 patients
were randomly selected from batch 1 across reviewers who had returned their vignettes at that time
(reviewer 1). These vignettes were then sent to multiple reviewers, selected randomly from those who
had agreed to receive a second batch at that time, in batch 2 (reviewer 2). Similarly, to assess the intrarater
reliability for the reviewers, vignettes from a further 30 patients were randomly selected from batch 1
(first review). These vignettes were then sent to the same reviewer in batch 2 (second review); the
substudy was designed so that each reviewer considered the same vignettes twice.
Assessments and outcomes
Reviewers were asked to consider each vignette and comment as to (1) whether or not they considered
there to be pathogens identified in the laboratory report that were not covered by the empirical
antimicrobial regimen (where ‘regimen’ includes no prescription or name of prescribed antibiotic); and
(2) if so, whether or not knowing this information would have led them to prescribe an alternative
antibiotic regimen. The following questions were put to reviewers:
l Q1: ‘Are there any pathogens identified in the laboratory report that are not covered by the prescribed
antimicrobial regimen? (Y/N)’
l Q2: ‘If you answered ‘yes’ to question 1, would knowing this information lead you to prescribe an
alternative antibiotic regimen for this patient? (Y/N)’.
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The clinical panel’s judgement of how a patient’s prescribed empirical antibiotic regimen would change
(i.e. either initiation of antibiotic therapy or change to existing antibiotic regimen after review of the
microbiology results) were derived as:
l no change required to regimen (including initiation of therapy) (either Q1: N, or Q1: Y and Q2: N)
l change required to regimen (Q1: Y and Q2: Y, or Q1: N and Q2: Y).
When pathogens that were not covered by the prescribed empirical antibiotic regimen were identified,
sample pairs (swab and tissue samples) were further coded as:
l swab but not tissue sample indicates pathogens that are not covered by the prescribed empirical
antimicrobial regimen
l tissue but not swab sample indicates pathogens that are not covered by the prescribed empirical
antimicrobial regimen
l swab and tissue sample in agreement on whether or not pathogens are covered by the prescribed
empirical antimicrobial regimen.
A summary of the requirement for a change in antibiotic therapy (including initiation of antibiotics) was
coded as:
l swab but not tissue sample indicates a need for change
l tissue sample but not swab indicates a need for change
l swab and tissue sample in agreement on a need for change.
Sample size
The a priori sample size of 250 patients provided the following scenario of the power available to detect a
difference in the proportion of samples in which results indicate an inappropriate empirical
antibiotic regimen:
l 80% power to detect a difference of 5.5%, with a discordance of 10% (overall proportion of sample
pairs whose results lead to a differing decision). For example, this assumed that the proportion of
results from one sample (swab or tissue) indicating an inappropriate empirical antibiotic regimen is
2.25%, versus 7.75% in the corresponding paired sample.
Two further subsamples of 30 patients (based on feasibility) were randomly selected from the main
substudy to provide data to assess the inter- and intrarater reliability of the reviewers in an exploratory
manner. A sample size was selected based on the general rule of thumb that it takes at least 30 patients
to estimate a parameter (the κ-statistic).82,83 This number of samples also prevented overburdening
reviewers with additional vignettes to those in the main clinical review.
Patient population
The clinical review population consisted of the sample of patients whose antibiotic regimen and
microbiology results underwent review by the clinical panel. The clinical panel were all principal
investigators on the CODIFI study and all had prescribing rights.
Analysis
Main substudy
Summaries were generated for each sample on whether pathogens that were or were not covered by the
empirical antimicrobial regimen were identified and on whether or not a change/initiation in therapy was
required. McNemar’s test was used to identify if one sample identified significantly more patients requiring
a change/initiation in therapy.
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Multinomial regression analysis was conducted (in which baseline factors were included as a single fixed
effect) to evaluate the association between baseline factors on the requirement for a change/initiation of
therapy (i.e. swab and tissue sample in agreement on change/initiation in therapy, etc.). Baseline factors
to determine whether or not agreement on the requirement for a change in therapy (including initiation
of antibiotic therapy) was influenced by any of the specified covariates were type of ulcer (ischaemic,
neuroischaemic/neuropathic); Wagner ulcer grade (1–5); recent receipt of systemic or topical antimicrobial
therapy or dressing; and wound duration. Owing to the wound duration being highly positively skewed,
this factor was assessed in two ways: (1) logarithm of wound duration on the continuous scale;
and (2) dichotomised at the median of 56 days (8 weeks).
A term for reviewer was included in the model as a random effect (regardless of significance) to allow for
additional variability in outcome by reviewer and for estimates of the effect of baseline factors without
directly requiring the estimation of individual reviewer effects. The impact of centre on agreement was also
investigated in the model; however, it was not included in the model alongside reviewer owing to the
large number of degrees of freedom each category required.
Multiple imputation was used to handle missing data,76 thereby allowing inclusion of the 21 (8.5%)
patients with missing data for at least one candidate baseline factor. (For the pattern and extent of missing
data, see Tables 81 and 82.) The outcome and all baseline covariates (including type of ulcer, Wagner ulcer
grade, recent systemic or topical antimicrobial therapy or dressing, wound duration) to be considered in
the regression analyses were included in the MI models alongside centre. A total of 10 imputations were
made using the MCMC method77 with multiple chains, initial values from the EM algorithm, 200 burn-in
iterations and the assumption of normality for baseline factors with missing data (thus, imputations were
made on a continuous scale).71 For dichotomous factors, imputations were not restricted for ‘implausible
values’ and, therefore, continuous imputations were rounded to plausible values for the dichotomous
factor.78 This method was used as the pattern of missing data was arbitrary and non-monotone.
Model fit statistics were compared between models with and without each baseline factor as a fixed
effect. A chi-squared test (with degrees of freedom equal to the reduction in the degrees of freedom
between each model) was used to test whether or not the reduction in the –2 log-likelihood between each
model suggested a significant improvement in model fit.
For the 10 imputed data sets, the odds ratios generated through the regression analyses were combined
using Rubin’s rules;79 therefore, reported estimates reflect the average of estimates across the imputed
data sets and estimated standard errors include variability across the imputed sets as well as the usual
uncertainty in parameter estimates. The mean change in –2 log-likelihood was used to calculate the
overall p-value.
Inter- and intrarater reliability substudy
Summaries were generated to compare the results of sample reviews by different reviewers, and from one
time point to another, to assess inter- and intrarater reliability.
As each of the inter-rater reliability validation samples were not reviewed by the same two reviewers, the
κ-statistic is not appropriate. Instead, samples were each reviewed by two reviewers from a set of multiple
reviewers and Krippendorff’s alpha reliability estimate84 is reported (with 95% CIs produced through
bootstrapping with 2000 samples), which is applicable to any number of reviewers and where there are
incomplete data (samples were not reviewed by all reviewers). Krippendorff’s alpha ranges from 0.00 to
1.00 and, for interpretation, Krippendorff states that ‘It is customary to require α ≥ 0.800. Where tentative
conclusions are still acceptable, α≥ 0.667 is the lowest conceivable limit’.84,85 The κ-statistic is reported
as a sensitivity analysis and to provide continuity with results from the main review and intrarater
test–retest validation.
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Similarly, the intrarater test–retest validation was not undertaken by a single reviewer; however, we were
not interested in the differences between reviewers here, but rather we wished to obtain an estimate of
within-reviewer reliability and so the κ-statistic is reported.
Sample pairs were further coded as (1) reviewers agree on requirement for a change in therapy for both
swab and tissue sample; (2) reviewers disagree on requirement for a change in therapy for both swab and
tissue sample; (3) reviewers disagree on requirement for a change in therapy for swab but not tissue
sample; and (4) reviewers disagree on requirement for a change in therapy for tissue but not swab sample.
The proportion of pairs within each group was reported.
Results
The clinical panel review involved a total of 13 reviewers and sample results from 250 patients.
Of the 250 patients whose microbiology results were included in the clinical review, 30 were also used as
an inter-rater ‘validation’ sample to assess the reliability between reviewers, and another 30 were used
as an intrarater ‘validation’ sample to assess reliability within reviewers (i.e. comparing their responses on
the same data on two different occasions). This corresponded to a total of 310 paired patient vignettes
reviewed (310 swab sample and 310 tissue samples). Three patients were excluded from the evaluable
clinical review population: one from batch 1, as the patient was subsequently found to have a protocol
deviation for which their swab sample was not sent to the laboratory; and two from batch 2, as a result of
missing responses from reviewers. Therefore, a total of 247 patients were included in the evaluable clinical
review population, corresponding to 307 paired patient vignettes across the main study and the inter- and
intrarater reliability substudies. Figure 12 presents a diagram of the process, the number of patient
vignettes and the number of reviewers involved in the clinical review. Patterns of missing data and samples
of patient vignettes are presented in Appendix 2.
Reviewers were each sent between 13 and 31 paired patient vignettes, provided in two batches, each
consisting of two rounds (in order to separate vignettes from patients swab and tissue samples).
Table 33 presents a summary of all the reviewers involved in the clinical review and the number of patients
whose vignettes (pairs of vignettes) were reviewed. This includes those forming the main clinical review
sample used to address the comparison of the appropriateness of the empirical antibiotic regimen between
swab and tissue samples and also the additional inter- and intrarater validation samples.
Summaries of the appropriateness of empirical antibiotic regimen
Pathogens identified in the laboratory report that are not covered by the
prescribed antimicrobial regimen
As presented in Table 34, reviewers concluded that for 103 (41.7%) patients, the empirical antibiotic
regimen would not cover the pathogens reported from the swab sample results and that for 131 (53%)
patients the empirical antibiotic regimen would not cover the pathogens reported from the tissue sample.
Note that this includes 24 patients for whom no empirical antibiotic therapy had been prescribed; in these
cases, clinicians had (presumably) elected to wait for results from the swab and/or tissue sample before
prescribing an antibiotic regimen. The overall agreement for whether the swab or tissue sample results
suggested that the empirical antibiotic regimen was sufficient to cover the range of pathogens reported
within each sample and their corresponding antibiotic sensitivities was 71.7%. Discordance was observed
for 49 (19.8%) patients, for whom the tissue sample results suggested that the empirical antibiotic
regimen did not cover the pathogens reported, whereas the swab sample results did. Furthermore, in 21
(8.5%) patients, the swab sample results suggested that the empirical antibiotic regimen did not cover the
pathogens reported, whereas the tissue sample results did.
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Clinical review population n = 250
Batch 1: clinical review samples
200 patient vignettes
Generated for the first 200 registered patients
198 patient vignettes
Sent to 15 reviewers (13–14 each)
39 patients excluded owing to lack of
response from three reviewers
One patient excluded as subsequently found to have a 
protocol deviation (swab not processed by laboratory)
159 patient vignettes
Returned by 12 reviewers
Two patients excluded owing
to incomplete review
Two patients excluded owing 
to protocol deviation (swab
and currettage sample lost,
swab sample lost)
Clinical review sample
91 patient vignettes sent to 
nine reviewers (9–13 each)
Inter-rater sample
30 patient vignettes from
batch 1 (nine reviewers, 2–5
each) sent and returned by
nine different reviewers
(three to four each)
Inter-rater sample
30 patient vignettes from
batch one resent and 
returned by seven of the 
same reviewers
(four to five each)
198 patient vignettes sent to 15 reviewers
(13–14 each)
Batch 2: clinical review, inter- and intrarater samples
151 patient vignettes sent to nine reviewers
(16–17 each, eight reviewers from batch 1 and 
one new reviewer)
Overall
307 patient vignettes (247 unique 
patient vignettes returned by reviewers, 
each reviewing 13–31)
Evaluable clinical review population
247 patient vignettes 
from 13 reviewers (13–24 each)
  52 new
  39 re-allocated 
  (from batch 1)
   •
   •
FIGURE 12 Diagram of the clinical review process, population and reviewers.
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TABLE 33 Summary of reviewers by the number of patient vignettes reviewed for the main clinical review and inter- and intrarater validation samples from the evaluable
clinical review sample
Reviewer
Batch 1 Batch 2 Overall
Clinical reviewa (inter-rater
reviewer 1) Total
Clinical
reviewa
Inter-rater
reviewer 2 Intrarater Total
Clinical review (inter-rater
reviewer 1)
Inter-rater
reviewer 2 Intrarater Total
Ab 13 (4) 13 13 (4) 13
B 13 (2) 13 9 3 5 17 22 (2) 3 5 30
Cb 13 (5) 13 13 (5) 13
Dc 13 4 17 13 4 17
Eb 14 14 14 14
F 13 13 9 3 4 16 22 3 4 29
G 14 (4) 14 10 3 4 17 24 (4) 3 4 31
H 13 (2) 13 8d 4 4 16 21 (2) 4 4 29
I 13 (3) 13 10 3 4 17 23 (3) 3 4 30
J 13 (4) 13 9 3 5 17 22 (4) 3 5 30
Kb 13 (3) 13 13 (3) 13
L 13 (3)d 13 11d 4 15 24 (3) 4 28
M 13 13 10 3 4 17 23 3 4 30
Total 158 158 89 30 30 149 247 30 30 307
a Main clinical review sample.
b Batch 1 only.
c Batch 2 only.
d One patient vignette was excluded as a result of subsequent deviation/incomplete review.
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Table 35 summarises the presence of pathogens in the laboratory report that were or were not covered by the
empirical antimicrobial regimen depending on whether or not there was a prescribed antimicrobial regimen.
Change/initiation in therapy required?
Reviewers’ responses in relation to the need for a change/initiation in therapy depending on results from
swab or tissue sample are cross-tabulated in Table 36. Reviewers concluded that for 132 (53.4%) patients,
results from the swab or tissue sample suggested that a change/initiation in therapy was required. For 110
(44.5%) patients, a change from the empirical antibiotic regimen would be required based on the results
of the tissue sample, whereas in 88 (35.6%) patients, a change from the empirical antibiotic regimen
would be required based on the results of the swab sample. There was, therefore, a discordance for 66
(26.7%) patients over whether the swab or tissue sample results suggested the requirement for a change
in patients’ empirically prescribed antibiotic regimen. For 22 (8.9%) patients, the tissue sample results
suggested no change, whereas the swab sample results suggested that a change was required, and there
were 44 (17.8%) patients for whom the swab sample results suggested no change, whereas the tissue
sample results suggested that a change/initiation was required.
TABLE 34 Cross-tabulation of the presence of pathogens in the laboratory report that were or were not covered
by the prescribed antimicrobial regimen
Swab results
Tissue results, n (%)
Total, n (%)Covered Not covered
Covered 95 (38.5) 49 (19.8) 144 (58.3)
Not covered 21 (8.5) 82 (33.2) 103 (41.7)
Total 116 (47.0) 131 (53.0) 247 (100.0)
TABLE 35 Cross-tabulation of the presence of pathogens in the laboratory report that were or were not covered
by the prescribed antimicrobial regimen according to whether or not there was a prescribed antimicrobial regimen
Patients on an empirical antimicrobial
regimen
Patients not on an empirical antimicrobial
regimen
Tissue results, n (%) Total, n (%) Tissue results, n (%) Total, n (%)
Swab results Covered Not covered Covered Not covered
Covered 93 (41.7) 47 (21.1) 140 (62.8) 2 (8.3) 2 (8.3) 4 (16.7)
Not covered 20 (9.0) 63 (28.3) 83 (37.2) 1 (4.2) 19 (79.2) 20 (83.3)
Total 113 (50.7) 110 (49.3) 223 (100.0) 3 (12.5) 21 (87.5) 24 (100.0)
TABLE 36 Cross-tabulation of the requirement for a change/initiation in therapy
Swab results
Tissue results, n (%)
Total, n (%)
Change/initiation to
therapy required
No change/initiation to
therapy required
Change/initiation to
therapy required
66 (26.7) 22 (8.9) 88 (35.6)
No change/initiation
to therapy required
44 (17.8) 115 (46.6) 159 (64.4)
Total 110 (44.5) 137 (55.5) 247 (100.0)
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Table 37 summarises the requirement for a change/initiation in therapy in accordance with whether or not
there was a prescribed empirical antimicrobial regimen.
Based on the requirement for a change/initiation in therapy, Table 38 presents associated statistics and
McNemar’s test for a difference between samples.
There was 73.3% overall agreement on the requirement for a change/initiation in therapy between swab
and tissue samples, with a kappa value of 0.45 (95% CI 0.34 to 0.56), which represents moderate
agreement.70 The PABAK of 0.47 similarly represents moderate agreement after adjusting the kappa for
imbalances caused by differences in the prevalence [the 132 (53.4%) patients for whom swab or tissue
sample results suggested a change/initiation in therapy] and bias.
TABLE 37 Cross-tabulation of the requirement for a change/initiation in therapy according to whether or not there
was a prescribed antimicrobial regimen
Swab results
Patients on an empirical
antimicrobial regimen
Patients NOT on an empirical
antimicrobial regimen
Tissue results, n (%) Total, n (%) Tissue results, n (%) Total, n (%)
Change/
initiation
to therapy
required
No change/
initiation
to therapy
required
Change/
initiation
to therapy
required
No change/
initiation
to therapy
required
Change/initiation to
therapy required
50 (22.4) 21 (9.4) 71 (31.8) 16 (66.7) 1 (4.2) 17 (70.8)
No change/initiation to
therapy required
39 (17.5) 113 (50.7) 152 (68.2) 5 (20.8) 2 (8.3) 7 (29.2)
Total 89 (39.9) 134 (60.1) 223 (100.0) 21 (87.5) 3 (12.5) 24 (100.0)
TABLE 38 Statistics associated with the requirement for a change/initiation in therapy
Statistic Overall
Patients on an empirical
antimicrobial regimen
Patients not on an empirical
antimicrobial regimen
Overall prevalence of
required change/initiation, %
53.4 49.3 91.7
Overall agreement, % 73.3 73.1 75.0
Unadjusted kappa
Value (95% CI) 0.45 (0.34 to 0.56) 0.42 (0.30 to 0.54) 0.27 (–0.13 to 0.68)
Asymptotic standard error 0.06 0.06 0.21
PABAK 0.47 0.46 0.50
Difference in percentage of patients requiring a change/initiation in therapy (tissue – swab)
Value (95% CI) 8.9% (2.6% to 15.3%) 8.1% (1.3% to 14.8%) 16.7% (–2.2% to 35.5%)
McNemar’s testa
Degrees of freedom 1 1 1
Asymptotic p-value 0.0068 0.0201 0.1025
Exact p-value 0.0092 0.0273 0.2188
a The McNemar’s asymptotic p-value is valid when all cell counts are ≥ 5; where this is not the case, the exact p-value
is appropriate.
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There was significant evidence of a difference in the proportion of patients with a required change/
initiation in therapy in the two samples (p-value= 0.0068), with the requirement for change reported in
8.9% more tissue samples than swab samples (95% CI 2.6% to 15.3%).
Overall summary of the requirement for a change/initiation in therapy
Table 39 presents a summary of the requirement for a change/initiation in therapy by specimen type
for each patient, based on the outcomes for the multinomial logistic regression modelling. For almost
three-quarters (73.3%) of patients, the reviewer agreed on the need for a change/initiation in therapy or
not, based on the results of the swab and tissue sample. However, for 17.8% of patients, the reviewer
found that the tissue sample results suggested the need for a change to patients’ empirical antibiotic
regimen, whereas the swab sample results did not. Conversely, in 8.9% of patients, the reviewer found
that the swab sample results suggested the need for a change to patients’ empirical antibiotic regimen,
whereas the tissue sample results did not.
Table 40 presents the summary of the requirement for a change/initiation in therapy by whether the
patient was on an empirical prescribed antibiotic regimen or not, type of ulcer, ulcer grade, previous
antibiotic therapy (prior to initiation of empirical antibiotic regimen), presence of antimicrobial dressing or
agent, wound duration and reviewer. The clinical review panel was twice as likely to conclude that a
change in therapy was required based on tissue samples (vs. swabs) rather than on swab samples
(vs. tissue samples).
Association between baseline factors on extent of agreement on the
requirement for a change/initiation in therapy
Multinomial regression modelling with a random effect for reviewers (and MI to allow for missing data)
was used to assess whether extent of agreement, based on the overall summary of the requirement for a
change or initial in therapy, was influenced by the pre-specified baseline covariates (Table 41).
None of the baseline factors was found to be significant at the 10% level. Therefore, there was no
evidence of an association between any of baseline factors on the extent of agreement on the requirement
for a change/initiation in therapy between swab and tissue samples.
The overall test of the covariance parameter based on the change in likelihood for the model with and
without the random intercept for reviewer was not statistically significant (p-value= 0.5937). However,
it remains important to account for the variation in the data attributable to the reviewer, and, therefore,
the random effect for reviewer remained in the null model during testing of covariate effects. Figure 13
displays the ranked predicted random reviewer effect for the null model, for outcome ‘2 – Tissue but not
Swab indicates change/initiation in therapy’ compared with the reference ‘3 – Swab and Tissue agree on
change/initiation in therapy’.
The figure presents the ranked predicted random reviewer effect for the null model. Note that the
magnitude of the predicted reviewer effects are comparable to the natural log of the odds presented in
Table 41. For example, for the tissue but not the swab indicating a change in therapy versus the swab and
TABLE 39 Summary of the requirement for a change/initiation in therapy
Requirement for a change/initiation in therapy Total, n (%)
1: Swab but not tissue indicates change/initiation in therapy 22 (8.9)
2: Tissue but not swab indicates change/initiation in therapy 44 (17.8)
3: Swab and tissue agree on change/initiation in therapy 181 (73.3)
Total 247 (100)
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TABLE 40 Summary of the requirement for a change/initiation in therapy by patient characteristics
Patient
characteristics
Swab but not
tissue indicates
change/initiation in
therapy (N= 22)
Tissue but not
swab indicates
change/initiation in
therapy (N= 44)
Swab and tissue agree on
change/initiation in therapy
(N= 181)
Total
(N= 247)
On an empirical antibiotic regimen, n (%)
Yes 21 (9.4) 39 (17.5) 163 (73.1) 223 (90.3)
No 1 (4.2) 5 (20.8) 18 (75.0) 24 (53.9)
Type of ulcer, n (%)
Any ischaemia
(± neuropathy)
13 (10.5) 23 (18.5) 88 (71.0) 124 (50.2)
Neuropathic only 9 (7.3) 21 (17.1) 93 (75.6) 123 (49.8)
Ulcer grade, n (%)
Grade 1 4 (4.7) 14 (16.5) 67 (78.8) 85 (34.4)
Grade 2 11 (12.9) 14 (16.5) 60 (70.6) 85 (34.4)
Grade 3, 4 or 5 7 (9.1) 16 (20.8) 54 (70.1) 77 (31.2)
Wound duration, n (%)
< 56 days 8 (7.3) 18 (16.5) 83 (76.1) 109 (44.1)
≥ 56 days 14 (10.2) 25 (18.2) 98 (71.5) 137 (55.5)
Missing 0 (0.0) 1 (100.0) 0 (0.0) 1 (0.4)
Previous antibiotic therapy, n (%)
Yes 11 (9.3) 22 (18.6) 85 (72.0) 118 (47.8)
No 10 (8.8) 19 (16.7) 85 (74.6) 114 (46.2)
Missing 1 (6.7) 3 (20.0) 11 (73.3) 15 (6.1)
Antimicrobial dressing, n (%)
Yes 14 (8.5) 32 (19.5) 118 (72.0) 164 (66.4)
No 8 (10.3) 12 (15.4) 58 (74.4) 78 (31.6)
Missing 0 (0.0) 0 (0.0) 5 (100.0) 5 (2.0)
TABLE 41 Multinomial regression analyses for individually fitted baseline factors with random reviewer effect
Baseline characteristics
‘Swab and tissue agree on
requirement for change/initiation
in therapy’ vs. a change/initiation
in therapy indicated by Odds ratioa (95% CI) AICb p-valuec
Null model 376.64
Patient on an empirical antimicrobial regimen: yes vs. no 379.68 0.6203
1: Swab but not tissue 2.32 (0.29 to 18.48)
2: Tissue but not swab 0.86 (0.30 to 2.50)
Ulcer type: any ischaemia (± neuropathy) vs. neuropathic only 379.68 0.6205
1: Swab but not tissue 1.53 (0.62 to 3.77)
2: Tissue but not swab 1.16 (0.59 to 2.25)
Ulcer grade 380.12 0.3408
Grade 2 vs. grade 1 1: Swab but not tissue 3.07 (0.92 to 10.22)
2: Tissue but not swab 1.11 (0.48 to 2.54)
continued
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TABLE 41 Multinomial regression analyses for individually fitted baseline factors with random reviewer effect
(continued )
Baseline characteristics
‘Swab and tissue agree on
requirement for change/initiation
in therapy’ vs. a change/initiation
in therapy indicated by Odds ratioa (95% CI) AICb p-valuec
Grade 3/4/5 vs. grade 1 1: Swab but not tissue 2.17 (0.60 to 7.86)
2: Tissue but not swab 1.43 (0.63 to 3.22)
Pre-sampling antibiotic therapy: yes vs. nod 380.47 0.9218
1: Swab but not tissue 1.07 (0.43 to 2.65)
2: Tissue but not swab 1.08 (0.54 to 2.15)
Antimicrobial dressing: yes vs. nod 379.97 0.7171
1: Swab but not tissue 0.85 (0.34 to 2.15)
2: Tissue but not swab 1.29 (0.62 to 2.71)
Wound duration: < 56 days vs. ≥ 56 daysd 379.69 0.6211
1: Swab but not tissue 0.67 (0.27 to 1.69)
2: Tissue but not swab 0.82 (0.41 to 1.64)
Log-wound duration (continuous)d 377.93 0.2576
1: Swab but not tissue 1.23 (0.90 to 1.66)
2: Tissue but not swab 1.15 (0.91 to 1.45)
AIC, Akaike information criterion.
a Smaller is better.
b Based on the reduction in –2 log-likelihood from the null model.
c An odds ratio of > 1.0 indicates an increase in the odds of the specified outcome (change/initiation in therapy indicated
by swab but not tissue, or by tissue but not swab) compared with the reference group (swab and tissue agree on
change/initiation in therapy) for the specified factors.
d Factors with missing data.
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FIGURE 13 Plot of predicted random reviewer effect in the null model for outcome: tissue but not swab indicates
change/initiation in therapy.
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tissue agreeing on the requirement to change therapy for patients on an empirical antibiotic regimen
against those who are not, the odds ratio is 0.86, with a log-odds of –0.15.
Validation of reviewers’ assessments of appropriateness of empirical
antibiotic regimen: inter-rater reliability
A total of 12 of the 13 reviewers were involved in the review of patients’ samples contributing to the
inter-rater reliability validation at varying levels, providing at least one of the following: a review of initial
patient vignettes for the main clinical review and inter-rater reliability by another reviewer only (three
reviewers); a review of a copy of initial patient vignettes for inter-rater reliability only (three reviewers) or
both (six reviewers) (see Table 33).
Table 42 presents a cross-tabulation of reviewers’ agreement on whether or not there were pathogens
present in swab or tissue results that were not covered by the empirically prescribed antibiotic regimen.
Within swab samples, reviewers agreed for 21 (70%) patients, and reviewers agreed for 24 (80%) patients
based on their tissue results.
Cross-tabulations for reviewers’ responses in relation to the requirement for a change/initiation in antibiotic
regimen based on swab and tissue sample results are presented in Table 43 and corresponding agreement
statistics are presented in Table 44. Based on patients’ swab samples, reviewers agreed for 21 (70%)
patients, and based on patients’ tissue sample results, reviewers agreed for 25 (83.3%) patients.
Krippendorff’s alpha reliability estimate of 0.35 (95% CI 0.16 to 0.55) for reviewers’ agreement for swab
samples represents fair agreement;70 however, this falls well below the conceivable limit of 0.667 proposed
by Krippendorff. For reviewers’ agreement for tissue samples, the kappa value of 0.66 (95% CI 0.51 to
0.80) represents substantial agreement70 and is in line with Krippendorff’s conceivable limit.
TABLE 42 Cross-tabulation of reviewers’ agreement in the presence of pathogens in the laboratory report that
were or were not covered by the empirical antimicrobial regimen by swab and tissue samples
Swab, n (%) Tissue, n (%)
Reviewer 2 Reviewer 2
Reviewer 1 Covered Not covered Total Covered Not covered Total
Covered 13 (43.3) 4 (13.3) 17 (56.7) 11 (36.7) 3 (10.0) 14 (46.7)
Not covered 5 (16.7) 8 (26.7) 13 (43.3) 3 (10.0) 13 (43.3) 16 (53.3)
Total 18 (60.0) 12 (40.0) 30 (100.0) 14 (46.7) 16 (53.3) 30 (100.0)
TABLE 43 Cross-tabulation of reviewers’ agreement on the requirement for a change/initiation in therapy by swab
and tissue samples
Swab, n (%) Tissue, n (%)
Reviewer 2 Reviewer 2
Reviewer 1 Change/
initiation
to therapy
required
No change/
initiation
to therapy
required
Total Change/
initiation
to therapy
required
No change/
initiation
to therapy
required
Total
Change/initiation to
therapy required
6 (20.0) 6 (20.0) 12 (40.0) 10 (33.3) 3 (10.0) 13 (43.3)
No change/initiation
to therapy required
3 (10.0) 15 (50.0) 18 (60.0) 2 (6.7) 15 (50.0) 17 (56.7)
Total 9 (30.0) 21 (70.0) 30 (100.0) 12 (40.0) 18 (60.0) 30 (100.0)
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Table 45 further compares reviewers’ opinions on the requirement for a change/initiation in therapy by
linking reviewers’ responses for swab and tissue results from the same patients. For the largest proportion
of patients, 19 (63.3%) patients, reviewers agreed on the requirement for a change/initiation in therapy
for both swab and tissue sample results. However, for three (10%) patients, reviewers disagreed on the
requirement for a change/initiation in therapy for both swab and tissue sample results; in six (20%)
patients, reviewers disagreed on the requirement for a change/initiation in therapy for swab but agreed for
tissue sample results; and in two (6.7%) patients, reviewers disagreed on the requirement for a change/
initiation in therapy for tissue but agreed for swab sample results.
Validation of reviewers’ assessment of appropriateness of empirical
antibiotic regimen: intrarater reliability
A total of 7 of the 13 reviewers were involved in the review of patients’ samples that contributed to the
intrarater reliability validation, each re-reviewing an additional four to five patient vignettes during the
second batch of reviews.
Table 46 presents a cross-tabulation of reviewers’ agreement on whether or not there were pathogens
present on the swab or tissue results that were not covered by the empirical antibiotic regimen given to
the patient. For the swab samples, reviewers agreed on re-review in 26 (86.7%) patients; similarly, they
agreed on re-review for the tissue samples in 26 (86.7%) patients.
Cross-tabulations for reviewers’ responses in relation to the requirement for a change/initiation in antibiotic
regimen based on swab and tissue sample results are presented in Table 47 and corresponding agreement
statistics are presented in Table 48. Based on patients’ swab samples, reviewers agreed on re-review for
27 (90%) patients, and based on patients’ tissue sample results, reviewers agreed on re-review for 24 (80%)
patients. The κ-statistic of 0.77 (95% CI 0.53 to 1.00) for reviewers’ agreement on re-review for swab
samples represents substantial agreement, as does the PABAK of 0.8 after adjusting the kappa for imbalances
caused by differences in prevalence and bias.70 For reviewers’ agreement for tissue samples on re-review, the
κ-statistic of 0.59 (95% CI 0.29 to 0.88) represents moderate agreement,70 as does the PABAK of 0.60.
TABLE 44 Agreement and Krippendorff’s alpha reliability estimate associated with reviewers’ agreement on the
requirement for a change/initiation in therapy
Sensitivity analysis
Overall
agreement
Krippendorff’s
alpha reliability
estimate (95% CI)
Unadjusted
kappa (95% CI)
Unadjusted
kappa ASE PABAK
Swab samples (n= 30) 70.0% 0.35 (0.16 to 0.55) 0.35 (0.01 to 0.69) 0.17 0.40
Tissue samples (n= 30) 83.3% 0.66 (0.51 to 0.80) 0.66 (0.38 to 0.93) 0.14 0.67
ASE, asymptotic standard error.
TABLE 45 Summary of reviewers’ agreement on the requirement for a change/initiation in therapy
Reviewers’ agreement Total, n (%)
Reviewers agree on requirement for a change/initiation in therapy for both swab and tissue sample 19 (63.3)
Reviewers disagree on requirement for a change/initiation in therapy for both swab and tissue sample 3 (10.0)
Reviewers disagree on requirement for a change/initiation in therapy for swab but not tissue sample 6 (20.0)
Reviewers disagree on requirement for a change/initiation in therapy for tissue but not swab sample 2 (6.7)
Total 30 (100)
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Table 49 further compares reviewers’ re-reviews on the requirement for a change/initiation in therapy by
linking responses for swab and tissue results from the same patients. For 21 (70.0%) patients (the largest
proportion), the reviewer agreed on re-review on the requirement for a change/initiation in therapy for
both swab and tissue sample results. However, for three (10%) patients, the reviewer disagreed on the
requirement for a change/initiation in therapy for both swab and tissue sample results on re-review; and in
six (20%) patients, the reviewer disagreed on the requirement for a change/initiation in therapy for swab
but agreed for tissue sample results on re-review.
TABLE 46 Cross-tabulation of reviewer agreement in the presence of pathogens in the laboratory report that were
or were not covered by the empirical antimicrobial regimen by swab and tissue samples (intrarater reliability)
First review
Swab, n (%) Tissue, n (%)
Second review Total Second review Total
Covered Not covered Covered Not covered
Covered 17 (56.7) 1 (3.3) 18 (60.0) 14 (46.7) 1 (3.3) 15 (50.0)
Not covered 3 (10.0) 9 (30.0) 12 (40.0) 3 (10.0) 12 (40.0) 15 (50.0)
Total 20 (66.7) 10 (33.3) 30 (100.0) 17 (56.7) 13 (43.3) 30 (100.0)
TABLE 47 Cross-tabulation of reviewer agreement on the requirement for a change/initiation in therapy by swab
and tissue samples (intrarater reliability)
First review
Swab, n (%) Tissue, n (%)
Second review
Total
Second review
Total
Change/
initiation to
therapy
required
No change/
initiation to
therapy
required
Change/
initiation to
therapy
required
No change/
initiation to
therapy
required
Change/initiation to
therapy required
8 (26.7) 3 (10.0) 11 (36.7) 9 (30.0) 4 (13.3) 13 (43.3)
No change/initiation
to therapy required
0 (0.0) 19 (63.3) 19 (63.3) 2 (6.7) 15 (50.0) 17 (56.7)
Total 8 (26.7) 22 (73.3) 30 (100.0) 11 (36.7) 19 (63.3) 30 (100.0)
TABLE 48 Agreement and κ-statistics associated with reviewer agreement on the requirement for a
change/initiation in therapy (intrarater reliability)
Label
Overall
agreement, %
Unadjusted
κ-statistics (95% CI)
Unadjusted
κ-statistic ASE PABAK
Swab samples (n= 30) 90.0 0.77 (0.53 to 1.00) 0.12 0.80
Tissue samples (n= 30) 80.0 0.59 (0.29 to 0.88) 0.15 0.60
ASE, asymptotic standard error.
TABLE 49 Summary of reviewers’ agreement on the requirement for a change/initiation in therapy
(intrarater reliability)
Summary of reviewers’ agreement Total, n (%)
Reviewer agreed on requirement for a change/initiation in therapy for both swab and tissue sample 21 (70.0)
Reviewer disagreed on requirement for a change/initiation in therapy for swab but not tissue sample 3 (10.0)
Reviewer disagreed on requirement for a change/initiation in therapy for tissue but not swab sample 6 (20.0)
Total 30 (100)
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Discussion
This substudy set out to investigate the potential clinical impact of providing either a swab result or a tissue
result to a clinician who was tasked with making a decision on antibiotic therapy for a patient with an
infected DFU. The previous chapter discussed the finding that tissue samples usually identified more
pathogens than swabs, but we wanted to determine if this equated to providing more clinically useful
information. We therefore assessed if there was a difference in a swab sample compared with a tissue
sample for providing information indicating that empiric antimicrobial therapy was adequate and if the
reports from swab or tissues indicated whether or not a change in antimicrobial therapy was needed
(including the need to initiate antibiotic). In order to understand the reliability of the data collected
through the panel review, we also assessed the inter- and intrarater reliability for the clinical assessors
making these judgements. We are not aware of any previous studies that have attempted to understand
the potential clinical impact of differences in microbiology reports by using clinical vignettes in this way.
We found that one in five patients had swab results that indicated that all the pathogens were covered,
but the tissue results indicated that all pathogens were not covered by the empirical antibiotic regimen.
Correspondingly, clinicians reported that in nearly one in five patients (17.8%), the swab results indicated
that no change in therapy was required, whereas the tissue results did suggest that a change in therapy
was required. In a smaller number of cases (8.9%), the swab results indicated that a change in therapy
was required when the tissue samples did not. These recommended changes to antibiotic regimen
(including patients who had received no antibiotics at the outset) were based only on clinical vignette
information and hence did not represent the full set of information that should be available to clinicians
when reviewing the appropriateness of antibiotic therapy, such as change in ulcer state and changes in
local and systemic findings of infection, for example.
Overall, we observed that 9% more tissue samples than swab samples indicated that a change in therapy
was required (17.8% vs. 8.9%). Therefore, if the treating clinician had the tissue sample results rather
than the swab results they would probably change the antibiotic regimen for 1 in every 11 patients. This is
a potential ‘number needed to treat differently’ of 11. If the additional cost, skill and/or discomfort
associated with tissue compared with swab sampling is perceived as modest, then for every 11 people in
whom a tissue sample is taken (rather than a swab), a different treatment decision may be taken.
The inter-rater reliability results suggested slight to modest overall agreement between different reviewers
(Krippendorff’s alpha of 0.35 and 0.66 for swab and tissue samples, respectively), indicating substantial
variability between reviewers. This emphasises the importance, therefore, of ensuring that the same
reviewer reviewed swab and tissue samples in the main clinical review.
There are a number of limitations to this work. As mentioned, we provided the reviewing clinicians with a
limited data set which did not include all the information usually available in clinical practice to evaluate
whether or not a change in antibiotic therapy was needed. We note, however, that the study also asked
reviewing clinicians to make a judgement on whether or not empiric antibiotics were appropriate, and this
judgement did not require additional clinical cues, such as ulcer status.
We provided blinded, paired information to clinicians and attempted to mask them to whether the result
came from tissue or swab samples, to prevent bias. We do not, however, know if our blinding was
successful. As tissue samples reported more pathogens, the reviewing clinicians might have guessed that
longer reports (with more isolates) came from tissue samples and shorter reports from swab samples.
Given the increased attention on providing appropriate antibiotic therapy, these results may indicate a
potentially higher rate of change in therapy (one would hope, but cannot guarantee, from broad-spectrum
to targeted narrow-spectrum antimicrobials) following collection of a tissue result. It is not known,
however, if a clinician would always initiate the change from broad- to narrow-spectrum antibiotics if
an ulcer is improving, or what factors would prompt such a change (such as audit of prevalence of
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broad- and narrow-spectrum regimens). Identifying additional pathogens might lead to an increased used
of broad-spectrum antimicrobials, thus threatening best practice antibiotic stewardship.
The current data also do not tell us anything about whether or not resampling after initiation of empiric
antibiotics is needed to tailor the antibiotic regimen post receipt of the microbiology report. If a change/
initiation in therapy is indicated or required, then should a patient’s ulcer be recultured when microbiology
results are returned?
The fact that there were 9% of patients in whom swab results indicated a change/initiation in therapy
when tissue results did not means that choosing either approach will potentially miss microbiology
information that might lead to a change/initiation in therapy. Therefore, each method provides
complementary information and, in certain circumstances, it might be appropriate to use both methods,
for example if empiric therapy has not resulted in improvement.
It also needs to be borne in mind that tissue sampling may not be appropriate in all clinical cases or
settings. In some patients, for example those with clotting disorders at high risk of bleeding, then the
risk/benefit of tissue sampling over swabbing will differ from other patients.
Further work would be needed to determine whether clinical review of the swab and tissue results in these
patients actually led to a real change in antibiotic regimen, rather than these ‘virtual panel’ results.
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Chapter 4 A pilot comparative study of plating
and culture techniques versus polymerase
chain reaction
Introduction
Traditional methods of pathogen detection, such as microscopy of stained smears, plating specimens for
culture and performing biochemical tests to identify the isolated organism, have major limitations.86–89
These include the inability to culture some pathogens, a low sensitivity of pathogen detection,86–88 a lack of
diagnostic specificity89 and the length of time and cost for processing.89 Furthermore, in patients receiving
antibiotic therapy, cultures may be falsely negative. Recent years have seen the advent of novel molecular
(genotypic) methods, such as PCR, which have transformed the characterisation of organisms and
diagnosis.52 Traditional (phenotypic) culture methods may not identify minor, although possibly important,
components of a mixed bacterial population; molecular methods provide an alternative with increased
sensitivity (partly related to their ability to retrieve information on organisms that do not survive transport
to the laboratory or are difficult to culture) and reduced time to identify the pathogens.52,53,86,87,89
A study by Davies et al.86 compared bacterial microflora of 18 (8 healing and 10 non-healing) chronic
venous leg ulcers identified by using plating/culture methodologies and by PCR techniques. Although
culture-based methods revealed that the majority of both wound types carried the aerobes Staphylococcus
and Pseudomonas spp. (89% and 80% in healing and non-healing ulcers, respectively), PCR also identified
strains not detected by plating/culture methods. The results of this86 study are consistent with a previous
study87 in which the molecular approaches demonstrated significantly greater bacterial diversity of
the wound microflora than that revealed by plating/culture methods. Thomsen et al.90 also compared the
plating/culture and PCR techniques in 14 chronic venous ulcers. They reported that PCR identified flora
not found by traditional methods. Importantly, they found variation in the flora within the wound, such
that a single sample may not represent the biome adequately. Similarly, other studies have consistently
demonstrated the conflicting results of plating/culture methods and molecular techniques, the latter
being more sensitive than the former.91–93 More importantly, application of the molecular methods in
guiding treatment enables a targeted approach to wound care, which has the potential to improve
patient outcomes.94–96
Ideally, wounds would be treated with antibiotics only after receiving results from microbial analysis, in
order to limit overprescription and to ensure that narrow-spectrum antibiotics are used when possible.
This is, however, only possible with rapid techniques, such as PCR. Furthermore, traditional culturing
methods may be biased as a diagnostic tool as they select for easily cultured organisms, such as S. aureus,
and select against difficult to culture bacteria, such as obligate anaerobes.97 The main disadvantage of
DNA-based PCR techniques is the inability to distinguish viable DNA sequences from inactive or dead
organisms,98–100 unless supplementary methods are used.101,102
This small substudy examined the identification of pathogens present in suspected infected DFUs using
both conventional plating and culture-based techniques and PCR. This enabled us to investigate the
agreement between the two analysis techniques (i.e. whether or not organisms identified by PCR
reflected the bacterial load captured by plating/culture techniques). Moreover, we were able to obtain
further detailed information on the agreement in identification of organisms between the two
analysis techniques.
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Aims and objectives
The aim of the CODIFI PCR substudy was to examine the agreement between organisms identified by
traditional analytical techniques (plating/culture) compared with state-of-the-art-PCR molecular methods in
suspected infected DFUs.
The objectives were to:
1. compare the pathogens reported by conventional plating and culture for both swab and tissue samples
against those identified by PCR
2. compare the pathogens reported from swab and tissue samples based on PCR (alongside the culture
results as reference).
Methods
For patients included in the substudy, a second swab sample was taken and the tissue sample was cut in
two so that samples obtained using either sampling technique could be analysed using both PCR and
conventional plating/culture.
Eligibility and consent
All patients registered into the main CODIFI study were eligible and able to consent to the substudy.
Sample collection and transportation
One swab sample and half of the tissue samples taken for molecular PCR analysis, identified by study
number, patients’ date of birth and date taken, were sent by first class post at ambient temperature to
Micropathology Ltd (Coventry, UK). Upon receipt, samples were stored at –70°C. Batches were defrosted
before being processed. Further details on the methods for the PCR analysis were developed into a study
standard operating procedure.
Polymerase chain reaction analysis
A semiquantitative PCR analysis was conducted by Micropathology Ltd. This method included a reference
standard in each PCR test. The level of amplified DNA in each sample was expressed as a ratio of the
reference standard. This method enabled comparison of species prevalence across a variety of samples.
PCR analysis results provided by Micropathology Ltd contained details of pathogens detected from each of
the swab and tissue samples for those pathogens comprising at least 5% of the total microbial load within
a sample. This cut-off point was chosen to enable potentially clinical relevant pathogens to be analysed,
rather than the potentially large number of pathogens with very low prevalence that would be identified
by PCR and sequencing but not necessarily by routine culture. Reported pathogens were detailed at a mix
of the species and genus levels, and the within-sample percentage of the pathogen relative to the total
microbial load within a sample was also provided.
End points
Results were compared using conventional plating and culture versus PCR techniques for:
l the number and presence of pathogens reported via conventional plating and molecular PCR
techniques from swab samples
l the number and presence of pathogens reported via conventional plating and molecular PCR
techniques from tissue samples.
Swab versus tissue sampling:
l the number and presence of pathogens reported via molecular PCR techniques from the swab and
tissue sample.
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Statistical methods
Sample size
The pilot substudy planned to collect samples from approximately 20 patients, based on feasibility, to allow
an evaluation of the level of agreement and inform a powered, definitive study.
Patient population
The evaluable microbiology substudy population consisted of patients for whom evaluable swab and tissue
samples were available, by both plating/culture and PCR techniques, and where PCR results were also
obtainable; and written informed consent has been received, with no withdrawal of consent for the use of
their samples for research purposes.
Analysis methods
Conventional plating and culture versus molecular polymerase chain reaction techniques
An overall summary of pathogens reported using plating/culture and PCR was generated independently for
both the swab and tissue samples. Each pair of results (‘PCR’ and ‘cultured’) for both swab and tissue
samples were coded as:
l PCR and culture reports the same pathogens
l PCR reports same pathogens as culture plus extra pathogens
l culture reports same pathogens as PCR plus extra pathogens
l both culture and PCR report different pathogens (with or without overlap in pathogens found;
for example, culture reports coliforms and S. aureus and PCR reports S. aureus and E. coli).
Summaries (including cross-tabulations) on the number of pathogens reported were produced.
Swab versus tissue sampling
An overall summary of pathogens reported using PCR techniques by swab and tissue sample was
produced. Each pair of results (swab and tissue samples) was coded as follows, with corresponding codes
for the plating/culture results provided as a reference:
l swab and tissue sampling report the same pathogens
l swab reports same pathogens as tissue sampling plus extra pathogens
l tissue sampling reports same pathogens as swab plus extra pathogens
l both tissue and swab sampling report different pathogens (with or without overlap in pathogens found).
Summaries (including cross-tabulations) on the number of pathogens reported were produced.
Derivation
Derivation followed that of the main study, as detailed below.
Isolates from the plating and culture results that were considered not likely to represent pathogenic
organisms (yeasts, skin flora, normal flora, mixed flora, skin organisms, bacterial flora, enteric flora and
faecal flora) were excluded.
Given the range of taxonomic levels for reported pathogens, pathogens were primarily summarised and
included at the genus level, with the exception of S. aureus, for which the interest lay at the species level.
Pathogens reported at a taxonomic rank higher than the genus level were retained for the analysis and
included at the level reported.
The summary and number of pathogens reported per specimen were calculated independently for both
plating and culture and PCR for swab and tissue samples. Where more than one strain or species of a
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pathogen (in which we were interested in the genus level) was reported, a single pathogen at the level of
interest was retained for comparison in the summary of pathogens and the count of the number of
pathogens within the sample from the specific technique.
Results
Substudy population
A total of 14 patients from four centres were involved in the substudy; however, the evaluable
microbiology substudy population consisted of 12 patients with evaluable swab and tissue samples, by
both plating/culture and PCR techniques (Table 50). Two patients were excluded: one because both swab
and tissue samples provided to Micropathology Ltd were insufficient and a subsequent review of the
culture result for both swab and tissue sample found that no isolates had been reported in these either;
and the other because the swab sample was insufficient and subsequent review of the culture results for
both swab and tissue sample found only ‘mixed skin/normal flora’ reported from each sample, whereas
for the evaluable tissue sample sent to Micropathology Ltd PCR reported Providencia alcalifaciens.
Furthermore, there was one patient included within the evaluable microbiology substudy population,
whose second swab sample was taken after collection of the tissue sample.
Reported pathogens
Table 51 presents the groups of pathogens reported in order of overall prevalence, with pathogens
reported via PCR comprising those that made up at least 5% of the total microbial load within the sample
(reported in any one of swab or tissue sample by PCR or culture techniques).
Overall, the most prevalent pathogen was S. aureus, reported in at least one sample and for at least one
technique in six (50%) patients; Enterococcus, Finegoldia and Prevotella were reported in four (33.3%)
patients; anaerobes, Anaerococcus and Proteus in three (25%) patients; Enterobacter, Enterobacteriaceae,
Lactobacillus and Streptococcus in two (16.7%) patients; and Acinetobacter, Arthrobacter, Candida,
coliforms Corynebacterium, Fusobacterium, Helcococcus, Klebsiella, Peptoniphilus, Providencia and
Pseudomonas in one (8.3%) patient.
Conventional plating/culture versus polymerase chain reaction techniques
Table 52 presents an overall summary of pathogens reported using plating/culture and PCR. Each pair of
results (PCR and culture) for both swab and tissue samples was compared to assess if PCR and culture
report the same pathogens, if additional pathogens were reported via one technique but not the other, or
if different pathogens were reported with or without overlap. The same distribution of this response was
observed for both swab and tissue samples; however, it should be noted that these do not all correspond
to the same patient samples finding the same response for swab and tissue samples.
TABLE 50 Availability of PCR results by centre
Availability of PCR results by centre Total (N= 14)
Yes, n (%) 12 (85.7)
N00006: James Cook University Hospital 1 (8.3)
N00036: Norfolk and Norwich University Hospital 4 (33.3)
N00040: Pinderfields General Hospital 1 (8.3)
N00488: Royal Oldham Hospital 6 (50.0)
No, n (%) 2 (14.3)
N00488: Royal Oldham Hospital 2 (100.0)
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For both swab and tissue samples, the PCR and culture resulted in the reporting of the same pathogens
for four (33.3%) patients, whereas for six (50%) patients, PCR resulted in the reporting of additional
pathogens compared with the culture results. In the remaining two (16.7%) patients, different isolates
were reported via PCR and culture reports (with or without overlap), and there were no samples in which
additional pathogens were reported from the culture results.
TABLE 51 Reported pathogens (derived) for each method and sample type for patients in the PCR evaluable
population in order of overall prevalence
Pathogens
Swab, n (%) Tissue, n (%)
Overall prevalence
(N= 12), n (%)PCR (N= 12) Culture (N= 12) PCR (N= 12) Culture (N= 12)
S. aureus 5 (41.7) 5 (41.7) 4 (33.3) 5 (41.7) 6 (50.0)
Enterococcus 2 (16.7) 0 (0.0) 0 (0.0) 4 (33.3) 4 (33.3)
Finegoldia 4 (33.3) 0 (0.0) 0 (0.0) 0 (0.0) 4 (33.3)
Prevotella 2 (16.7) 0 (0.0) 3 (25.0) 0 (0.0) 4 (33.3)
Anaerobes 0 (0.0) 1 (8.3) 0 (0.0) 2 (16.7) 3 (25.0)
Anaerococcus 3 (25.0) 0 (0.0) 1 (8.3) 0 (0.0) 3 (25.0)
Proteus 2 (16.7) 0 (0.0) 2 (16.7) 1 (8.3) 3 (25.0)
Enterobacter 2 (16.7) 0 (0.0) 1 (8.3) 0 (0.0) 2 (16.7)
Enterobacteriaceae 2 (16.7) 0 (0.0) 1 (8.3) 0 (0.0) 2 (16.7)
Lactobacillus 2 (16.7) 0 (0.0) 2 (16.7) 0 (0.0) 2 (16.7)
Streptococcus 1 (8.3) 1 (8.3) 2 (16.7) 2 (16.7) 2 (16.7)
Acinetobacter 1 (8.3) 0 (0.0) 1 (8.3) 0 (0.0) 1 (8.3)
Arthrobacter 0 (0.0) 0 (0.0) 1 (8.3) 0 (0.0) 1 (8.3)
Candida 0 (0.0) 1 (8.3) 0 (0.0) 0 (0.0) 1 (8.3)
Coliform 0 (0.0) 0 (0.0) 0 (0.0) 1 (8.3) 1 (8.3)
Corynebacterium 0 (0.0) 0 (0.0) 1 (8.3) 0 (0.0) 1 (8.3)
Fusobacterium 1 (8.3) 0 (0.0) 1 (8.3) 0 (0.0) 1 (8.3)
Helcococcus 1 (8.3) 0 (0.0) 0 (0.0) 0 (0.0) 1 (8.3)
Klebsiella 0 (0.0) 0 (0.0) 0 (0.0) 1 (8.3) 1 (8.3)
Peptoniphilus 1 (8.3) 0 (0.0) 1 (8.3) 0 (0.0) 1 (8.3)
Providencia 1 (8.3) 0 (0.0) 1 (8.3) 0 (0.0) 1 (8.3)
Pseudomonas 0 (0.0) 0 (0.0) 1 (8.3) 0 (0.0) 1 (8.3)
TABLE 52 Summary of pathogens reported using culture and PCR
Summary of pathogens reporteda Swab (N= 12), n (%) Tissue (N= 12), n (%)
PCR and culture report the same pathogens 4 (33.3) 4 (33.3)
PCR reports additional pathogens to the culture 6 (50.0) 6 (50.0)
Culture reports additional pathogens to PCR 0 (0.0) 0 (0.0)
Different pathogens reported (with or without overlap) 2 (16.7) 2 (16.7)
a Five swab cultures reported no pathogens and two tissue cultures reported no pathogens.
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Where PCR resulted in the reporting of additional pathogens compared with the culture results, for swab
samples this was attributable to the reporting of no pathogens in the culture results for five (42%)
patients, and for the tissue samples there were two (17%) patients for whom the culture results reported
no pathogens. These proportions are slightly higher in this subpopulation than in the full evaluable
population, at 29.9% and 13.9%, respectively.
Number of pathogens
Tables 53 and 54 present cross-tabulations of the number of pathogens reported using PCR and plating/
culture for swab and tissue samples, respectively, and Table 55 presents summary statistics for the number
of pathogens for each type of sample and technique.
Comparison of swab and tissue samples based on polymerase chain
reaction results
An overall summary of pathogens reported using PCR by swab and tissue sample is presented in Table 56,
with the corresponding culture results also presented to provide reference. Table 57 presents a
cross-tabulation of the number of pathogens reported from swab and tissue samples using PCR analysis.
TABLE 53 Cross-tabulation of the number of pathogens reported from swab samples using PCR and
culture techniques
PCR results
Culture results, n (%)
Total, n (%)0 1 2
0 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
1 0 (0.0) 4 (33.3) 0 (0.0) 4 (33.3)
2 1 (8.3) 1 (8.3) 0 (0.0) 2 (16.7)
3 1 (8.3) 1 (8.3) 1 (8.3) 3 (25.0)
4 2 (16.7) 0 (0.0) 0 (0.0) 2 (16.7)
5 1 (8.3) 0 (0.0) 0 (0.0) 1 (8.3)
Total 5 (41.7) 6 (50.0) 1 (8.3) 12 (100.0)
Green text represents agreement.
TABLE 54 Cross-tabulation of the number of pathogens reported from tissue samples using PCR and
culture techniques
PCR results
Culture results, n (%)
Total, n (%)0 1 2 3
0 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
1 1 (8.3) 4 (33.3) 1 (8.3) 0 (0.0) 6 (50.0)
2 0 (0.0) 1 (8.3) 0 (0.0) 1 (8.3) 2 (16.7)
3 1 (8.3) 0 (0.0) 2 (16.7) 0 (0.0) 3 (25.0)
4 0 (0.0) 0 (0.0) 1 (8.3) 0 (0.0) 1 (8.3)
Total 2 (16.7) 5 (41.7) 4 (33.3) 1 (8.3) 12 (100.0)
Green text represents agreement.
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Based on the results of the PCR analysis, overall it appears that greater numbers and types of pathogens
were reported within swab samples compared with tissue samples. However, it may be that swab samples
resulted in more polymorphous samples with a lower total microbial load (more reported pathogens
but each at a lower within-sample prevalence relative to total microbial load and with a lower total
microbial load overall) compared with tissue samples.
TABLE 55 Summary statistics of the number of pathogens reported per specimen using PCR and culture techniques
Number of pathogens
Swab Tissue
PCR Culture PCR Culture
(N= 12) (N= 12) (N= 12) (N= 12)
Mean (SD) 2.5 (1.38) 0.7 (0.65) 1.9 (1.08) 1.3 (0.89)
Median (range) 2.5 (1–5) 1.0 (0–2) 1.5 (1–4) 1.0 (0–3)
IQR (1.0–3.5) (0.0–1.0) (1.0–3.0) (1.0–2.0)
Number of pathogens: frequency, n (%)
0 0 (0.0) 5 (41.7) 0 (0.0) 2 (16.7)
1 4 (33.3) 6 (50.0) 6 (50.0) 5 (41.7)
2 2 (16.7) 1 (8.3) 2 (16.7) 4 (33.3)
3 3 (25.0) 0 (0.0) 3 (25.0) 1 (8.3)
4 2 (16.7) 0 (0.0) 1 (8.3) 0 (0.0)
5 1 (8.3) 0 (0.0) 0 (0.0) 0 (0.0)
IQR, interquartile range; SD, standard deviation.
TABLE 56 Summary of pathogens reported from swab and tissue samples using PCR and culture techniques
Summary of pathogens PCR (N= 12), n (%) Culture (N= 12) , n (%)
Swab and tissue report the same pathogens 3 (25.0) 6 (50.0)
Swab reports additional pathogens to the tissue 4 (33.3) 0 (0.0)
Tissue reports additional pathogens to the swab 2 (16.7) 4 (33.3)
Different pathogens reported (with or without overlap) 3 (25.0) 2 (16.7)
TABLE 57 Cross-tabulation of the number of pathogens reported from swab and tissue samples using PCR
Swab results
Tissue results, n (%)
Total, n (%)1 2 3 4
1 3 (25.0) 1 (8.3) 0 (0.0) 0 (0.0) 4 (33.3)
2 1 (8.3) 0 (0.0) 1 (8.3) 0 (0.0) 2 (16.7)
3 1 (8.3) 1 (8.3) 0 (0.0) 1 (8.3) 3 (25.0)
4 1 (8.3) 0 (0.0) 1 (8.3) 0 (0.0) 2 (16.7)
5 0 (0.0) 0 (0.0) 1 (8.3) 0 (0.0) 1 (8.3)
Total 6 (50.0) 2 (16.7) 3 (25.0) 1 (8.3) 12 (100.0)
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Discussion
This study has found that PCR techniques, when used to analyse either swab or tissue samples, yield a
higher number of reported pathogens than conventional plating and culture, with the number of
pathogens reported by PCR dependent on the applied percentage cut-off of total microbial load within a
sample, selected to be 5% in our study. Whether the higher number of pathogens is meaningful clinically
is not clear, as the yield in PCR may be of persistent microbial DNA that is not associated with any current
infection but that remains in the wound.
In our study, we used a single laboratory to analyse wound flora with PCR techniques. Although for this
study the results were not available for clinical decision-making as they were batch processed, the results
from such a laboratory can be returned within 24 hours. The arguments for greater use of PCR techniques
(over culture and plating) are twofold: they make available increased amounts of information (often
including identification of new bacterial species); and they allow for quicker analysis. This, however, needs
to be set against the patchy availability and cost (which may change as technology advances) of such
techniques. Furthermore, the impact of a higher yield from PCR on the complexity of laboratory results
may affect clinical decision-making, particularly because clinicians have been accustomed to microbiology
reports in which there has been selection of organisms for reporting (as identified in a small number of
cases from our survey of practice) rather than reporting of the wound biome overall. The identification of a
large number of species at low frequency provides clinical teams with increased data, this then requires
selection of the meaningful information on likely pathogens associated with the current clinical picture,
and hence ability to identify contaminants.
Although PCR techniques are often represented as a gold-standard, they too are vulnerable to
contamination and (as per plating and culture) require standardised techniques and validated processes.
There is a potential for false-positive results associated with the very high sensitivity.103,104 Fenollar et al.104
reported a comparison of plating and culture techniques in sampling for bone and joint infections
(525 patients) and identified 50 discordant results: seven cases where different organisms were identified
by the two analysis techniques, 21 where PCR only was positive (culture was negative), and 22 cases
where the culture was positive (13 culture contaminants and nine ‘false-negative’ PCR results) and the PCR
negative. They identified that in 475 out of 525 cases, the results were in agreement but their baseline
event rate was much lower than in this study, as their patients did not have to be infected to enter the
study. The utility of comparing PCR and plating/culture techniques in uninfected wounds is not clear given
that these techniques are, currently, not used to determine the presence, or otherwise, of infection.
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Chapter 5 Prognosis of infected diabetic
foot ulcers
Introduction
Understanding the natural history of DFUs is an important pre-requisite to the planning of clinical trials
to examine new interventions in the management of DFUs. It enables an informed approach when
incorporating various design parameters, such as sample size estimates, follow-up period, frequency of
visits and important outcomes.
The natural history of a condition can be reported from inception cohorts, but these are not commonly
available in the DFU literature. The largest relevant prospective cohort study is the Eurodiale (European Study
Group on Diabetes and the Lower Extremity) study,105 which recruited 1232 patients from 14 European
countries. The study collected data on the characteristics of patients with DFUs, diagnostic and management
procedures, health-care organisation, quality of life measurement and resource use. Patients with a new
DFU were followed up monthly until healing of the foot, lower-leg amputation, death or non-healing after
1 year.106 They reported that 58% of ulcers were infected at first presentation, with the prevalence of
infection varying markedly between centres (range 28–74%); this may be due to referral patterns, standards
of care or sensitivity of infection diagnosis. Data are reported on healing for 998 patients, of whom 77%
healed within the follow-up period (12 months). This high rate of healing requires further confirmation, as
the Eurodiale study reported higher healing and lower adverse outcome rates than earlier studies: only 5%
of patients underwent a major amputation and 6% died.106 This may reflect the potential reporting bias
associated with a large proportion of missing data.
As well as overall prognosis, we also wanted to understand the relationship between patient and wound
characteristics and outcomes. In the UK, Ince et al.107 explored the relationships between time to healing
of DFUs and baseline characteristics of the patients and their ulcers in a large prospective cohort study.
They reported on 449 participants referred to a specialist clinic and found four variables independently
associated with median time to healing: (1) area of the ulcer; (2) severity of peripheral arterial disease
(PAD); (3) ulcer site; and (4) duration of diabetes.
In our previous systematic review,61 we identified that there were no data available specifically exploring
the influence of infection status on the time to healing. Trials designed to investigate agents for treating
DFUs, such as topical agents/antibiotics, may recruit populations that are homogeneous in respect of their
infection status (infected ulcers or uninfected ulcers only). It would be useful to know the clinical outcomes
in infected ulcers, as these are at highest risk of adverse sequelae. Characterising this patient population
should allow both event rate estimation for trial planning, as well as providing data on prognosis that
would be useful for the patients, their families and health-care service planning. It is essential that future
trials commissioned in the area of DFUs are informed by accurate data on natural history, in the context of
modern diabetes management protocols.
Some studies have reported that factors such as ulcer area, diabetes duration, severity of PAD and ulcer
site provide prognostic information. However, the prognostic value of the newest tools, such as the PEDIS
classification scheme, has not been assessed in this way. When Schaper et al.108 examined the relationship
between infection, neuropathy and ischaemia, they concluded that infection itself had no effect on healing
in people with neuropathy, but it did have an effect on the healing of those with ischaemia (healing rate
of 77% in people with ischaemia and no infection and 64% in those with ischaemia and infection). This
suggests that treatment of infection in people with peripheral neuropathy may restore the potential for
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healing, whereas in people with lower extremity ischaemia, usual care for infection in the absence of
addressing their ischaemia may be insufficient. This could be due to poor antibiotic penetration when
administered systemically in those with PAD.
Schaper et al.108 concluded that the profile of people with DFUs is changing, with a move away from the
simple neuropathic foot to a more complex clinical presentation. This is in the context of an ageing
population in which more people may have concurrent arterial disease. They note that more emphasis
should be placed on developing strategies to improve outcome for neuroischaemic foot ulcers and, in
particular, those with PAD and infection.
Aims and objectives
The aim of the CODIFI prognosis of foot infection study was to determine the medium-term outcome of
patients with a suspected infected DFU at 12 months post registration and to explore various prognostic
factors that may be related to time to wound healing.
The objectives were to:
1. describe the medium-term clinical outcome of patients with a suspected infected DFU, including wound
healing, need for surgical treatment (amputation/revascularisation) or death during follow-up
2. conduct an exploratory analysis of the prognostic factors related to time to wound healing in patients
with a suspected infected DFU.
Methods
The CODIFI prognosis of foot infection follow-up study was an extension to the original multicentre
cross-sectional CODIFI study design involving 400 patients with a DFU with suspected infection requiring
antibiotic therapy64 (see Chapter 2).
The prognosis study involved the addition of a case-note review to allow identification of clinical outcomes
12 months after baseline swab and tissue sampling.
The prognostic substudy was submitted as a substantial amendment (version 4.0) for ethical approval
on 19 October 2012. Approval was granted on 29 November 2012. By the time of this approval,
248 participants had been recruited into CODIFI. We therefore needed to obtain both prospective consent
for subsequent participants for follow-up at 12 months (via a revised protocol sent for ethical review), as
well as obtain retrospective consent for those recruited under the initial protocols (again via an application
to the Research Ethics Committee).
Eligibility and consent
All patients registered into the main CODIFI study were eligible to consent to the prognosis study.
The CODIFI main study patient information leaflet was updated (version 4.0) to incorporate additional
information on the prognostic 12-month case-note review substudy (see Appendix 4) and to request
permission to access patient notes 12 months post registration. The patient information leaflet was used
not only to gain consent for new patients recruited to the main study but also to retrospectively gain the
consent of patients already in the study for the 12-month case-note review.
As the rate of return of retrospective consent forms was low, with no improvement over time, a new short
‘addendum consent’ form was designed to improve return. This simplified two-page consent form asked
patients to give consent for the case-note review only rather than for the full CODIFI study; however, this
had little impact on the rates of consent (18 consents over a 2-month period). Following consultation with
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sites and the study’s public patient involvement officer, the study team contacted the National Research
Ethics Service Sheffield committee to explore the possibility of obtaining verbal consent for the 12-month
case-note review over the telephone, and a verbal consent ‘script’ was produced and submitted to ethics.
Following its approval and implementation, the impact of this approach was significant (95 consents
obtained over a 2-month period) and proved an invaluable tool to obtain retrospective consent for
case-note review.
Case-note review/assessments
A detailed case-note review, conducted by research nurses and podiatrists at each centre, captured
information regarding patient status at the time of review and clinical outcomes relating to the patients’
index ulcer in the 12-month period after CODIFI baseline swab and tissue sampling, referred to herewith
as 12 months post sampling. This information included healing, reoccurrence, revascularisation surgery,
surgical amputation and other events considered to be clinically relevant.
End points
Medium-term outcomes of patients with an infected diabetic foot ulcer
Medium-term outcomes were defined as clinically important events relating to the index ulcer within
12 months of collection of the wound samples and included wound healing, reoccurrence, lower extremity
amputation, lower extremity revascularisation and death. The index ulcer was the ulcer from which swab
and tissue samples were collected in the main CODIFI study. We did not collect information about new
infection or the date on which infection was said to have resolved.
Prognostic factors relating to healing
Pre-specified baseline patient and wound characteristic factors were identified to explore the relationship
with time to healing of the index ulcer, and to determine whether or not differential rates of healing
were indicated.
Patients’ clinical characteristics from the detailed baseline assessment and microbiological data from the
swabs and tissue samples were included. The full list of baseline assessment candidate factors include:
l age (continuous and median split)
l type of ulcer (ischaemic or neuroischaemic/neuropathic)
l ulcer grade (Wagner grade: 1/2/≥ 3)
l PEDIS:
¢ PAD: perfusion (grade 1/≥ 2)
¢ ulcer area: extent (continuous)
¢ depth (grade 1/2/3)
¢ infection (grade ≤ 2/3/4)
¢ sensation (grade 1/2)
l ulcer site (apex/interdigital/digital/plantar/dorsum/calcaneal/other)
l incident or recurrent ulcer
l diabetes duration (continuous and median split)
l glycated haemoglobin (HbA1C) (continuous)
l patient receiving insulin therapy (yes/no)
l type of diabetes (type 1/type 2)
l wound duration (< 56 days, ≥ 56 days)
l prior antibiotic therapy (at the time of baseline sampling: yes/no)
l prior antimicrobial dressing on ulcer (at the time of baseline sampling: yes/no).
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The full list of baseline microbiology factors include:
l any reported pathogens (no pathogens reported/at least one pathogen reported)
l most prevalent pathogens, reported in either swab or tissue sample (yes/no):
¢ anaerobes
¢ MRSA
¢ Gram-positive cocci
¢ Gram-negative bacilli
¢ Enterobacteriaceae
¢ Gram-positive bacilli
¢ S. aureus
¢ Streptococcus
¢ Enterococcus excluding vancomycin-resistant species
¢ CNS
¢ Corynebacterium
¢ Pseudomonas.
Statistical methods
Sample size
As the prognosis study was an extension of the original CODIFI design, at the time of the funding request
it was anticipated that the follow-up population would contain at least 200 patients and up to a maximum
of 400 patients should all patients be willing to reconsent.
Medium-term outcomes
Considering the healing rate at 12 months, we estimated the accuracy with which we would be able to
estimate the healing rate for varying numbers of patients and rates of healing, with accuracy based on
‘precision’ corresponding to the half width of the 95% CI. Assuming a healing rate of 50%, the minimum
expected sample size of 200 patients would provide ± 6.9% precision and the maximum sample size of
400 patients would provide ± 4.9% precision, with improved precision as the healing rate departs from
50% (Table 58).
Prognostic factors relating to healing
The number of parameter estimates that could be included in the exploratory prognostic model of time
to healing was also considered for varying numbers of participants and healing rates.105 Assuming a
healing rate of 50%, the minimum expected sample size of 200 patients would allow for a maximum of
TABLE 58 Precision of 95% CI for healing rate
Number of patients Healing rate, % Precision (half width of 95% CI), %
200 40 or 60 ±6.8
50 ±6.9
300 40 or 60 ±5.5
50 ±5.7
350 40 or 60 ±5.1
50 ±5.2
400 40 or 60 ±4.8
50 ±4.9
PROGNOSIS OF INFECTED DIABETIC FOOT ULCERS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
84
10 parameter estimates in the model, and the maximum sample size of 400 patients would allow for
20 parameter estimates, with a reduction in the number of estimates if the healing rate should be
< 50% (Table 59).
Analysis methods
Patient populations
The follow-up population consisted of the sample of all registered and consented CODIFI patients for
whom written or verbal informed consent for the 12-month case review had been obtained (or the patient
had died) and the 12-month case-note review had been conducted. If either one of these criteria was not
met, the patient was excluded from the follow-up population.
Medium-term outcomes
The numbers of patients with a healing, reoccurrence, amputation, revascularisation or other event for
their index ulcer and time to event were summarised overall and by patients’ healing status.
A competing risk analysis using cumulative incidence functions was conducted in order to estimate the
cumulative incidence of healing at 12 months, adjusted for lower extremity amputation and death. Lower
extremity amputation or death were considered to be competing risks, as the occurrence of either event
made it impossible to subsequently observe the event of interest, namely healing. Therefore, in patients
with a lower extremity amputation or in patients who had died, healing was unobserved. Cumulative
incidence functions were therefore used to adjust for these competing events, as the standard
Kaplan–Meier method would lead to a biased estimate of the healing rate, as it assumes that patients with
a competing event could still heal if observed for a longer period of time, which as detailed is not the case
for such competing risks.
Under the competing risk analysis, patients who were alive, without a lower extremity amputation and
without healing of their index ulcer at 12 months were censored at the earliest of the dates of their
case-note review or 12 months after sampling. As death or amputation meant that healing of the index
ulcer could no longer be observed, where an ulcer was not reported to have healed and death or
amputation were reported, they were considered to be competing risks. As such, patients whose index
ulcer had not healed and who had an amputation or who had died prior to the end of the 12 months’
follow-up were considered to have a competing event at the date of amputation or at their date of death,
respectively. The use of cumulative incidence functions to account for the competing risks means that
TABLE 59 Number of parameter estimates included in the exploratory analysis
Number of patients Healing rate, % Number of parameter estimatesa
200 40 8
50 10
300 40 12
50 15
350 40 14
50 17
400 40 16
50 20
a Number of parameter estimates is rounded down where required.
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participants were removed from the at-risk set at the time of their competing event (i.e. those whose
ulcers have the opportunity to heal).
Prognostic factors relating to healing
An exploratory analysis was conducted to model the relationship of baseline factors with the cumulative
incidence of healing, using the proportional subdistribution hazards model109 for competing risks data.
Pre-specified baseline factors were individually fitted in a univariate analysis to explore the association with
time to healing, and all factors were subsequently fitted in the same model in a preliminary multivariable
analysis to examine the independent effects of baseline factors with time to healing. Factors found to be
significant at the 10% level in the preliminary multivariable analyses, based on the presented p-value
associated with the Wald test, were selected for inclusion in a final multivariable model. Healing estimates
at 12 months were calculated as predicted from the univariate analysis, in which each factor was
considered individually and independent of other baseline factors.
Cross-tabulations were generated for all baseline factors found to be significant at the 10% level in
the univariate analysis, and the chi-squared test statistic was calculated to examine associations
between factors.
In order to test the assumption of proportional hazards, competing risks were treated as censored events
in order to generate log-cumulative hazards plots by the selected factor. Under the proportional hazards
assumption, the lines were expected to be parallel and not to cross, for each level of the factor. The plots
presented were from the first imputed data set. To further investigate departures from the proportional
hazards assumption, a time-dependent covariate was included in the univariate model for two
level factors.
Missing data
As part of the study design, efforts were made to collect complete follow-up data for patients in the
follow-up population; however, where data remained missing this was assumed to be missing at random
and MI76 was used to impute the time of healing for patients whose index ulcer was known to have
healed but date of healing was unknown, and for patients for whom at least one baseline covariate was
missing. This allowed for the inclusion of 43 (14.4%) patients with missing data for at least one missing
baseline covariate or date of healing; for details of missing data items and imputed healing times,
see Appendix 3.
The outcome (healing) and all covariates to be considered in the prognostic model were included in
the MI model alongside centre and indicators for the occurrence of other outcomes (reoccurrence,
revascularisation, amputation, death). MI was conducted by patients’ healed status; thus, separate
imputation analyses were performed for patients in whom the index ulcer had healed and for patients in
whom it had not.
A total of 10 imputations were conducted using the MCMC method77 with multiple chains, initial values
from the EM79 algorithm, 200 burn-in iterations and the assumption of normality for factors with missing
data (thus, imputations were made on a continuous scale). For continuous variables with missing data
(healing time, extent of ulcer, diabetes duration and HbA1C), minimum imputation values of zero were
specified, whereas imputations for dichotomous factors were not restricted for ‘implausible values’ and,
thus, continuous imputations were rounded to plausible values for the dichotomous factor78 (owing to
the small proportion of missing data, the bias introduced as a result of this method is anticipated to
be minimal).
In order to present graphically the cumulative incidence of healing (in the presence of competing risks
amputation and death), the mean imputed healing time for each patient with missing data was used; to
present the number left at each month, the mean number left across all 10 imputed data sets was used.
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Estimated healing rates at 6 and 12 months reflect the average healing rate across the imputed data sets,
and estimated CIs include variability across the imputed sets as well as the usual uncertainty in parameter
estimates. For the 10 imputed data sets, estimated healing rates (accounting for competing risks) were
combined using Rubin’s rules79 and to present the number healed and left at 12 months, the mean across
the 10 imputed data sets was used.
Results from the 10 imputed data sets for the proportional subdistribution hazards model109 were also
combined using Rubin’s rules;79 therefore, reported estimates reflect the average of estimates across the
imputed data sets, and estimated standard errors include variability across the imputed sets as well as the
usual uncertainty in parameter estimates. For categorical factors with more than two levels (ulcer site,
Wagner grade and PEDIS depth), the overall type-3 chi-squared statistics were pooled and p-values were
calculated via the procedure proposed by Li et al.110
Missing data were not imputed for patients recruited into CODIFI who were not part of the follow-up
population (owing to lack of reconsent) for whom no follow-up data were obtained, owing to the strong
assumptions required in order to impute multiple outcomes (healing, amputation, death) and the timing of
these outcomes in relation to baseline sampling. In order to assess the generalisability of our results, that
is, whether or not the follow-up population (n= 299) was representative of all patients including those not
followed up (n= 101), the characteristics of these patients are presented in Appendix 3.
Results
Follow-up population
Of the 400 patients who were part of the CODIFI cross-sectional study, the long-term follow-up analysis
population consisted of 299 (74.8%) patients with a completed case-note review at 12 months post
sampling and baseline swab and (or) tissue sampling from their index ulcer. Baseline characteristics of
patients in the follow-up population and those not included in the population can be found in Appendix 3.
Baseline characteristics are similar across both groups of patients, and observed differences appear to
occur by chance (owing to the number of variables compared) as differences do not consistently suggest a
‘better’ or ‘worse’ population represented by either group. Table 60 summarises the number of patients
included and excluded from the follow-up population, the type of consent attained and the reasons
for exclusion.
As described in Methods, only 13 patients consented to the review of their case notes at 12 months post
sampling as part of their initial consent into the CODIFI study. The majority of patients 124 (41.5%)
consented in the subsequent CODIFI reconsent process; 18 (6%) consented by the addendum consent and
a further 95 (31.8%) consented via verbal consent over the telephone. At the time of obtaining consent,
49 (16.4%) patients in the follow-up population were found to have died. We considered how to ensure
that our data did not exclude those patients who died within 12 months of the study or between consent
and follow-up. We concluded that these data were crucial for a complete picture of the prognosis for
people with infected foot ulcers and identified that consent was not necessary for the collection of the
routine data we sought if a patient was deceased. The records of these patients were therefore included in
the follow-up review.
The most frequent reasons for patients not being part of the follow-up population were that the patient
was known to be alive but did not respond to the enrolment site’s consent request (54.5%) or the
patient was lost to follow-up (22.8%). Investigation of the time at which patients entered the study in
accordance with whether or not a case-note review had been conducted found no associated pattern of
missing data, such that patients were not more likely to be missing the case-note review if recruited earlier
into the trial (i.e. when reconsent would have been requested after a far longer period of time since their
last involvement in the study). Missing case-note reviews were also spread across centres rather than
occurring as a result of the lack of reviews in single centres.
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Follow-up summary
The case-note review was undertaken 12 months or more after baseline sample collection for the majority
of patients; however, the review took place prior to the anniversary of sample collection for 17 (5.7%)
patients reported to have been alive, resulting in a minimum follow-up length of 10.6 months (Table 61).
Events reported beyond the 12-month period were removed; however, three events (two healing and
one reoccurrence) reported just outside the 12-month follow-up period (within 13 months) are included in
the analysis for completeness.
Medium-term outcomes
Cross-tabulations of patients’ healing status, against the other outcomes of death, amputation,
revascularisation surgery and reoccurrence, are presented in Table 62. The index ulcer was reported to
have healed in 136 (45.5%) patients; however, of these, 13 (9.6%) patients’ index ulcers then reoccurred
TABLE 60 Patient long-term follow-up summary and form of consent
Included in the follow-up population Full analysis set (N= 400), n (%)
Yes 299 (74.8)
Full consent (at enrolment main study) 13 (4.3)
Full reconsent 124 (41.5)
Addendum reconsent 18 (6.0)
Verbal reconsent 95 (31.8)
Patient died: reconsent not collected 49 (16.4)
No 101 (25.3)
Patient did not respond to request for consent by site 55 (54.5)
Patient lost to follow-up 23 (22.8)
Consent was not attained, reason unknown 11 (10.9)
Patient had died and case-note review not completed 7 (6.9)
Patient unable to consent (dementia)/lacked capacity 2 (2.0)
Patient provided incomplete consent 1 (1.0)
Patient refused consent 1 (1.0)
Patient consented but case-note review not completed 1 (1.0)
Total 400 (100)
TABLE 61 Summary of the length of follow-up
Length of follow-up Total (N= 299)
Follow-up to at least 12 months or death, n (%)
Yes 282 (94.3)
No 17 (5.7)
Length of follow-up (months) for patients alive with follow-up < 12 months
N 17
Mean (SD) 11.5 (0.53)
Median (range) 11.9 (10.58–11.96)
SD, standard deviation.
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within the follow-up period. A total of 45 (15.1%) patients died within the 12-month follow-up period,
52 (17.4%) had an amputation of the same limb on which the index ulcer was found (or on the same
limb) and 18 (6.0%) had revascularisation surgery.
There were 12 (4.0%) patients whose index ulcer was reported to have healed and for whom an
amputation of, or on, the same limb as the index ulcer was also reported; for two of these patients, the
amputation occurred after the reported healing of the index ulcer, and for 10 patients the amputation
occurred prior to reported healing of the index ulcer (Table 63). Although it may appear counterintuitive
for there to be an amputation and later healing of the index ulcer, the area of amputation in relation to
the index ulcer suggests a different amputation site to that of the index ulcer. Amputations were
predominantly performed on one or more digits, confirming that healing was in reference to the index
ulcer rather than the amputation site.
TABLE 62 Cross-tabulation of healing against amputation, death, revascularisation surgery and reoccurrence within
12 months of sampling (these are not mutually exclusive outcomes)
Index ulcer healed?
TotalYes No
Patient died, n (%)
Yes 8 (2.7) 37 (12.4) 45 (15.1)
No 128 (42.8) 126 (42.1) 254 (84.9)
Total 136 (45.5) 163 (54.5) 299 (100.0)
Amputation (of or on the limb of the index ulcer), n (%)
Yes 12 (4.0) 40 (13.4) 52 (17.4)
No 124 (41.5) 123 (41.1) 247 (82.6)
Total 136 (45.5) 163 (54.5) 299 (100.0)
Revascularisation surgery, n (%)
Yes 8 (2.7) 10 (3.3) 18 (6.0)
No 128 (42.8) 153 (51.2) 281 (94.0)
Total 136 (45.5) 163 (54.5) 299 (100.0)
Index ulcer reoccurred, n (%)
Yes 13 (9.6) N/A 13 (4.3)
No 123 (90.4) N/A 123 (90.4)
Total 136 (100.0) N/A 136 (100.0)
N/A, not applicable.
TABLE 63 Summary of patients with index ulcer healed and amputation within 12 months post sampling
Summary Total (N= 12), n (%)
Amputation after index ulcer healed without reoccurrence of index ulcer 2 (16.7)
Amputation before index ulcer healed 10 (83.3)
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The time to each outcome by 12 months is presented in Table 64. Of the 136 patients whose index ulcer
healed (excluding 12 patients whose date of healing was missing), the median time to healing was
4.5 months (range 0.5–12.9 months). Of the 12 patients whose ulcers were reported to have reoccurred
after initially healing (excluding one patient with missing reoccurrence date), the median time to
reoccurrence from healing was 1.7 months (range 0.3–10.7 months). The median time to death for the
45 patients was 5.6 months (range 0.6–11.5 months) and the median time to amputation of the index
ulcer/limb for 52 patients was 2 months (range 0.0–10.6 months). Finally, of the 16 patients who
had revascularisation surgery (excluding 2 patients whose date of surgery was missing), the median time
to surgery was 3.0 months (range 0.1–9.5 months).
Table 65 presents the number and types of ‘other’ events as reported by the local team (podiatrists or
research nurses). A total of 45 ‘other’ events were reported in 37 (12.4%) patients with substantial
variability in the type of other events reported.
TABLE 64 Time to outcome within 12 months post sampling (months)
Time to outcomea Total
Time to first healing (n = 136)
Mean (SD) 5.5 (3.47)
Median (range) 4.5 (0.5–12.9)
Missing 12
Time from healing to reoccurrence (n = 13)
Mean (SD) 4.1 (4.01)
Median (range) 1.7 (0.3–10.7)
Missing 1
Time to death (n = 45)
Mean (SD) 5.9 (3.23)
Median (range) 5.6 (0.6–11.5)
Missing 0
Time to amputation (n = 52)
Mean (SD) 3.0 (3.05)
Median (range) 2.0 (0.0–10.6)
Missing 0
Time to revascularisation surgery (n = 18)
Mean (SD) 3.4 (2.85)
Median (range) 3.0 (0.1–9.5)
Missing 2
SD, standard deviation.
a Partial dates were imputed as the 15th of the month for nine patients’ dates of healing and three patients’ dates of
amputation. Furthermore, two patients with inconsistent dates of reported healing were corrected by the Clinical Trials
Research Unit based on other information provided for each patient.
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A summary of patients’ first occurring outcome (healing, revascularisation, surgery, amputation, death) is
presented in Table 66 and provides further detail of the outcomes reported subsequent to the first.
Cumulative incidence of healing in the presence of competing risks: death
and amputation
Table 67 presents the occurrence of amputation and death in patients whose index ulcer had not healed.
Of the 163 (54.5%) patients whose index ulcer had not healed, 93 (57.1%) were known to be alive and
without amputation at 12 months and were censored at the earliest of their case-note review or at
12 months post sampling; 33 (20.2%) were known to be alive with amputation before 12 months and
seven (4.3%) were known to have died with amputation before 12 months. These patients therefore had
a competing event at their date of amputation and 30 (18.4%) patients died without amputation before
12 months and therefore had a competing event at their date of death.
TABLE 65 Summary of the number of patients with an ‘other’ event reported
Other event occurred Total (n= 299)
Yesa 37 (12.4%)
No 262 (87.6%)
Type of other event (non-mutually exclusive categories)
Charcot 2
Further amputation 2
Further healing following reoccurrence 2
Further ulcer(s) 11
Further ulcer(s) and healing 3
Incision and drainage 1
Kidney and pancreas transplant 1
Necrobiosis lipoidica to legs 1
Osteomyelitis 1
Skin graft and negative pressure therapy 1
Surgical correction of deformity 1
Debridement (surgical and non-surgical) 7
Contralateral amputation 4
Contralateral angioplasty 1
Contralateral gangrene 1
Contralateral healing of ulcer 1
Contralateral osteomyelitis 1
Contralateral revascularisation 1
Contralateral ulceration 3
a Other events were reported for a further 13 patients; however, these events were not considered to be clinically relevant
in the context of CODIFI. Such events included discharge to the community team, state of open wound, redressing of
ulcer and hospital admissions with no detail of cause.
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TABLE 67 Healing within 12 months post sampling
Healing of the index ulcer Total (N= 299)
Number of patients with index ulcer healed, n (%)
Yes 136 (45.5)
No 163 (54.5)
Index ulcer not healed, n (%)
Patient alive with amputation before 12 months 33 (20.2)
Patient alive without amputation at 12 months 93 (57.1)
Patient died with amputation before 12 months 7 (4.3)
Patient died without amputation before 12 months 30 (18.4)
TABLE 66 Summary of clinical outcome sequence within 12 months post samplinga
Clinical outcome sequence Total (N= 299), n (%)
Index ulcer healed 122 (40.8)
Healed only 110 (90.2)
Healed then revascularisation surgery 1 (0.8)
Healed and revascularisation (order unknown missing) 1 (0.8)
Healed then amputation 2 (1.6)
Healed then patient died 8 (6.6)
Revascularisation surgery 10 (3.3)
Revascularisation surgery only 1 (10.0)
Revascularisation surgery then healed 4 (40.0)
Revascularisation surgery then amputation 3 (30.0)
Revascularisation surgery then patient died 1 (10.0)
Revascularisation surgery then amputation then healed 1 (10.0)
Amputation (of or on the limb of the index ulcer) 46 (15.4)
Amputation only 26 (56.5)
Amputation then healed 8 (17.4)
Amputation then revascularisation surgery 4 (8.7)
Amputation then patient died 6 (13.0)
Amputation then revascularisation surgery then healed 1 (2.2)
Amputation and revascularisation surgery then patient died 1 (2.2)
Patient died (without prior events) 29 (9.7)
Healing, amputation or death not reported 92 (30.8)
a When healing is reported to have taken place following amputation, amputation is assumed to be of part of the index
foot not containing the index ulcer.
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Figure 14 shows the estimated cumulative incidence curves of the time to healing or the competing risks
of death or amputation. Corresponding healing estimates at 6 and 12 months are presented in Table 68.
The estimated 6 months’ post sampling healing rate was 27.5% (95% CI 22.4% to 32.5%) and the
12 months’ post sampling healing rate was 44.5% (95% CI 38.9% to 50.1%). The median time to
healing for all patients in the follow-up population was not reached and is not estimated.
A total of 43 (14.4%) patients had at least one missing baseline covariate or date of healing (details of
missing data items and imputed healing times are provided in Appendix 3).
Prognostic factors relating to healing: exploratory analysis
Tables 69 and 70 present summary tables of patients’ healed status by baseline factors included in the
prognostic modelling.
Tables 71 and 72 summarise the results of the exploratory univariate and adjusted multivariable analysis
investigating the relationship of baseline factors with the cumulative incidence of healing. A proportional
subdistribution hazards model109 for competing risks data was used to adjust for each factor individually in
the univariate analysis and adjusted for all factors simultaneously in the multivariable analysis (as detailed
in the methods section).
TABLE 68 Cumulative incidence of healing estimates at 6 and 12 months in the presence of competing risks:
death and amputation
Month Healing estimate (95% CI)
Number
healed
Number with
competing
amputation event
Number with
competing
death event
Number
censored
Number
left
6 27.5% (22.4% to 32.5%) 82 32 17 0 168
12 44.5% (38.9% to 50.1%) 133 40 30 93 3a
a The number left at 12 months includes two participants known to have healed just after the 12-month time point,
and an additional participant, owing to the variability in the multiply imputed data sets.
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FIGURE 14 Cumulative incidence functions of healing in the presence of competing risks: death and amputation.
DOI: 10.3310/hta20820 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 82
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Nelson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
93
TABLE 69 Patients’ healed status by baseline explanatory variables: clinical characteristics
Baseline characteristics Healed, N= 136 (45.5%) Not healed, N= 163 (54.5%)
Age (median split), n (%)
≤ 63 years (n= 146) 58 (39.7) 88 (60.3)
> 63 years (n= 153) 78 (51.0) 75 (49.0)
Ulcer type, n (%)
Any ischaemia (± neuropathy) (n= 142) 49 (34.5) 93 (65.5)
Neuropathic only (n= 155) 85 (54.8) 70 (45.2)
Missing (n= 2) 2 (100.0) 0 (0.0)
Wagner ulcer grade, n (%)
Grade 1 (n= 104) 56 (53.8) 48 (46.2)
Grade 2 (n= 93) 41 (44.1) 52 (55.9)
Grade 3, 4 or 5 (n= 102) 39 (38.2) 63 (61.8)
PEDIS (perfusion: PAD), n (%)
Grade 1 (n= 147) 85 (57.8) 62 (42.2)
Grade ≥ 2 (n= 152) 51 (33.6) 101 (66.4)
PEDIS (depth), n (%)
Grade 1 (n= 96) 51 (53.1) 45 (46.9)
Grade 2 (n= 100) 47 (47.0) 53 (53.0)
Grade 3 (n= 103) 38 (36.9) 65 (63.1)
PEDIS (infection), n (%)
Grade 2 (n= 104) 55 (52.9) 49 (47.1)
Grade 3 (n= 185) 78 (42.2) 107 (57.8)
Grade 4 (n= 10) 3 (30.0) 7 (70.0)
PEDIS (sensation), n (%)
Grade 1 (n= 20) 12 (60.0) 8 (40.0)
Grade 2 (n= 279) 124 (44.4) 155 (55.6)
Ulcer site, n (%)
Apex, interdigital, digital (n= 119) 56 (47.1) 63 (52.9)
Plantar (n= 133) 62 (46.6) 71 (53.4)
Dorsum (n= 38) 15 (39.5) 23 (60.5)
Other/missing (n= 9) 3 (33.3) 6 (66.7)
Incident or recurrent, n (%)
Incident (n= 206) 88 (42.7) 118 (57.3)
Recurrent (n= 91) 46 (50.5) 45 (49.5)
Missing (n= 2) 2 (100.0) 0 (0.0)
Diabetes duration (median split), n (%)
< 15 years (n= 136) 65 (47.8) 71 (52.2)
≥ 15 years (n= 161) 71 (44.1) 90 (55.9)
Missing (n= 2) 0 (0.0) 2 (100.0)
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TABLE 69 Patients’ healed status by baseline explanatory variables: clinical characteristics (continued )
Baseline characteristics Healed, N= 136 (45.5%) Not healed, N= 163 (54.5%)
Patient receiving insulin therapy, n (%)
Yes (n= 211) 89 (42.2) 122 (57.8)
No (n= 88) 47 (53.4) 41 (46.6)
Type of diabetes, n (%)
Type 1 (n= 40) 17 (42.5) 23 (57.5)
Type 2 (n= 259) 119 (45.9) 140 (54.1)
Wound duration (median split), n (%)
< 56 days (n= 143) 77 (53.8) 66 (46.2)
≥ 56 days (n= 152) 56 (36.8) 96 (63.2)
Missing (n= 4) 3 (75.0) 1 (25.0)
Prior antibiotic use (at the time of baseline sampling), n (%)
Yes (n= 139) 60 (43.2) 79 (56.8)
No (n= 145) 71 (49.0) 74 (51.0)
Missing (n= 15) 5 (33.3) 10 (66.7)
Prior antimicrobial dressing on ulcer (at the time of baseline sampling), n (%)
Yes (n= 175) 69 (39.4) 106 (60.6)
No (n= 119) 64 (53.8) 55 (46.2)
Missing (n= 5) 3 (60.0) 2 (40.0)
Only ulcer on index foot, n (%)
Single index ulcer on index foot (n= 222) 113 (50.9) 109 (49.1)
> 1 ulcer on index foot (n= 77) 23 (29.9) 54 (70.1)
TABLE 70 Patients’ healed status by baseline explanatory variables: baseline microbiology
Baseline microbiologya Healed, N= 136 (45.5%) Not healed, N= 163 (54.5%)
Any reported pathogens, n (%)
Yes (n= 263) 118 (44.9) 145 (55.1)
No (n= 36) 18 (50.0) 18 (50.0)
Overall anaerobes, n (%)
Yes (n= 69) 28 (40.6) 41 (59.4)
No (n= 230) 108 (47.0) 122 (53.0)
MRSA, n (%)
Yes (n= 27) 8 (29.6) 19 (70.4)
No (n= 272) 128 (47.1) 144 (52.9)
continued
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TABLE 70 Patients’ healed status by baseline explanatory variables: baseline microbiology (continued )
Baseline microbiologya Healed, N= 136 (45.5%) Not healed, N= 163 (54.5%)
Gram-positive cocci, n (%)
Yes (n= 217) 95 (43.8) 122 (56.2)
No (n= 82) 41 (50.0) 41 (50.0)
Gram-negative bacilli, n (%)
Yes (n= 110) 45 (40.9) 65 (59.1)
No (n= 189) 91 (48.1) 98 (51.9)
Enterobacteriaceae
Yes (n= 79) 31 (39.2) 48 (60.8)
No (n= 220) 105 (47.7) 115 (52.3)
Gram-positive bacilli, n (%)
Yes (n= 31) 15 (48.4) 16 (51.6)
No (n= 268) 121 (45.1) 147 (54.9)
S. aureus, n (%)
Yes (n= 107) 51 (47.7) 56 (52.3)
No (n= 192) 85 (44.3) 107 (55.7)
Streptococcus, n (%)
Yes (n= 44) 21 (47.7) 23 (52.3)
No (n= 255) 115 (45.1) 140 (54.9)
Enterococcus (excluding vancomycin resistant), n (%)
Yes (n= 48) 18 (37.5) 30 (62.5)
No (n= 251) 118 (47.0) 133 (53.0)
CNS, n (%)
Yes (n= 38) 24 (63.2) 14 (36.8)
No (n= 261) 112 (42.9) 149 (57.1)
Corynebacterium, n (%)
Yes (n= 26) 13 (50.0) 13 (50.0)
No (n= 273) 123 (45.1) 150 (54.9)
Pseudomonas, n (%)
Yes (n= 24) 10 (41.7) 14 (58.3)
No (n= 275) 126 (45.8) 149 (54.2)
a A total of three patients in the follow-up population were not in the evaluable population and without swab results;
however, patients’ available tissue sample results alone were used in order to include patients in the analysis. Pathogens
are classed as ‘yes’ if reported in either patients’ baseline swab or tissue samples.
PROGNOSIS OF INFECTED DIABETIC FOOT ULCERS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
96
TABLE 71 Healing estimates at 12 months (based on the univariate analysis)
Baseline factors Healing estimate at 12 months (95% CI)
Ulcer type
Any ischaemia (± neuropathy) 33.2% (25.4% to 41.0%)
Neuropathic only 55.3% (47.6% to 63.0%)
Wagner ulcer grade
Grade 1 56.1% (46.3% to 65.8%)
Grade 2 41.6% (32.5% to 50.8%)
Grade 3, 4 or 5 36.2% (27.3% to 45.1%)
PEDIS: perfusion
Grade 1 58.0% (50.1% to 65.8%)
Grade ≥ 2 31.8% (24.9% to 38.8%)
PEDIS: depth
Grade 1 55.8% (45.6% to 66.0%)
Grade 2 43.6% (35.0% to 52.3%)
Grade 3 35.5% (27.0% to 44.0%)
PEDIS: infection
Grade 2 54.2% (45.2% to 63.2%)
Grade 3 and 4 39.6% (33.2% to 46.0%)
Ulcer on index foot only
Single index ulcer on index foot 49.7% (43.4% to 55.9%)
> 1 ulcer on index foot 29.6% (19.5% to 39.7%)
Wound duration (median split)
≥ 56 days 35.3% (28.4% to 42.3%)
< 56 days 55.1% (46.5% to 63.7%)
Antimicrobial dressing
Yes 38.8% (32.0% to 45.6%)
No 53.1% (44.9% to 61.4%)
MRSA
Yes 26.8% (11.5% to 42.2%)
No 46.3% (40.6% to 52.1%)
CNS
Yes 60.4% (46.7% to 74.1%)
No 42.1% (36.3% to 48.0%)
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TABLE 72 Subdistribution hazard regression analysis
Baseline factors df
Univariate
Preliminary
multivariable Final multivariable
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Age (continuous) 1 1.00
(0.99 to 1.02)
0.5887 1.02
(1.00 to 1.04)
0.0169* 1.02
(1.01 to 1.04)
0.0081*
Age: > 63 vs. ≤ 63 years 1 1.39
(0.99 to 1.95)
0.0543*
Diabetes duration years
(continuous)
1 0.99
(0.98 to 1.01)
0.5268 1.00
(0.98 to 1.02)
0.7518
Diabetes duration:
≥ 15 vs. < 15 years
1 0.85
(0.61 to 1.20)
0.3615
Diabetes type: type 2 vs.
type 1
1 1.11
(0.67 to 1.84)
0.6915 0.78
(0.41 to 1.49)
0.4524
Patient receiving insulin
therapy: yes vs. no
1 0.80
(0.57 to 1.13)
0.2038 0.84
(0.54 to 1.32)
0.4578
HbA1C (continuous) 1 0.96
(0.89 to 1.03)
0.2518 0.99
(0.89 to 1.09)
0.8237
Ulcer type: any ischaemia
vs. neuropathic only
1 0.50
(0.35 to 0.71)
< 0.0001* 1.09
(0.59 to 2.02)
0.7837
Ulcer grade 2 0.0113* 0.3343
Grade 2 vs. grade 1 0.65
(0.44 to 0.98)
0.0397 0.56
(0.25 to 1.23)
0.1477
Grade ≥ 3 vs. grade 1 0.55
(0.36 to 0.82)
0.0038 0.59
(0.25 to 1.37)
0.2159
PEDIS perfusion:
grade ≥ 2 vs. grade 1
1 0.44
(0.31 to 0.62)
< 0.0001* 0.43
(0.22 to 0.83)
0.0113* 0.37
(0.25 to 0.55)
< 0.0001*
Ulcer extent (continuous) 1 0.99
(0.97 to 1.01)
0.2766 1.00
(0.99 to 1.01)
0.8500
PEDIS: depth 2 0.0172* 0.3298
Grade 2 vs. grade 1 0.70
(0.47 to 1.05)
0.0843 1.61
(0.74 to 3.49)
0.2311
Grade 3 vs. grade 1 0.54
(0.35 to 0.83)
0.0046 1.16
(0.47 to 2.91)
0.7451
PEDIS: infection – grade 3
and 4 vs. grade 2
1 0.65
(0.46 to 0.91)
0.0135* 0.91
(0.59 to 1.41)
0.6831
PEDIS: sensation – grade 2
vs. grade 1
1 0.70
(0.40 to 1.23)
0.2139 0.60
(0.33 to 1.11)
0.1036
Incident or recurrent ulcer:
recurrent vs. incident
1 1.11
(0.79 to 1.56)
0.5603 1.27
(0.85 to 1.91)
0.2487
Only ulcer on index foot:
yes vs. no
1 1.96
(1.25 to 3.07)
0.0034* 1.91
(1.15 to 3.17)
0.0122* 1.90
(1.18 to 3.06)
0.0081*
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TABLE 72 Subdistribution hazard regression analysis (continued )
Baseline factors df
Univariate
Preliminary
multivariable Final multivariable
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Ulcer location 3 0.6810 0.9856
Dorsum vs. apex/
interdigital/digital
0.72
(0.41 to 1.27)
0.2572 1.01
(0.52 to 1.94)
0.9828
Other/missing vs.
apex/interdigital/digital
0.68
(0.20 to 2.33)
0.5371 1.08
(0.25 to 4.74)
0.9141
Plantar vs. apex/
interdigital/digital
0.92
(0.64 to 1.32)
0.6451 1.09
(0.70 to 1.70)
0.7007
Wound duration:
≥ 56 vs. < 56 days
1 0.54
(0.39 to 0.76)
0.0004* 0.46
(0.30 to 0.70)
0.0003* 0.55
(0.39 to 0.77)
0.0005*
Previous antibiotic therapy:
yes vs. no
1 0.86
(0.61 to 1.21)
0.3791 0.91
(0.61 to 1.36)
0.6475
Antimicrobial dressing:
yes vs. no
0.65
(0.46 to 0.91)
0.0123* 0.77
(0.52 to 1.14)
0.1934
Any reported pathogens:
yes vs. no
1 0.82
(0.50 to 1.36)
0.4487 0.79
(0.36 to 1.70)
0.5414
Overall anaerobes:
yes vs. no
1 0.83
(0.55 to 1.26)
0.3884 0.78
(0.48 to 1.27)
0.3146
MRSA: yes vs. no 1 0.50
(0.26 to 0.97)
0.0419* 0.67
(0.28 to 1.63)
0.3802
Gram-positive cocci:
yes vs. no
1 0.83
(0.58 to 1.19)
0.3039 0.82
(0.39 to 1.69)
0.5841
Gram-negative bacilli:
yes vs. no
1 0.77
(0.54 to 1.10)
0.1474 1.34
(0.56 to 3.17)
0.5071
Enterobacteriaceae
including coliforms:
yes vs. no
1 0.75
(0.51 to 1.11)
0.1449 0.63
(0.27 to 1.49)
0.2952
Gram-positive bacilli:
yes vs. no
1 1.08
(0.64 to 1.81)
0.7768 1.06
(0.26 to 4.38)
0.9364
MSSA: yes vs. no 1 1.20
(0.84 to 1.70)
0.3170 1.27
(0.79 to 2.05)
0.3229
Streptococcus: yes vs. no 1 1.08
(0.68 to 1.72)
0.7383 1.10
(0.65 to 1.83)
0.7292
Enterococcus excluding
vancomycin resistant:
yes vs. no
1 0.72
(0.44 to 1.15)
0.1702 0.86
(0.50 to 1.47)
0.5713
CNS: yes vs. no 1 1.69
(1.11 to 2.59)
0.0147* 1.98
(1.08 to 3.61)
0.0270* 1.53
(0.98 to 2.40)
0.0603*
Corynebacterium:
yes vs. no
1 1.17
(0.67 to 2.07)
0.5794 0.89
(0.18 to 4.35)
0.8894
Pseudomonas: yes vs. no 1 0.82
(0.45 to 1.48)
0.5055 0.66
(0.27 to 1.66)
0.3818
df, degrees of freedom.
*Significant at the 10% level (green text).
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Univariate analysis of incidence of healing
Univariate analysis (see Table 72) showed a significant association (p-value < 0.1) between the incidence
of healing and perfusion (p-value < 0.0001), ulcer type (p-value=< 0.0001), wound duration
(p-value= 0.0004), presence of other ulcers (p-value= 0.0034), Wagner ulcer grade (p-value= 0.0113),
presence of an antimicrobial dressing (p= 0.0123), infection (p-value= 0.0135), ulcer depth
(p-value= 0.0172), CNS (p-value= 0.0147) and MRSA (p-value= 0.0419).
Significant associations were such that the incidence of healing was lower for patients with:
l ischaemic ulcers compared with neuropathic ulcers, with a hazard ratio (HR) of 0.5 (95% CI 0.35 to 0.71)
l a Wagner ulcer grade of 2 (ulcer extension without abscess or osteomyelitis) or ≥ 3 (at least a deep
ulcer with abscess, osteomyelitis or sepsis) compared with a grade 1 ulcer (superficial), with HRs of 0.65
(95% CI 0.44 to 0.98) and 0.55 (95% CI 0.36 to 0.82), respectively
l a perfusion grade ≥ 2 (indicating PAD), with a HR of 0.44 (95% CI 0.31 to 0.62)
l a depth/tissue loss grade 2 (penetrating to skin structures) or grade 3 ulcer (penetrating all layers of
foot) compared with a grade 1 ulcer (superficial), with HRs of 0.70 (95% CI 0.47 to 1.05) and 0.54
(95% CI 0.35 to 0.83), respectively
l a ≥ grade 3 infection (extensive erythema or systemic inflammatory response) compared with a
grade 2 infection (infection without involvement of deeper tissues or systemic signs), with a HR of 0.65
(95% CI 0.46 to 0.91)
l older ulcers (≥ 56 days), with a HR of 0.54 (95% CI 0.39 to 0.76)
l an antimicrobial dressing on their ulcer at baseline, with a HR of 0.65 (95% CI 0.46 to 0.91)
l MRSA reported from their index ulcer at baseline, with a HR of 0.50 (95% CI 0.26 to 0.97).
The incidence of healing was higher for patients with:
l a single ulcer on their index foot, with a HR of 1.96 (95% CI 1.25 to 3.07)
l CNS reported from their index ulcer at baseline, with a HR of 1.69 (95% CI 1.11 to 2.59).
Age, categorised at the median, was also found to be associated with an increased incidence of healing
for patients > 63 years of age; however, this result is somewhat counterintuitive and is not supported by
the analysis performed using a continuous age parameter. This association was not supported by an
association with healing for other categorisations of age, suggesting a spurious result for the significant
association for age.
Table 71 presents 12-month healing estimates for factors found to have a significant relation to the
incidence of healing in the univariate analysis (excluding age). Furthermore, plots of the cumulative
incidence of healing, by each of these factors can be found in Appendix 3.
Preliminary multivariable analysis
Preliminary multivariable analysis included all potentially prognostic factors in a single proportional
subdistribution hazards model, with the following showing a significant association with the incidence
of healing: wound duration (p-value= 0.0003), perfusion (p-value= 0.0113), presence of other ulcers
(p-value= 0.0122), age (continuous, p-value= 0.0169) and CNS (p-value= 0.0270) (see Table 72).
The slightly increased healing incidence for age should, however, be interpreted with some caution owing
to both the proximity of the HR to 1 (with the lower limit of the CI including 1, which represents no
difference) and the lack of consistency between the univariate and multivariable model in which there was
no evidence of a difference in healing when age was considered independently of other factors on the
continuous scale. Age was further investigated in terms of associations with other factors in order to
identify if this result was attributable to an unusual case mix of patients, for example, whether or not older
patients had less severe ulcers. The Cochran–Armitage test for trend between age, split according to
quartiles, found significant trends (at the 10% level) with ulcer type, death, dressing, wound duration,
PEDIS infection and perfusion; however, in each case the trend was such that older patients had the more
severe ulcer in terms of each prognostic factor.
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The assumption of proportional hazards was valid for the majority of factors (see Appendix 3). However,
there was some evidence against the proportional hazards assumption for CNS, with an increased
incidence of healing in patients without CNS prior to 1 month post sampling, but an increased and
increasing incidence of healing in patients with CNS after 1 month (i.e. non-constant HR). The assumption
is satisfied for the reference grade 1 of both the depth/tissue loss classification and Wagner ulcer grade;
however, there is some suggestion of non-proportionality for grades 2 and 3+ (for the Wagner scale)
owing to the reduced differences observed in the cumulative incidence for these levels, which may suggest
that grouping grades > 1, for both the depth/tissue loss classification and Wagner ulcer grade, may not
result in a substantial loss of information on the likely incidence of healing.
Final multivariable analysis
The final multivariable analysis included only those factors found to be significant in the preliminary
multivariable model: perfusion (p-value=< .0001), wound duration (p-value= 0.0005), presence of other
ulcers (p-value= 0.0081), age (continuous, p-value= 0.0081) and CNS (p-value= 0.0603) (see Table 72).
Similar to estimates for the previous models, these factors were such that the incidence of healing was
lower for patients with:
l perfusion grade ≥ 2 relative to patients with grade 1, with a HR of 0.37 (95% CI 0.25 to 0.55)
l older ulcers (≥ 56 days), with a HR of 0.55 (95% CI 0.39 to 0.77).
The incidence of healing was higher for:
l patients with a single ulcer on their index foot relative to patients with more than one ulcer, with a HR
of 1.90 (95% CI 1.18 to 3.06)
l older patients, increasing with each year of age, with a HR of 1.02 (95% CI 1.01 to 1.04); however,
this is suspected to be a spurious relationship
l patients with CNS reported from their ulcer at baseline, with a HR of 1.53 (95% CI 0.98 to 2.40).
Associations between factors
When all factors were included in the complete multivariable model, ulcer type, depth, infection, Wagner
ulcer grade, antimicrobial dressing and MRSA were no longer significant at the 10% level owing to
correlations with other baseline factors. The influence of these factors on the incidence of healing was
therefore better explained by other associated factors, in this case the remaining significant factors: PEDIS
perfusion, only ulcer, wound duration, CNS and age. Details of associations between factors with a
significant association with healing in the univariate analysis (excluding age) can be found in Table 73.
Ulcer type, perfusion, depth, infection and Wagner ulcer grade were all found to have significant pairwise
associations; of these, perfusion was the only factor to remain significant in the complete multivariable
model, with a higher perfusion grade associated with ischaemic ulcers, higher depth grade, higher
infection grade and higher Wagner ulcer grade.
Ulcer type was also further associated with only ulcer, wound duration and CNS, which remained
significant in the multivariable model, such that ischaemic ulcers were associated with having more than
one ulcer, older ulcers and less presence of CNS.
The presence of an antimicrobial dressing, non-significant in the multivariable model, was associated with
higher perfusion grades and older ulcers which remained significant in the multivariable model, suggesting
that the association between antimicrobial dressing and a reduced incidence of healing may be explained
by the antimicrobial dressing having been present on more severe ulcers.
Finally, MRSA was also found to be non-significant in the multivariable model, which may be explained by
the association with ulcer types in which there was a greater presence of MRSA for ischaemic ulcers.
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There was also a negative association with CNS, in which MRSA and CNS were not reported from the
same sample for any patients; therefore, MRSA was present only when CNS was not and vice versa, which
may also help explain the greater incidence of healing when CNS was present (i.e. because MRSA
was not).
Discussion
This substudy has reported on the prognosis associated with infected DFUs. This information is necessary
for the planning of clinical trials of interventions for infected foot ulcers and, in our analysis, we have been
able to identify relationships between factors associated with poor prognosis, as well as competing risks,
which are important for trial planning.
For clinicians, these data confirm the poor prognosis associated with infected DFUs. The healing rate is
lower than other published healing rates from non-selected cohorts. For example, in the largest study,
Eurodiale, the 12-month outcome (in 1232 consecutive patients, of whom 58% had infection at first
presentation) found that 77% of the patients healed (with or without a minor amputation), 5%
underwent a major amputation and 6% died.22 Although one may suggest that our results lend credence
to the proposal that infection is associated with poor outcomes, Prompers et al.22 did not find this within
Eurodiale, and the authors observed no differences for major amputation or healing rate between
neuropathic ulcers with and without infection. They did observe that infection was a risk factor for minor
amputation and suggest that their result indicates that aggressive treatment of infection in the
participating centres meant that the impact of infection on healing was minimised.22
This study confirmed the prognostic value (using univariable analysis techniques) of ulcer perfusion grade
(PAD vs. no PAD), ulcer type (ischaemic vs. non-ischaemic), wound duration (< 56 days, ≥ 56 days),
presence of other ulcers, Wagner ulcer grade, presence of antimicrobial dressing, infection grade,
TABLE 73 Association between factors that were significant in the univariate analysis presenting significant
p-valuesa
Ulcer
type
Ulcer
grade
PEDIS
perfusion
PEDIS
depth
PEDIS
infection
Only
ulcer
Wound
duration
Dressing MRSA CNS
< 0.0001 < 0.0001 < 0.0001 0.0036 0.0300 0.0219 0.0012 0.0042 0.0453 Ulcer type
< 0.0001 < 0.0001 < 0.0001 Ulcer grade
< 0.0001 0.0002 0.0423 < 0.0001 PEDIS
perfusion
< 0.0001 PEDIS depth
PEDIS
infection
Only ulcer
0.0201 Wound
duration
Dressing
0.0376 MRSA
CNS
a Shaded cells in the top row and final column indicate factors that were no longer significant in the multivariable analysis,
whereas non-shaded cells indicate factors that remained significant. Non-shaded cells containing a p-value indicate
associations where one factor remained significant in the multivariable model while the other did not, and cells without
a p-value indicate non-significant associations at the 5% level.
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depth grade, presence of CNS, presence of MRSA and age with the incidence of healing. We propose that
the association of increased healing with higher age may be spurious as we are unaware of biological
mechanisms that might explain increase healing at older age, and the association did not endure when
age was modelled as a continuous factor rather than dichotomised one.
The association of CNS with an increased risk of healing may be in part attributable to a negative
association between MRSA and CNS.
The observation of reduced healing for ulcers that had an antimicrobial dressing on at baseline was not
expected. However, this is not an indication that antimicrobial dressings per se are associated with delayed
healing (there is, in fact, very little robust evidence of the relationship between antimicrobial dressings and
improved outcomes such as healing). It may be, in this population, a proxy for wound severity (i.e. the
most severe ulcers were those that had an antimicrobial dressing applied).
There were correlations between many of the factors associated with healing. Subsequent multivariable
modelling to account for this suggested that wound duration, ulcer perfusion grade and presence of other
ulcers provide the best independent predictors of healing.
We found no association between diabetic control and outcomes, and this may represent low power to
detect an association. This is in contrast to the recent work of Christman et al.111 who found that HbA1C
was associated with healing outcomes in a retrospective study of 187 Americans with diabetes (average
2.3 wounds per patient, the majority of which were foot ulcers). Diabetic control was a significant factor
only in insensate neuropathic wounds rather than in the whole sample, however.
Unlike Ince et al.,107 we found no association between duration of diabetes and outcomes. Margolis et al.112
identified an association between wound area, wound depth, wound duration and healing (using
multivariate analysis on a data set with > 31,000 patients); however, we found no association between
these variables and healing in our population. This may be due to power or to the overwhelming effect of
infection in determining healing outcomes for this group.
Of the domains within the PEDIS assessment tool, perfusion proved to be the strongest prognostic factor
in our study. Depth and infection were both also shown to be associated with healing but were not,
however, retained in the multivariate model including all factors, and sensation and area (extent) did not
emerge from the model at all. All participants were clinically diagnosed as infected; therefore, infection
compared ulcers with extensive erythema or systemic inflammatory response to those without involvement
of deeper tissues or systemic signs. The lack of association between area and healing is also is different
from other studies. Our analysis has investigated the association of single pathogens with healing and, in
future, we may be able to investigate the associations for different spreads of pathogens. This would allow
us to determine the impact of infection profiles on clinical outcomes.
One of the strengths of this study is the acknowledgement of and the approach to dealing with competing
risks. This is the first study we are aware of that has dealt with patient death or amputation in this way
when estimating time to healing and the prognostic value of different clinical factors. In using cumulative
incidence functions to account for the competing risks of death or amputation, which prohibit the incidence
of healing, rather than censoring patients at their date of death or amputation (i.e. Ince et al.107), we have
not overestimated the rate of healing. Indeed, had a conventional proportional hazards regression analyses
been applied, the healing rate at 12 months would have been overestimated by almost 10%.
One of the limitations of this study is the incomplete patient follow-up. We are not able to determine
whether or not those missing from the follow-up population were systematically different from those who
we did include. We were able to determine that missing case-note reviews for the 101 patients without
follow-up data were not found to be associated with the timing of patient entry into CODIFI, or by study
centre with patients appearing to be missing a case-note review at random. Missing case-note review
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could indicate that a patient lost contact with a site (i.e. owing to healing and no need for contact) or
equally that they were ill or still with ulcer and did not want to provide consent.
As the pattern of having both healing and amputation at different sites on the foot made for complex
data collection and analysis, researchers in this area may wish to design studies to ensure completeness of
data recording in terms of the relationship between multiple ulcers and how to reference the index ulcer
> 12 months after initial sample collection. It would have been useful also to collect overall patient
outcome (i.e. ulcer free, not just index ulcer).
In this follow-up study, we did not control recall to hospital for follow-up or frequency of patient
appointments. Given that we undertook case-note review at 12-month follow-up, some patients would
have been between appointments or would not have been seen for some length of time at 365 days.
Clinicians completing the follow-up data additionally provided data on a range of ‘other’ events. These
‘other’ reported events may be clinically important events to collect in future studies.
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Chapter 6 Conclusions
Results from main study: agreement between swab and
tissue sampling
We compared the reported presence of isolates likely to be pathogens using both techniques. Swab results of
395 patients with DFUs and suspected infection yielded no bacterial isolates at all in 20% of samples. Despite
these wounds being clinically assessed as infected, 29.9% of swab reports noted no potential pathogens.
For tissue sampling the rates were lower: 10% had no bacterial isolates reported and 13.9% of reports cited
no pathogens (only contaminating/colonising flora). Given that wounds are not sterile, the high ‘no isolates’
rate suggests that sample collection and/or transport were less than optimal. In addition, the ‘no pathogens’
rate might indicate that clinicians have a low threshold for suspecting infection in DFUs given the clinical
consequences of failing to detect and treat foot infection promptly. This may result in some wounds with
suspected infection being merely colonised (i.e. yielding no pathogens). However, the high ‘no isolates’ rate
suggests that another explanation is that collection and transport of samples were suboptimal and, hence,
pathogens in the wound were either not collected or did not survive transport. Tissue samples were better
than wound swabs in collecting and transporting to the laboratory live bacteria from DFUs, with half the
chance of reporting no isolates compared with wound swabbing (10% vs. 20%). To improve the collection of
microbiology samples from wounds with suspected infection, it may be necessary to improve collection and
transport such that fastidious and anaerobic organisms are preserved for subsequent culture and analysis.
We had specified that clinicians used the Levine et al.48 technique for swab sample collection, noting that this
was identified as superior to two other swab techniques by Gardner et al.;113 however, the pragmatic nature
of the study meant that we did not restrict sampling to a subset of clinical staff whose technique had been
assessed as producing the sufficient wound surface pressure to express wound fluid from the ulcer bed, nor did
our protocol require validation regarding the level of cleansing and debridement performed prior to sampling.
Overall, the most frequently reported pathogens were S. aureus (35.7%), Streptococcus (16.7%),
Enterococcus (14.9%), CNS (12.2%), Corynebacterium (9.4%), Pseudomonas (8.6%) and MRSA (8.1%).
Considering each of the potential pathogens separately allowed us to determine patterns of agreement
across different pathogens. This was important, as combining pathogens would mask potentially important
differences. It is possible to have disagreement in identification of pathogens when both methods report
the same prevalence: swab reports 10% and tissue sample reports 10%, but there is symmetrical
disagreement whereby some tissue results are positive and swab reports are negative for a particular
pathogen and vice versa. We therefore reported both prevalence of identification of pathogens and
agreement rates by pathogen.
Reported prevalence of pathogens was identical for S. aureus and Pseudomonas and very similar (1%
different) for MRSA, whereas for all other groups of potential pathogens the prevalence was statistically
significantly higher from tissue samples than from swab samples. In 80% of patients there was agreement
in the parameter ‘at least one pathogen identified’, meaning that the disagreement rate was 20% for
‘≥ 1 pathogen’. This does not convey the extent of variation between pathogens, however, and the
disagreement was low for MRSA (1.5%), Pseudomonas (4.1%) and S. aureus (8.1%). For anaerobes,
by way of contrast, disagreement was 16.5%. Overall, therefore, the agreement between wound
swabbing and tissue sampling is high for three of the most prevalent pathogens, S. aureus, MRSA and
Pseudomonas. For other pathogens, the swab reported organisms significantly less often than tissue
samples. This might indicate that wound swabbing and tissue sampling have comparable yields for these
three organisms. When sampling is designed to provide information on the wound biome with no prior
expectation of the infecting organisms, however, then using a tissue sample will more often report the
presence of organisms than a swab sample. It is not possible from these data to determine whether
the higher yield is associated with higher survivability of organisms or better collection.
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As well as measuring disagreement (proportion of samples in which the tissue and swab samples did not
agree regarding the presence/absence of a specified organism), the commissioning brief determined that we
should also report the agreement using the κ-statistic. There is discussion among statisticians about the use
of Cohen’s kappa in measuring agreement (which will not be rehearsed here), but, for completeness, we
reported percentage disagreement as well as kappa and PABAK. Although the kappa and PABAK for these
outcomes were at a level usually associated with ‘fair’ to ‘high’ agreement, researchers have argued that
they are imperfect summary statistics for determining the ability to replace one assessment tool with
another, as the consequences of disagreement (such as not identifying an aggressive pathogen with one
method), and hence the clinical implications of delayed diagnosis and treatment need to be considered.
Guidelines for reporting agreement studies note that some authors require high agreement levels when tools
are used to make individual and important clinical decisions, for example, suggesting that a tool should have
reliability levels of at least 0.9 when being used to make an individual assessment of pressure ulcer risk.114
The number of different bacterial pathogens reported differed between tissue sampling and wound
swabbing. Overall, tissue sampling identified more species than wound swabbing, with a median of
1.5 pathogens identified per tissue sample and 1 per wound swab. Given that the wound swab collected
wound tissue from a greater area than the tissue sample, it might be expected that wound swabs would
report a higher number of potential pathogens; therefore, this finding might be attributable to poorer
pathogen survival in swab samples than tissue samples or insufficient pressure used during swab sample
collection to allow deeper-wound-fluid-containing pathogens to be expressed.
We also reported the proportions of patients in whom the same bacteria were identified in each report,
where additional bacteria were identified in the tissue sample over the swab sample (but all the swab
bacteria were also identified), where additional bacteria were identified in the swab over the tissue sample
(but all the tissue sample bacteria were reported in the swab sample) and where there was a difference in
pathogens reported. Swab and tissue results reported the same pathogens in 42% of patients; a swab
reported additional pathogens to those in the tissue sample in 8.1% of patients; tissue samples reported
additional pathogens to those in the swab in 36.7% of patients; and, the tissue sample and swab
specimens reported different pathogens, with or without overlap, in 13.2% of patients. These differences
were unrelated to any clinical characteristics (type of ulcer, etc.) except potentially the wound duration:
for wounds open for > 56 days, the odds of their tissue sample reporting additional pathogens (compared
with swab sample) was lower than for young wounds, although this relationship was not present when
duration was analysed as a continuous variable. This may be due to the change in biome as wounds age
and become increasingly polymicrobial, for example, or may be a chance finding; therefore, it is worthy of
further study in future research. The chance of identifying additional isolates (likely pathogens) with a tissue
sample is therefore potentially clinically significant; however, if these isolates are present in low numbers
then it may represent an increase in overall information about the wound biome with no impact on the
clinical assessment regarding the likely cause of infection and the appropriate antibiotic regimen. For this
reason, we added the substudy whereby a clinical panel review was undertaken to determine whether or
not the (usually) higher amount of information from tissue samples translated into different analyses by
clinicians reviewing the microbiology reports while blind to source (swab or tissue). Overall, the microbial
diversity (number of species) was higher when wounds were sampled using tissue rather than swab.
The microbial load, assessed semiquantitatively, was compared between tissue and swab. Agreement
between the two techniques for MRSA (overall κ= 0.73), Pseudomonas (overall κ= 0.58), Streptococcus
(overall κ= 0.65) and S. aureus (overall κ= 0.64) was in the ‘moderate’ to ‘substantial’ range, but was
lower for anaerobes (overall κ= 0.32). We were unable to conclude overall if the microbial load
(as summarised in +/++/+++) was consistently higher for either sampling technique.
The presence of antimicrobial resistance among likely pathogens was low (33 patients overall), and there
was disagreement about the presence of resistance in only 6 patients and, hence, detailed analysis was
not undertaken.
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The rates of sampling-related AEs were higher for tissue sampling than for wound swabbing, both in terms
of the pain reported by patients and sampling-related bleeding (6% in cases related to tissue sampling
alone, 0.8% cases related to swab sampling alone, and related to sampling of any form in 0.8% of other
cases). This equates to a number needed to harm of 20: for every 20 patients undergoing tissue sampling
rather than wound swabbing, there would be one additional case of clinically concerning bleeding. We did
not have any reports of further sequelae of sampling; we did not collect data at the next visit, for example,
but there were no reports of RUSAEs throughout the study.
One-quarter of patients reported pain before sampling, and we recorded sampling-associated pain after
swabbing and again after tissue sampling (swabbing always preceded tissue sample collection). A total of
5 patients (1.3%) reported that pain increased (from baseline) on swabbing, and 37 patients (9.3%) reported
that it increased after tissue sampling. This equates to a number needed to harm of 13, although overall
(in 89.5% of patients) ulcer pain remained the same after sampling. Despite the vast majority of these patients
having neuropathy, we cannot assume that these wounds are painless, that patient comfort is not affected by
sampling technique or that, overall, swab sampling is associated with a lower risk of sampling pain.
We sought to report the costs of sampling using each of the two techniques but found limited information
on the real costs of techniques, with some centres considering such information commercially sensitive and
hence being unwilling to provide it. The cost of sampling can include a number of elements, not all of which
will have been included in the costs quoted by those centres providing information. For example, the clinical
time involved in wound bed preparation (cleansing and debridement) may not be captured. The relative
differences between swab costs and tissue sample costs was 4% in one site (£15.55 vs. £16.53) and 49% in
another (£3.91/£5.85). These costs do not include sampling equipment, transport or clinician time. Further
work is required to understand the economics of wound swabbing versus tissue sampling.
It appears, therefore, that if one wishes to identify the presence of S. aureus, MRSA or Pseudomonas in a
clinically infected wound (diagnosed with regard to clinical appearance, signs and symptoms) then tissue
sampling is, broadly speaking, comparable to swab sampling for these clinically important pathogens
both in terms of identifying the presence of the pathogen and in determining the bacterial load in a
semiquantitative manner. By taking a tissue sample instead of a swab, however, it is likely that a larger
number of pathogens will be identified. It is not clear whether this difference in yield is due to poorer
collection, survival in transport or lower reporting of the bacteria collected using wound swabs.
Interestingly, the small number of swabs analysed in the substudy of molecular microbiology (PCR)
techniques had a higher number of pathogens identified than either the cultured swab results, or the
tissue samples (cultured or PCR), and as PCR is able to identify and multiply dead bacteria, this suggests
that swabs collect more bacteria than tissue but that more of the species die in transport.
In a small proportion of cases, swab samples identify pathogens in addition to those identified from tissue
sampling, which is likely to be attributable to the heterogeneity in location of pathogens across the wound
surface and the fact that a wound swab gathers material from a larger area. This means that choosing
one sample technique leads to a trade-off in information for 58% of patients. One approach might be to
consider the two techniques as complementary, but performing both procedures would lead to increased
costs and patient pain/bleeding complications. Choosing to take a tissue sample over a swab also leads to
a small increase in the number of patients experiencing pain and bleeding of clinical concern.
Results from the substudies
Clinical review panel
A clinical panel review substudy was undertaken to identify if any differences identified in the main study
in sampling yield were potentially clinically relevant. If one sampling technique provided more information
but did not result in any therapeutic changes (compared with a reference method of sampling), then the
additional information may not be clinically important. As all patients in this study had both samples taken
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and clinicians had access to both reports, we were not able to identify whether or not any clinical changes
initiated were attributable to either swab or tissue sampling microbiology reports. We presented paired
and blinded microbiology reports to clinicians to ask them if patients’ antimicrobial regimes ‘covered’ the
pathogens reported, and also if a change in therapy was warranted, based solely on the microbiology
results. The decision to change antimicrobial therapy would not, in practice, be taken on the basis of a
laboratory test result alone, with clinical assessment of the patients and their wound playing a major part
in clinical decision-making; however, as clinicians were presented with imperfect information (i.e. with no
clinical data) for both swabs and tissue sample microbiology reports, we propose that this approach allows
some analysis of the amount of clinically relevant information provided by the laboratory reports.
We assessed the inter- and intrarater reliability of these assessments and determined that the intrarater
reliability for 7 of 13 assessors was ‘moderate to substantial’70 for a change in therapy (κ= 0.59 for tissue
and κ= 0.77 for swab results), with inter-rater reliability lower at κ= 0.35 for swab and κ= 0.66 for tissue
samples, meaning that there was at least ‘fair’70 agreement between the clinical reviewers for swab
samples but substantial agreement for tissue samples. Having established adequate agreement between
clinicians (and where agreement was low, this was overcome as each clinician reviewed both patients
swab and tissue sample vignettes), we determined the proportion of patients for whom the prescribed
antimicrobial regimen was deemed to be insufficient. For 1 in 5 patients (19.8%), a tissue sample report
was assessed by clinicians as indicating that the empirical antibiotic regimen did not cover the pathogens
reported (whereas the swab sample results did). Conversely, for 1 in 12 (8.5%) patients, the swab sample
results suggested that the empirical antibiotic regimen did not cover the pathogens reported, whereas the
tissue sample results did. A change of strategy from swab sampling to tissue sampling would result in
11.5% (1 in 9) of patients additionally being deemed to ‘not be covered’ by their current regimen. Any
sampling regimen using a single method of ulcer sampling would be associated with potentially missing
pathogens and the resultant assessment would be influenced by the source of the laboratory report.
The results for ‘change in therapy required’ were very similar, given the relationship between these two
outcomes. For 1 in 12 (8.9%) patients, the tissue sample results suggested no change, whereas the swab
sample results did suggest that a change was required. For 1 in 6 (17.8%) patients, the swab sample
results suggested no change, whereas the tissue sample results did suggest that a change/initiation was
required. A change of strategy from swab sampling to tissue sampling would result in 8.9% (1 in 11) of
patients potentially having a change in antimicrobial regimen.
Although it is tempting to conclude that clinicians should use the sampling technique that result in the
highest number of pathogens and the highest rate of potential therapeutic changes, the data from this
study cannot determine whether or not tissue sampling is necessarily associated with better clinical
outcomes. In managing infected DFUs, there may be a trade-off between tissue sampling and swabbing.
Swabbing may be less expensive and require less training to perform, fewer patients may experience
sampling pain or bleeding, and the reduced report of pathogens may be sufficient to guide therapy
changes at clinical reassessment. Indeed, the survey of practice at sites indicated that microbiologists,
working with clinicians in the clinics/wards, sometimes used their expertise to filter the content of the
laboratory reports so that they included the material most relevant to the clinical condition (and omitting
some low number isolates likely to be non-pathogenic) (see Appendix 3). Neither swab result nor tissue
sample microbiology results produced by plating and culture arrive in the clinic in sufficient time to guide
initiation of antimicrobials for the vast majority of patients and, hence, currently the role of wound
sampling is to guide the tailoring of therapy at day 3 and beyond, when a clinical assessment will also be
undertaken. Although plating and culture are the mainstay of microbiological analysis in wounds, there are
a number of potential sampling scenarios, as outlined below:
l Sampling to be undertaken upon first clinical assessment of infection using a swab, and any
subsequent sampling to be undertaken by tissue sample. This would be, for example, should the
clinical assessment or microbiology report determine that the empirical antimicrobial regimen is
inadequate. This would expose only patients for whom additional information was needed to the
potential harms of tissue sampling.
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l Initial sampling with both swab and tissue sample performed to capture the maximum amount of
wound microbiology information. This would expose all patients to the harms of tissue sampling.
l Sampling undertaken at initial assessment by taking a piece of tissue, knowing that this gives a better
yield than swabbing, after determining that the risk of pain and bleeding is warranted. Some
organisms are likely to be missed by tissue sampling alone, however.
l Sampling undertaken at initial assessment by swabbing using Levine et al.’s technique,48 as happens in
some sites at present. This gives a lower yield than tissue sampling but reduces the risk of pain and
bleeding. A large proportion of potential pathogens are likely to be missed by swabbing alone, however.
For other clinical scenarios (e.g. not DFUs) in which wound samples are taken with the goal of identifying
the infecting organisms prior to antibiotic prescription, the trade-offs may be different.
Comparing culture and polymerase chain reaction techniques
For 14 patients, both swab and tissue samples were sent for analysis of bacterial RNA (dead and alive) and
the results were compared with culture microbiology results. There was agreement between PCR and
culture for one in three patients, but in half the patients, PCR analysis reported additional pathogens. PCR
techniques more frequently reported the presence of a higher number of pathogens (in terms of bacterial
diversity); for example, for the two swabs taken from each wound, the PCR analysed swab reported a
median of 2.5 pathogens and the culture results a median of 1 pathogen. The difference was smaller for the
tissue results, with PCR reporting a median of 1.5 pathogens and culture results a median of 1 pathogen.
In contrast to the results found using culture techniques, swab samples reported more pathogens than
tissue samples (when both analysed by PCR). For the 12 samples with complete data, the culture results
were that the swab and tissue agreed in 50% of patients and that tissue samples reported additional
pathogens (i.e. over swab in 33%, with disagreement in 16.7%). Using PCR, however, the agreement rate
was lower at 25%, and swabs identified more pathogens than tissue samples in 33% of patients, tissue
identified additional pathogens in 16.7% of patients and there was disagreement in 25%. This indicates
that both the choice of sampling technique and the method of analysis affects the yield from swabbing
versus tissue sampling. The lower yield from swab samples and culture may be related to low viability of
the bacteria sampled, secondary to sampling technique, transport media or delay in analysis owing to
timing of collection from clinic/ward or at the laboratory. Any change in sampling technique (e.g. from
swab to tissue) must be considered with reference to the sample analysis technique as the roll-out of PCR
facilities in more hospitals may mean that wound samples can be analysed more quickly and that the
differential yield identified using culture techniques is minimised when using PCR. This would influence the
trade-off between swabbing and tissue sampling.
Prognosis of foot ulcer infection
We determined, at around 12 months, if patients had experienced ulcer healing, a revascularisation
procedure, amputation, reulceration or had died. As there are no validated tools available to make a
clinical diagnosis of resolution of infection, we did not collect data on the time to resolution. Over the
12-month period after ulcer infection, some patients experienced multiple events and, therefore, we used
competing risks analyses to appropriately consider the risks of events. The relationship between these
outcomes and baseline characteristics, including pathogens identified, were assessed.
The ulcer healing rate at around 12 months was 45.5%, indicating the poor prognosis associated with
infected foot ulcers. Of those unhealed ulcers, 20% were not healed at 12 months despite an amputation,
57% of patients had an unhealed ulcer, and the remaining 22.7% of patients had died. Accounting for
the competing risks of death or amputation, the estimated cumulative incidence of healing at 12 months
post sampling was 44.5% (95% CI 38.9% to 50.1%).
With a univariate analysis we identified an association between reduced risk of healing and the following
factors: ischaemic (vs. neuropathic) aetiology, increasing Wagner grade, increasing perfusion grade,
increased ulcer depth/tissue loss, infection at grade 3 or above (extensive erythema or systemic
DOI: 10.3310/hta20820 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 82
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Nelson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
109
inflammatory response), ulcer duration ≥ 56 days (vs. < 56 days), presence of an antimicrobial dressing
and MRSA.
Factors associated with increased risk of healing included having a single foot ulcer, the presence of CNS
and age (> 63 years vs. ≤ 63 years).
Following multivariable analyses, the remaining prognostic factors for healing were as follows (direction of
association not specified unless not identified in previous studies): perfusion, wound duration, presence
of other ulcers (a single ulcer more likely to heal), patient age, and the presence of CNS (ulcer more likely
to heal in presence of this organism, probably because presence of CNS was inversely related to the
presence of MRSA). The associations with ulcer duration and perfusion have been identified previously; we
believe the higher risk of healing with increasing age to be a spurious association and that antimicrobial
dressing may not be independent of the ulcer status, rather than it having a direct effect of
delaying healing.
Scope of the study
This study did not set out to determine whether swabbing or tissue sampling were more accurate at
identifying infection. We understood that in the UK the normal practice is to make a diagnosis of wound
infection in DFU by considering signs and symptoms and not by using a laboratory test (such as swab
or tissue sample). This is due to the time delay associated with getting a result, the potential for a
false-negative result (e.g. owing to organism death during transport/media not supporting fastidious
anaerobes) and the need for rapid (if not immediate) initiation of antibiotics. The lack of an agreed and
validated definition of chronic wound infection means that we were not able either to compare sampling
results with a gold-standard diagnosis or to determine reliably when ulcer infection was resolved.
This study cannot identify the exact source of the difference between tissue sampling, for example did the
two techniques collect organisms differentially, did organisms survive the trip to the laboratory differentially,
or were they handled differently in the laboratory (plating, culture), or were the differences at report stage?
To study this we would have needed to change current practice, and we sought to provide information to
guide UK NHS practice (as per the HTA remit) rather than to undertake more explanatory analyses.
Strengths of this study
This is the largest comparison of the two main methods of sampling and the first study to report detailed
data on paired ulcers for each pathogen and to examine the relationship between baseline characteristics
and agreement using multivariable modelling. A strength of the study is its external validity – there were
few exclusion criteria and patients were recruited in normal practice settings (specialist clinics and hospital
wards) resulting in a generalisable study population. In addition, samples were taken by members of
the attending clinical teams and processed by local laboratories, providing a ‘real world’ comparison of the
two techniques.
All centres received training updates on swab and tissue sampling to minimise sample differences; the overall
agreement between the isolates reported from the two types of specimens was relatively high but overall
tissue sampling (and subsequent culture) reported more pathogens than swab sampling with culture.
Previous reports comparing swab to tissue specimens have been small, single-centre, studies but generally
had findings similar to ours. Bill et al.60 compared culture results for a variety of chronic wounds from a swab
with a punch biopsy (the reference standard) and found the sensitivity to be 79%. Their study of only
38 patients with several sources of bias regarded quantitative culture of the biopsy as a gold-standard
reference test for infection, rather than the alternative, namely clinical signs and symptoms. In a retrospective
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study of 89 concomitantly obtained pairs of samples from 54 patients with DFUs (87% clinically infected),
Mutluoglu et al.62 found that culture results of superficial swabs did not correlate well with those obtained
from deep tissue. Compared with tissue specimens, swab cultures had a positive predictive value of 84.4%,
negative predictive value of 44.0% and overall accuracy of 73.0%. The use of the term ‘predictive value’
presumes the presence of a gold-standard for diagnosis, which we have not done. In keeping with our study,
52% of their patients had received antibiotic therapy at presentation. In a study of 50 patients with an
infected DFU (who had not recently received antibiotic therapy), Demetriou et al.63 used a tissue specimen
culture against which to compare a swab specimen culture. The results obtained from tissue cultures were
the same as those obtained by swab in only 50% of patients. Whereas the sensitivity of swab compared
with tissue cultures was 100%, the specificity was ≤ 40%, and because of the isolation of ‘contaminating’
flora it was < 20% for ‘true pathogens’. Similar to our results, they noted no important differences in results
between patients with neuropathic compared with neuroischaemic ulcers.
The substantial proportion of samples in our study that reported no pathogens may reflect the difficulty in
establishing a diagnosis threshold for clinical infection in the diabetic foot, which is related to the frequent
presence of peripheral neuropathy and arterial disease.115 Alternatively, it may be related to poor sampling
technique, transport media that fail to maintain viability of pathogens, or a choice by the microbiologist
to report only those pathogens, according to their professional judgement threshold, necessary for reporting
(i.e. they may be assessing ‘necessity for reporting’ when faced with a modest number of mixed flora).
Implications for practice
A key issue is how much, and what type of, information on ulcer flora is most useful for clinicians
managing patients with a DFU. Certainly, clinicians want to know which organisms are causing infection
so they can optimally target antibiotic therapy. However, providing them with comprehensive microbiology
reports listing many organisms in addition to the predominant pathogen, perhaps including unusual
isolates present in low numbers, may not necessarily aid clinical decision-making. We do not know if
treatment based on a more detailed microbiogram leads to more effective care in terms of the likelihood
of, or time to resolution of, infection, or the prevention of treatment-associated adverse effects and
antibiotic resistance.
Given the global emergency associated with antibiotic-resistance related to overuse of this precious and
limited resource, we need to be cautious about recommending a technique that may lead to unnecessarily
broad-spectrum prescribing. Furthermore, the bacterial flora present in the wound at the time of sampling
presentation may differ from those present after initial empiric antibiotic therapy, when culture results are
reported. Studies have found swabs reporting additional isolates in 11%62 and 8.1% of samples (CODIFI),
and different isolates in 6.7%62 and 13.2% (CODIFI) of sample, hence the more invasive technique of
tissue sampling cannot be relied on to identify all the organisms identified by the less invasive technique.
The two techniques collect information from two different parts of the ulcer biome: deep collection in one
small area (another part of the wound may have a different bacterial profile) or superficial collection from
a slightly larger area (again noting that other parts of the wound may have a different profile), and the
final report depends on not only sampling, but also transport and microbiologist practice.
Implications for research
Future studies should determine whether or not one of the methods of sampling would lead to improved
patient outcomes and better antimicrobial stewardship.
Further work is needed to understand the value of sampling at presentation with infection (plus empiric
antimicrobial therapy as per local protocol) in terms of both clinical outcomes and antimicrobial stewardship.
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Further studies are needed to confirm the variation in difference in reporting according to the observed
pathogens which we observed.
We do not understand the role that laboratory tests have in the assessment and tailoring of further
therapy in people with infected DFUs. Future research should therefore determine (1) the merits of rapid
diagnostic testing over plating and culture when managing infected DFUs and (2) the impact of sampling
followed by rapid PCR in terms of definitive (rather than empiric) therapy at first presentation.
CONCLUSIONS
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Appendix 1 Supplementary information for
Chapter 2
Main study sample size: patterns of agreement and
disagreement
The sample size required depended on two key factors: the proportion of pairs for which the two samples
disagree (discordance) and the clinically significant difference. The amount of discordance is dependent
on the prevalence of the pathogen, with pathogens with low prevalence having much lower levels of
discordance than pathogens with a high degree of prevalence. Therefore, the sample size had to cover
both low and high levels of discordance to allow for pathogens with low and high prevalence. Assuming a
lower prevalence level of 10% and 5% discordance, we assumed the following scenario, as summarised in
Table 74.
This allowed us to formulate the sample size based on the McNemar’s test for a difference as follows
(Figure 15):
l significance: two-sided 5% level of significance
l power, %: 80
l discordance, %: 1+ 4= 5
l difference, %: 4 – 1= 3
l McNemar’s test: n= 399 pairs
l kappa: rounding up to n= 400 provides κ= 0.7299.
All participating centres are listed in Table 75.
FIGURE 15 nQuery Advisor output for the CODIFI main sample size.
TABLE 74 Distribution of swab and tissue sample results for the presence of a pathogen
Sample Tissue + Tissue – Total
Swab + 7.5% 1% 8.5%
Swab – 4% 87.5% 91.5%
Total 11.5% 88.5% 100%
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Pathogen derivations: group and summary of pathogens
To account for pathogens reported at various taxonomic ranks and to determine whether or not swab and
tissue results reported the same pathogens, pathogens were compared according to predefined groups set
out in Table 76 and in the details below [i.e. largely at the genus level and at the higher group level where
further detail was not reported from the laboratory result (e.g. Gram-positive cocci rather than S. aureus)].
l For the majority of pathogens, interest was at the genus level.
¢ If, however, over all the sample results, only one species belonging to the genus is reported, the
species is reported.
TABLE 75 List of all participating centres
Centre
Code Name
N00003 Queen Elizabeth Hospital, Birmingham
N00006 James Cook University Hospital, Middlesbrough
N00034 New Cross Hospital, Wolverhampton
N00036 Norfolk and Norwich University Hospital, Norwich
N00040 Pinderfields General Hospital, Wakefield
N00050 St James’s University Hospital, Leeds
N00073 South Tyneside District General, South Shields
N00075 Bradford Royal Infirmary, Bradford
N00076 Harrogate District Hospital, Harrogate
N00077 Huddersfield Royal Infirmary, Huddersfield
N00080 Manchester Royal Infirmary, Manchester
N00081 Royal Lancaster Infirmary, Lancaster
N00163 Queen Elizabeth Hospital, King’s Lynn
N00199 Scarborough General Hospital, Scarborough
N00251 University Hospital Lewisham, London
N00260 North Manchester General Hospital, Manchester
N00294 Weston General Hospital, Weston-super-Mare
N00390 University Hospital of North Tees, Stockton-on-Tees
N00449 Fairfield General Hospital, Bury
N00470 Tameside General Hospital, Ashton-under-Lyne
N00488 Royal Oldham Hospital, Oldham
N00511 University Hospital, Coventry
N00522 University Hospital of North Staffordshire, Stoke-on-Trent
N00936 Bensham Hospital, Gateshead
N09829 Chorley and South Ribble Hospital, Chorley
N15868 Minerva Centre, Preston
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TABLE 76 Summary of isolates/pathogens contained within each group
Level grouping Isolate/s Isolates belonging to this group
Groups of
isolates
Gram-positive cocci Enterococcus, Gemella, Helcococcus, Peptoniphilus, Staphylococcus,
Streptococcus, Pediococcus
Gram-negative cocci Neisseria
Gram-positive bacilli Actinomyces, Bacillus, Clostridium, Corynebacterium,
Propionibacterium
Gram-negative bacilli Achromobacter, Acinetobacter, Alcaligenes, Bacteroides, Citrobacter,
Enterobacter, Escherichia, Fusobacterium, Klebsiella, Morganella,
Prevotella, Proteus, Pseudomonas, Raoultella, Serratia,
Stenotrophomonas, Moraxella, Pasteurella
Enterobacteriaceae including
coliforms (interest at the
genus level)
Enterobacter, Citrobacter, Escherichia, Klebsiella, Morganella, Proteus,
Raoultella, Serratia, coliform
Overall anaerobes (interest
at the cocci/rod level)
Anaerobes
Anaerobic cocci: Peptococcus, Peptoniphilus, Peptostreptococcus,
Veillonella
Anaerobic rods: Actinomyces, Bacteroides, Clostridium,
Fusobacterium, Lactobacillus, Prevotella, Propionibacterium
Genus-level
isolates
Achromobacter Achromobacter xylosoxidans
Acinetobacter Acinetobacter baumannii
Alcaligenes Alcaligenes faecalis
Bacteroides Bacteroides fragilis
Candida Candida albicans, Candida guilliermondii, Candida parapsilosis
Citrobacter Citrobacter braakii, Citrobacter sedlakii, Citrobacter freundii,
Citrobacter koseri
CNS Staphylococcus capitis, Staphylococcus epidermidis, Staphylococcus
haemolyticus, Staphylococcus lugdunensis, Staphylococcus
pettenkoferi, Staphylococcus simulans
Corynebacterium Corynebacterium amycolatum, Corynebacterium striatum, diptheroid
Enterobacter Enterobacter aerogenes, Enterobacter cloacae
Enterococcus (excluding
vancomycin resistant)
Enterococcus faecalis (excluding vancomycin resistant), Enterococcus
raffinosus (excluding vancomycin resistant), group D Streptococcus
(excluding vancomycin resistant)
Enterococcus (vancomycin
resistant)
E. faecalis (vancomycin resistant), E. raffinosus (vancomycin resistant),
group D Streptococcus (vancomycin resistant)
Escherichia E. coli
Gemella Gemella morbillorum
Helcococcus Helcococcus kunzii
Klebsiella Klebsiella oxytoca, Klebsiella pneumoniae
Morganella Morganella morganii
Neisseria
Pasteurella Pasteurella dagmatis
Pediococcus
Peptoniphilus Peptoniphilus asaccharolyticus
Prevotella Prevotella bivia, Prevotella melaninogenica
Proteus Proteus mirabilis, Proteus vulgaris
continued
DOI: 10.3310/hta20820 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 82
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Nelson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
125
l Interest was at the subgenus or species level for: CNS; S. aureus, by meticillin resistance; and at the
subgenus level for Enterococcus, depending on vancomycin resistance.
l Pathogens could also be reported at a level higher than genus, either at the family level or as per the
below groups. In the comparison of pathogens within each sample, the groups of pathogens were
compared as per:
¢ Gram-positive cocci
¢ Gram-negative cocci
¢ Gram-positive bacilli
¢ Gram-negative bacilli
¢ anaerobes:
¢ anaerobic cocci
¢ anaerobic rods
¢ family name.
l If a pathogen was reported at the genus level in one sample but at the family or group level in
another, samples were not considered to contain the same pathogens. Table 76 sets out a number
of examples.
l Enterobacteriaceae (including coliforms) is included in Table 77 (and in cross-tabulations within Chapter 2)
as a group of pathogens in addition to the respective genus-level pathogens of interest comprising this
group, owing to the reporting of ‘coliforms’ without detail of the specific genus or species.
Derivation for the summary and number of pathogens in the
presence of multiple pathogens at the level of interest
As detailed in Chapter 2, Methods, where more than one strain or species of a pathogen was reported
within a sample, a single pathogen at the level of interest was retained for comparison with the
corresponding swab or tissue sample in the summary of pathogens and included in the count of the
number of pathogens within the sample. Table 78 presents the data for which this derivation was applied.
TABLE 76 Summary of isolates/pathogens contained within each group (continued )
Level grouping Isolate/s Isolates belonging to this group
Pseudomonas Pseudomonas aeruginosa
Raoultella Raoultella planticola
Serratia Serratia marcescens
Stenotrophomonas Stenotrophomonas maltophilia
Streptococcus Streptococcus agalactiae, Streptococcus anginosus, Streptococcus
constellatus, Streptococcus dysgalactiae, Streptococcus gallolyticus,
Streptococcus milleri, group B, C, G Streptococcus, Viridans,
Streptococcus
Species-level
isolates
S. aureus (excluding MRSA)
MRSA
Other Coccobacillus, Gram-positive coccobacillus, Staphylococcus
Isolates not likely to represent pathogenic
organisms
Enteric flora, faecal flora, mixed skin/normal flora, pus, yeast
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TABLE 77 Summary of pathogens examples
Outcome Swab results Tissue results
Swab and tissue sampling report the
same pathogens
E. coli (Genus= Escherichia) Escherichia
Corynebacterium Diptheroid (used to
represent
corynebacteria)
Coliforms (these are Enterobacteriaceae) Enterobacteriaceae
Swab sampling reports same pathogens
as tissue sampling plus extra pathogens
Acinetobacter, Escherichia Acinetobacter
Coliforms, S. aureus Enterobacteriaceae
Gram-positive bacilli, Corynebacterium Gram-positive bacilli
Tissue sampling reports same pathogens
as swab plus extra pathogens
Anaerobic cocci Anaerobic cocci,
Peptococcus
Pseudomonas Pseudomonas,
Citrobacter
Gram-negative bacilli Gram-negative bacilli,
Gram-negative cocci
Both tissue and swab sampling report
different pathogens (with or without
overlap)
Gram-positive cocci (Enterococcus is a Gram-positive
cocci, but insufficient information is available to
determine if they refer to the same isolate)
Enterococcus
MRSA (interested at species level) Staphylococcus
CNS (interested in differentiating this group) Staphylococcus
Anaerobes (insufficient information to determine
type), Acinetobacter
Anaerobic cocci,
Acinetobacter
TABLE 78 Patients’ sample results with multiple strains or species
Sample Trial number Pathogen retained (at level of interest) Pathogens reported
Swab 234 Streptococcus Streptococcus and group B Streptococcus
235 Coliform Coliform × 2
298 S. aureus (excluding MRSA) S. aureus × 2
386 Coliform Coliform × 2
Tissue 167 CNS CNS × 2
212 Streptococcus Group B and group C Streptococcus
235 Escherichia E. coli × 2
278 Streptococcus Streptococcus and Streptococcus dysgalactiae
294 Corynebacterium Corynebacterium × 2 and diptheroid
304 Corynebacterium Corynebacterium × 2
344 CNS CNS and Staphylococcus pettenkoferi
386 Coliform Coliform × 2
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Derivation for the summary and number of pathogens in the
presence of results from a Gram stain
As detailed in Chapter 2, Methods, a derivation was applied for samples from which results of a Gram
stain were reported in addition to those from the culture. As per Table 79, Gram stain results (in shaded
boxes) were compared with pathogens reported within the corresponding culture result and pathogens
belonging to the group of pathogens reported by the Gram stain were further identified (matched by
colour in Table 79). Where a pathogen belonged to the same group as that reported by the Gram stain, it
was considered likely that both referred to same pathogen and the corresponding Gram stain result was
excluded (indicated by a strikethrough in Table 79) from the summary and number of pathogens reported
from the swab or tissue sample. Conversely, where the results of a Gram stain were provided and no
pathogens identified by the culture belonged to the group identified by the Gram stain, all pathogens
were included
Semiquantitative extent of bacterial growth by type of diabetic
foot ulcer
Table 80 presents cross-tabulations for the extent of growth for the most prevalent pathogens by the type
of ulcer (ischaemic/both ischaemic and neuropathic and neuropathic only).
Missing data
Table 81 presents the pattern of missing baseline covariate data considered within the analysis models for
the coprimary end points for the evaluable population in which an arbitrary missing data pattern was
observed. There were no missing data on centre, 19 patients had missing ‘pre-sampling antibiotic therapy’
information, 5 patients had no information on use of antimicrobial wound dressing, 2 had wound duration
information missing and 2 had both wound duration and ulcer-type information missing.
Graphical plots to assess the proportional odds assumption for
the coprimary end point: number of pathogens
Figures 16–21 present graphical plots of the empirical cumulative logit function for each covariate included
in the ordinal regression analysis for the coprimary end point of number of pathogens.
Given that there are four ordered response levels (outcome: swab sampling had one or more extra isolate
reported; tissue and swab sampling had the same number of isolates reported; tissue sampling had one
extra isolate reported; tissue sampling had two or more extra isolates reported), three cumulative logits
were computed and plotted as per the SAS Note 37944.116 To assess the proportional odds assumption for
each covariate, if the empirical cumulative logits look approximately parallel, then this provides evidence
that a proportional odds model is appropriate.
Each figure supports the proportional odds assumption with the exception of centre, which was instead
fitted as a random effect in the regression model.
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TABLE 79 Patients’ sample results containing results of a Gram stain
Sample
Trial
number Pathogens Derivation
Swab 52 CNS Anaerobic GNB No change
154 Coliform Candida GPC GNB GNB removed as coliform in group
276 S. aureus GNB No change
279 GNB No change
Tissue 9 GPC GNB Coliform Anaerobes GNB removed as coliform in group
12 S. aureus GPB No change
43 Klebisella
oxytoca
GPC GNB GNB removed as K. oxytoca in group
45 S. aureus GPB No change
52 CNS Enterococcus Anaerobic GNB No change
55 GNB Coliform GNB removed as coliform in group
82 S. aureus GPC GPC removed as S. aureus in group
96 MRSA GPC GNB GPB GPC removed as MRSA in group
132 GNB Enterobacter GNB removed as Enterobacter in group
138 GPC No change
147 Anaerobic cocci GPB Group G
Streptococcus
GPC GPC removed as group G Streptococcus
in group
148 GPC No change
185 Group G
Streptococcus
GPC GPC removed as group G Streptococcus
in group
204 MRSA GNB Enterobacter
cloacae
GNB removed as E. cloacae in group
207 Pseudomonas GPC GNB GNB removed as Pseudomonas in group
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TABLE 79 Patients’ sample results containing results of a Gram stain (continued )
Sample
Trial
number Pathogens Derivation
215 GNB Pseudomonas
aeruginosa
GNB removed as P. aeruginosa in group
239 GPC GNB No change
253 S. aureus G. morbillorum GPB Gram positive
cocco-bacillus
Streptococcus
constellatus
GPC GNB GPC removed as S. aureus, G. morbillorum
and S. constellatus in group
254 Streptococcus
dysgalactiae
GPC GPC removed as S. dysgalactiae in group
270 MRSA GPC GPC removed as MRSA belongs to group
279 GNB GPC No change
292 S. aureus GPC GPC removed as S. aureus in group
293 S. aureus GPC GPC removed as S. aureus in group
299 GPB No change
301 GPC GNB No change
302 Diptheroid Neisseria Streptococcus
dysgalactiae
GPC GNB GPC removed as S. dysgalactiae in group
311 S. aureus Diptheroid Candida
guilliermondii
GPB GPC GPB removed as diptheroid in group/GPC
removed as S. aureus in group
322 S. aureus CNS GPC GPC removed as S. aureus and CNS in
group
331 S. aureus GPC GPC removed as S. aureus in group
354 S. aureus Streptococcus GNB No change
356 GPC GPB GNB No change
369 E. coli GPC GNB Citrobacter
koseri
Proteus
mirabilis
GNB removed as E. coli, C. koseri and
P. mirabilis in group
GNB, Gram-negative bacilli; GNC, Gram-negative cocci; GPB, Gram-positive bacilli; GPC, Gram-positive cocci.
Pathogens in shaded boxes represent pathogens from a Gram stain. Where a pathogen belonged to the same group as that reported by the Gram stain, both the Gram stain result and
pathogen are reported in colour (green/blue) and a strikethrough is indicated on the Gram stain.
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TABLE 80 Cross-tabulations on the semiquantitative extent of bacterial growth by type of DFU
Tissue results: level of growth, n (%)
Total, n (%)
Not reported Reported: no growth + ++ +++
Gram-positive cocci: ischaemic/both ischaemic and neuropathic
Swab results
Not reported 60 (30.9) 5 (2.6) 10 (5.2) 8 (4.1) 9 (4.6) 92 (47.4)
Reported: no growth 2 (1.0) 14 (7.2) 1 (0.5) 0 (0.0) 1 (0.5) 18 (9.3)
+ 2 (1.0) 0 (0.0) 11 (5.7) 1 (0.5) 0 (0.0) 14 (7.2)
++ 3 (1.5) 0 (0.0) 8 (4.1) 11 (5.7) 5 (2.6) 27 (13.9)
+++ 4 (2.1) 2 (1.0) 3 (1.5) 6 (3.1) 28 (14.4) 43 (22.2)
Total 71 (36.6) 21 (10.8) 33 (17.0) 26 (13.4) 43 (22.2) n= 194
Gram-positive cocci: neuropathic only
Swab results
Not reported 56 (28.1) 7 (3.5) 15 (7.5) 6 (3.0) 7 (3.5) 91 (45.7)
Reported: no growth 1 (0.5) 19 (9.5) 0 (0.0) 0 (0.0) 0 (0.0) 20 (10.1)
+ 2 (1.0) 1 (0.5) 11 (5.5) 2 (1.0) 0 (0.0) 16 (8.0)
++ 0 (0.0) 0 (0.0) 4 (2.0) 4 (2.0) 5 (2.5) 13 (6.5)
+++ 0 (0.0) 1 (0.5) 6 (3.0) 15 (7.5) 37 (18.6) 59 (29.6)
Total 59 (29.6) 28 (14.1) 36 (18.1) 27 (13.6) 49 (24.6) n= 199
Gram-negative bacilli: ischaemic/both ischaemic and neuropathic
Swab results
Not reported 122 (62.9) 2 (1.0) 6 (3.1) 6 (3.1) 11 (5.7) 147 (75.8)
Reported: no growth 1 (0.5) 12 (6.2) 1 (0.5) 1 (0.5) 1 (0.5) 16 (8.2)
+ 0 (0.0) 0 (0.0) 3 (1.5) 0 (0.0) 1 (0.5) 4 (2.1)
++ 1 (0.5) 1 (0.5) 0 (0.0) 4 (2.1) 0 (0.0) 6 (3.1)
+++ 0 (0.0) 0 (0.0) 3 (1.5) 2 (1.0) 16 (8.2) 21 (10.8)
Total 124 (63.9) 15 (7.7) 13 (6.7) 13 (6.7) 29 (14.9) n= 194
Gram-negative bacilli: neuropathic only
Swab results
Not reported 128 (64.3) 3 (1.5) 8 (4.0) 6 (3.0) 7 (3.5) 152 (76.4)
Reported: no growth 3 (1.5) 5 (2.5) 1 (0.5) 2 (1.0) 3 (1.5) 14 (7.0)
+ 2 (1.0) 1 (0.5) 3 (1.5) 0 (0.0) 1 (0.5) 7 (3.5)
++ 2 (1.0) 1 (0.5) 4 (2.0) 6 (3.0) 2 (1.0) 15 (7.5)
+++ 3 (1.5) 1 (0.5) 2 (1.0) 3 (1.5) 2 (1.0) 11 (5.5)
Total 138 (69.3) 11 (5.5) 18 (9.0) 17 (8.5) 15 (7.5) n= 199
Enterobacteriaceae (including coliforms): ischaemic/both ischaemic and neuropathic
Swab results
Not reported 142 (73.2) 3 (1.5) 5 (2.6) 1 (0.5) 9 (4.6) 160 (82.5)
Reported: no growth 1 (0.5) 12 (6.2) 0 (0.0) 1 (0.5) 1 (0.5) 15 (7.7)
+ 0 (0.0) 0 (0.0) 1 (0.5) 0 (0.0) 0 (0.0) 1 (0.5)
continued
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TABLE 80 Cross-tabulations on the semiquantitative extent of bacterial growth by type of DFU (continued )
Enterobacteriaceae (including coliforms): ischaemic/both ischaemic and neuropathic
Swab results
++ 1 (0.5) 1 (0.5) 0 (0.0) 2 (1.0) 0 (0.0) 4 (2.1)
+++ 0 (0.0) 0 (0.0) 1 (0.5) 1 (0.5) 12 (6.2) 14 (7.2)
Total 144 (74.2) 16 (8.2) 7 (3.6) 5 (2.6) 22 (11.3) n= 194
Enterobacteriaceae (including coliforms): neuropathic only
Swab results
Not reported 147 (73.9) 3 (1.5) 7 (3.5) 4 (2.0) 4 (2.0) 165 (82.9)
Reported: no growth 3 (1.5) 5 (2.5) 2 (1.0) 0 (0.0) 2 (1.0) 12 (6.0)
+ 2 (1.0) 1 (0.5) 1 (0.5) 0 (0.0) 0 (0.0) 4 (2.0)
++ 2 (1.0) 0 (0.0) 3 (1.5) 3 (1.5) 0 (0.0) 8 (4.0)
+++ 5 (2.5) 1 (0.5) 1 (0.5) 2 (1.0) 1 (0.5) 10 (5.0)
Total 159 (79.9) 10 (5.0) 14 (7.0) 9 (4.5) 7 (3.5) n= 199
Overall anaerobes: ischaemic/both ischaemic and neuropathic
Swab results
Not reported 150 (77.3) 2 (1.0) 6 (3.1) 5 (2.6) 6 (3.1) 169 (87.1)
Reported: no growth 3 (1.5) 2 (1.0) 0 (0.0) 0 (0.0) 0 (0.0) 5 (2.6)
+ 4 (2.1) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.5) 5 (2.6)
++ 0 (0.0) 0 (0.0) 1 (0.5) 2 (1.0) 3 (1.5) 6 (3.1)
+++ 3 (1.5) 0 (0.0) 0 (0.0) 0 (0.0) 6 (3.1) 9 (4.6)
Total 160 (82.5) 4 (2.1) 7 (3.6) 7 (3.6) 16 (8.2) n= 194
Overall anaerobes: neuropathic only
Swab results
Not reported 149 (74.9) 7 (3.5) 6 (3.0) 9 (4.5) 5 (2.5) 176 (88.4)
Reported: no growth 1 (0.5) 2 (1.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (1.5)
+ 3 (1.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (1.5)
++ 1 (0.5) 1 (0.5) 0 (0.0) 2 (1.0) 3 (1.5) 7 (3.5)
+++ 4 (2.0) 0 (0.0) 0 (0.0) 2 (1.0) 4 (2.0) 10 (5.0)
Total 158 (79.4) 10 (5.0) 6 (3.0) 13 (6.5) 12 (6.0) n= 199
Gram-positive bacilli: ischaemic/both ischaemic and neuropathic
Swab results
Not reported 174 (89.7) 4 (2.1) 5 (2.6) 4 (2.1) 5 (2.6) 192 (99.0)
++ 1 (0.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.5)
+++ 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.5) 0 (0.0) 1 (0.5)
Total 175 (90.2) 4 (2.1) 5 (2.6) 5 (2.6) 5 (2.6) n= 194
Gram-positive bacilli: neuropathic only
Swab results
Not reported 175 (87.9) 2 (1.0) 10 (5.0) 6 (3.0) 4 (2.0) 197 (99.0)
++ 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.5) 1 (0.5)
+++ 0 (0.0) 0 (0.0) 1 (0.5) 0 (0.0) 0 (0.0) 1 (0.5)
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TABLE 80 Cross-tabulations on the semiquantitative extent of bacterial growth by type of DFU (continued )
Gram-positive bacilli: neuropathic only
Swab results
Total 175 (87.9) 2 (1.0) 11 (5.5) 6 (3.0) 5 (2.5) n= 199
Streptococcus: ischaemic/both ischaemic and neuropathic
Swab results
Not reported 166 (85.6) 3 (1.5) 1 (0.5) 0 (0.0) 4 (2.1) 174 (89.7)
Reported: no growth 0 (0.0) 2 (1.0) 0 (0.0) 0 (0.0) 1 (0.5) 3 (1.5)
+ 2 (1.0) 0 (0.0) 3 (1.5) 0 (0.0) 0 (0.0) 5 (2.6)
++ 1 (0.5) 0 (0.0) 0 (0.0) 3 (1.5) 0 (0.0) 4 (2.1)
+++ 1 (0.5) 0 (0.0) 0 (0.0) 1 (0.5) 6 (3.1) 8 (4.1)
Total 170 (87.6) 5 (2.6) 4 (2.1) 4 (2.1) 11 (5.7) n= 194
Streptococcus: neuropathic only
Swab results
Not reported 161 (80.9) 3 (1.5) 4 (2.0) 1 (0.5) 2 (1.0) 171 (85.9)
Reported: no growth 0 (0.0) 2 (1.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (1.0)
+ 0 (0.0) 0 (0.0) 2 (1.0) 1 (0.5) 0 (0.0) 3 (1.5)
++ 0 (0.0) 0 (0.0) 1 (0.5) 1 (0.5) 2 (1.0) 4 (2.0)
+++ 1 (0.5) 0 (0.0) 2 (1.0) 6 (3.0) 10 (5.0) 19 (9.5)
Total 162 (81.4) 5 (2.5) 9 (4.5) 9 (4.5) 14 (7.0) n= 199
Enterococcus (excluding vancomycin resistant): ischaemic/both ischaemic and neuropathic
Swab results
Not reported 166 (85.6) 2 (1.0) 2 (1.0) 7 (3.6) 3 (1.5) 180 (92.8)
Reported: no growth 0 (0.0) 2 (1.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (1.0)
++ 1 (0.5) 1 (0.5) 0 (0.0) 3 (1.5) 1 (0.5) 6 (3.1)
+++ 3 (1.5) 0 (0.0) 0 (0.0) 0 (0.0) 3 (1.5) 6 (3.1)
Total 170 (87.6) 5 (2.6) 2 (1.0) 10 (5.2) 7 (3.6) n= 194
Enterococcus (excluding vancomycin resistant): neuropathic only
Swab results
Not reported 168 (84.4) 4 (2.0) 7 (3.5) 5 (2.5) 4 (2.0) 188 (94.5)
Reported: no growth 0 (0.0) 2 (1.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (1.0)
+ 2 (1.0) 0 (0.0) 1 (0.5) 0 (0.0) 0 (0.0) 3 (1.5)
+++ 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.5) 5 (2.5) 6 (3.0)
Total 170 (85.4) 6 (3.0) 8 (4.0) 6 (3.0) 9 (4.5) n= 199
CNS: ischaemic/both ischaemic and neuropathic
Swab results
Not reported 178 (91.8) 1 (0.5) 7 (3.6) 2 (1.0) 2 (1.0) 190 (97.9)
++ 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.5) 0 (0.0) 1 (0.5)
+++ 1 (0.5) 1 (0.5) 0 (0.0) 0 (0.0) 1 (0.5) 3 (1.5)
Total 179 (92.3) 2 (1.0) 7 (3.6) 3 (1.5) 3 (1.5) n= 194
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TABLE 80 Cross-tabulations on the semiquantitative extent of bacterial growth by type of DFU (continued )
CNS: neuropathic only
Swab results
Not reported 168 (84.4) 4 (2.0) 14 (7.0) 5 (2.5) 3 (1.5) 194 (97.5)
+ 0 (0.0) 0 (0.0) 2 (1.0) 0 (0.0) 0 (0.0) 2 (1.0)
++ 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (1.0) 2 (1.0)
+++ 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.5) 1 (0.5)
Total 168 (84.4) 4 (2.0) 16 (8.0) 5 (2.5) 6 (3.0) n= 199
Corynebacterium: ischaemic/both ischaemic and neuropathic
Swab results
Not reported 179 (92.3) 3 (1.5) 2 (1.0) 4 (2.1) 4 (2.1) 192 (99.0)
++ 1 (0.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.5)
+++ 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.5) 0 (0.0) 1 (0.5)
Total 180 (92.8) 3 (1.5) 2 (1.0) 5 (2.6) 4 (2.1) n= 194
Corynebacterium: neuropathic only
Swab results
Not reported 177 (88.9) 2 (1.0) 8 (4.0) 6 (3.0) 4 (2.0) 197 (99.0)
++ 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.5) 1 (0.5)
+++ 0 (0.0) 0 (0.0) 1 (0.5) 0 (0.0) 0 (0.0) 1 (0.5)
Total 177 (88.9) 2 (1.0) 9 (4.5) 6 (3.0) 5 (2.5) n= 199
Pseudomonas: ischaemic/both ischaemic and neuropathic
Swab results
Not reported 175 (90.2) 1 (0.5) 0 (0.0) 2 (1.0) 2 (1.0) 180 (92.8)
Reported: no growth 0 (0.0) 2 (1.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (1.0)
+ 1 (0.5) 0 (0.0) 2 (1.0) 0 (0.0) 1 (0.5) 4 (2.1)
++ 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.5) 0 (0.0) 1 (0.5)
+++ 1 (0.5) 0 (0.0) 1 (0.5) 0 (0.0) 5 (2.6) 7 (3.6)
Total 177 (91.2) 3 (1.5) 3 (1.5) 3 (1.5) 8 (4.1) n= 194
Pseudomonas: neuropathic only
Swab results
Not reported 184 (92.5) 1 (0.5) 1 (0.5) 1 (0.5) 187 (94.0)
Reported: no growth 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.5) 1 (0.5)
+ 3 (1.5) 1 (0.5) 0 (0.0) 0 (0.0) 4 (2.0)
++ 2 (1.0) 1 (0.5) 2 (1.0) 0 (0.0) 5 (2.5)
+++ 1 (0.5) 0 (0.0) 0 (0.0) 1 (0.5) 2 (1.0)
Total 190 (95.5) 3 (1.5) 3 (1.5) 3 (1.5) n= 199
S. aureus (excluding MRSA): ischaemic/both ischaemic and neuropathic
Swab results
Not reported 135 (69.6) 0 (0.0) 6 (3.1) 2 (1.0) 1 (0.5) 144 (74.2)
Reported: no growth 2 (1.0) 8 (4.1) 0 (0.0) 0 (0.0) 0 (0.0) 10 (5.2)
+ 0 (0.0) 0 (0.0) 5 (2.6) 1 (0.5) 0 (0.0) 6 (3.1)
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TABLE 80 Cross-tabulations on the semiquantitative extent of bacterial growth by type of DFU (continued )
S. aureus (excluding MRSA): ischaemic/both ischaemic and neuropathic
Swab results
++ 4 (2.1) 0 (0.0) 5 (2.6) 4 (2.1) 1 (0.5) 14 (7.2)
+++ 1 (0.5) 0 (0.0) 4 (2.1) 5 (2.6) 10 (5.2) 20 (10.3)
Total 142 (73.2) 8 (4.1) 20 (10.3) 12 (6.2) 12 (6.2) n= 194
S. aureus (excluding MRSA): neuropathic only
Swab results
Not reported 118 (59.3) 1 (0.5) 5 (2.5) 1 (0.5) 0 (0.0) 125 (62.8)
Reported: no growth 2 (1.0) 17 (8.5) 0 (0.0) 0 (0.0) 0 (0.0) 19 (9.5)
+ 3 (1.5) 1 (0.5) 9 (4.5) 0 (0.0) 0 (0.0) 13 (6.5)
++ 1 (0.5) 0 (0.0) 3 (1.5) 4 (2.0) 1 (0.5) 9 (4.5)
+++ 2 (1.0) 1 (0.5) 5 (2.5) 5 (2.5) 20 (10.1) 33 (16.6)
Total 126 (63.3) 20 (10.1) 22 (11.1) 10 (5.0) 21 (10.6) n= 199
MRSA: ischaemic/both ischaemic and neuropathic
Swab results
Not reported 171 (88.1) 0 (0.0) 1 (0.5) 1 (0.5) 1 (0.5) 174 (89.7)
Reported: no growth 0 (0.0) 4 (2.1) 0 (0.0) 0 (0.0) 0 (0.0) 4 (2.1)
+ 1 (0.5) 0 (0.0) 3 (1.5) 0 (0.0) 0 (0.0) 4 (2.1)
++ 0 (0.0) 0 (0.0) 2 (1.0) 1 (0.5) 2 (1.0) 5 (2.6)
+++ 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.5) 6 (3.1) 7 (3.6)
Total 172 (88.7) 4 (2.1) 6 (3.1) 3 (1.5) 9 (4.6) n= 194
MRSA: ischaemic/both ischaemic and neuropathic
Swab results
Not reported 190 (95.5) 0 (0.0) 0 (0.0) 1 (0.5) 1 (0.5) 192 (96.5)
+++ 0 (0.0) 0 (0.0) 0 (0.0) 2 (1.0) 5 (2.5) 7 (3.5)
Total 190 (95.5) 0 (0.0) 0 (0.0) 3 (1.5) 6 (3.0) n= 199
TABLE 81 Pattern of missing data for main study
Centre
Antimicrobial
dressing
Pre-sampling
antibiotic therapy Ulcer type
Wound
duration
Wagner
ulcer grade
Total (N= 395),
n (%)
✗ ✗ ✗ ✗ ✗ ✗ 367 (92.9)
✗ ✗ ✗ ✗ Missing ✗ 2 (0.5)
✗ ✗ ✗ Missing Missing ✗ 2 (0.5)
✗ ✗ Missing ✗ ✗ ✗ 19 (4.8)
✗ Missing ✗ ✗ ✗ ✗ 5 (1.3)
✗ represents non-missing data.
DOI: 10.3310/hta20820 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 82
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Nelson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
135
54
3
2
1
0c
1
–1
–2
–3
–4
–5
Any ischaemia (+ neuropathy) Neuropathic only
Ulcer type
c1
c2
c3
FIGURE 16 Plot to assess the proportional odds assumption for ulcer type (n= 393) (proportionality satisfied).
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FIGURE 17 Plot to assess the proportional odds assumption for ulcer grade (n= 395) (proportionality satisfied).
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FIGURE 18 Plot to assess the proportional odds assumption for previous antibiotic therapy (n= 376)
(proportionality satisfied).
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FIGURE 19 Plot to assess the proportional odds assumption for antimicrobial dressing (n= 390)
(proportionality satisfied).
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FIGURE 20 Plot to assess the proportional odds assumption for wound duration (n= 391) (proportionality satisfied).
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FIGURE 21 Plot to assess the proportional odds assumption for centre (n= 395) (proportionality not satisfied:
centre fitted in ordinal regression analysis as a random effect).
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Appendix 2 Supplementary information for
Chapter 3
Missing data
Table 82 presents the pattern of missing baseline covariate data considered within the analysis model for
the evaluable clinical review population, in which an arbitrary missing data pattern is observed. There were
no missing data on centre, 15 patients had missing ‘pre-sampling antibiotic therapy’ information, 5 had no
information on use of antimicrobial wound dressing and 1 had missing wound duration information.
Patient vignette: 82766
A 75-year-old male with diabetes attended the clinic a few days ago because of a clinically infected foot
ulcer. You are now asked to review the microbiology report and the antibiotics prescribed when the
patient attended the clinic, and answer the following questions.
Prescribed antibiotic regimen: flucloxacillin
Microbiology laboratory report: S. aureus (growth: scanty; sensitive to: co-fluampicil, clarithromycin and
erythromycin; resistant to: penicillin.)
Clinical assessment a few days ago indicated that the ulcer was classified as follows on the PEDIS scale:
Perfusion: grade 2
Extent: 2 cm × 2.5 cm
Depth: grade 1
Infection: grade 2
Sensation: grade 1
TABLE 82 Pattern of missing data for clinical review study
Centre
Antimicrobial
dressing
Pre-sampling
antibiotic therapy
Ulcer
type
Wound
duration
Wagner ulcer
grade
Total (N= 247),
n (%)
✗ ✗ ✗ ✗ ✗ ✗ 226 (91.5)
✗ ✗ ✗ ✗ Missing ✗ 1 (0.4)
✗ ✗ Missing ✗ ✗ ✗ 15 (6.1)
✗ Missing ✗ ✗ ✗ ✗ 5 (2.0)
✗ represents non-missing data.
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Question 1
Are there any pathogens identified in the laboratory report that are not covered by the prescribed
antimicrobial regimen? Please consider both the pathogens and their sensitivity and resistance.
Yes □
No □
If ‘yes’ please list which pathogens are not covered by the existing antibiotic regimen:
__________________________________________________________________________________
________________________________________________
Question 2
If you answered ‘yes’ to question 1, would knowing this information lead you to prescribe an alternative
antibiotic regimen for this patient?
Yes □
No □
If ‘yes’ please describe the antibiotic regimen you would prescribe for this patient:
___________________________________________________________________________________
_______________________________________________
Signature. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . . . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .
Name
Date. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . . . . . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .
Patient vignette: 85277
A 75-year-old male with diabetes attended the clinic a few days ago because of a clinically infected foot
ulcer. You are now asked to review the microbiology report and the antibiotics prescribed when the
patient attended clinic, and answer the following questions.
Prescribed antibiotic regimen: flucloxacillin
Microbiology laboratory report: Staphylococcus aureus (Growth: ++; sensitive to: flucloxacillin; resistant to:
no antibiotics recorded).
Clinical assessment a few days ago indicated that the ulcer was classified as follows on the PEDIS scale:
Perfusion: grade 2
Extent: 2 cm × 2.5 cm
Depth: grade 1
Infection: grade 2
Sensation: grade 1
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Question 1
Are there any pathogens identified in the laboratory report that are not covered by the prescribed
antimicrobial regimen? Please consider both the pathogens and their sensitivity and resistance.
Yes □
No □
If ‘yes’ please list which pathogens are not covered by the existing antibiotic regimen:
_________________________________________________________________________________
_________________________________________________
Question 2
If you answered ‘yes’ to question 1, would knowing this information lead you to prescribe an alternative
antibiotic regimen for this patient?
Yes □
No □
If ‘yes’ please describe the antibiotic regimen you would prescribe for this patient:
__________________________________________________________________________________
________________________________________________
Signature. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . . . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .
Name
Date. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . . . . . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .
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Appendix 3 Supplementary information for
Chapter 5
Baseline characteristics for the follow-up population, compared
with patients not in the follow-up population
Tables 83–85 present the baseline characteristics for patients in the follow-up population and those not in
the follow-up population.
Tables 86–93 present the clinical assessment, antibiotic regimen at baseline and ulcer characteristics
and classification.
TABLE 83 Recruiting centre
Recruiting centre
In the follow-up
population
(N= 299), n (%)
Not in the follow-up
population (N= 101),
n (%)
Total: full
analysis set
(N= 400), n (%)
N00003: Queen Elizabeth Hospital Birmingham 14 (4.7) 7 (6.9) 21 (5.3)
N00006: James Cook University Hospital 4 (1.3) 0 (0.0) 4 (1.0)
N00034: New Cross Hospital Wolverhampton 5 (1.7) 0 (0.0) 5 (1.3)
N00036: Norfolk and Norwich University Hospital 19 (6.4) 1 (1.0) 20 (5.0)
N00040: Pinderfields General Hospital 18 (6.0) 3 (3.0) 21 (5.3)
N00050: St James’s University Hospital Leeds 29 (9.7) 15 (14.9) 44 (11.0)
N00073: South Tyneside District General 1 (0.3) 2 (2.0) 3 (0.8)
N00075: Bradford Royal Infirmary 28 (9.4) 6 (5.9) 34 (8.5)
N00076: Harrogate District Hospital 7 (2.3) 0 (0.0) 7 (1.8)
N00077: Huddersfield Royal Infirmary 5 (1.7) 1 (1.0) 6 (1.5)
N00080: Manchester Royal Infirmary 19 (6.4) 7 (6.9) 26 (6.5)
N00081: Royal Lancaster Infirmary 14 (4.7) 3 (3.0) 17 (4.3)
N00163: Queen Elizabeth Hospital King’s Lynn 1 (0.3) 1 (1.0) 2 (0.5)
N00251: University Hospital Lewisham 2 (0.7) 0 (0.0) 2 (0.5)
N00260: North Manchester General Hospital 19 (6.4) 2 (2.0) 21 (5.3)
N00294: Weston General Hospital 5 (1.7) 0 (0.0) 5 (1.3)
N00390: University Hospital of North Tees 12 (4.0) 6 (5.9) 18 (4.5)
N00449: Fairfield Hospital 2 (0.7) 3 (3.0) 5 (1.3)
N00470: Tameside General Hospital 15 (5.0) 13 (12.9) 28 (7.0)
N00488: Royal Oldham Hospital 27 (9.0) 15 (14.9) 42 (10.5)
N00511: University Hospitals Coventry and Warwick 10 (3.3) 10 (9.9) 20 (5.0)
N00522: University Hospital of North Staffordshire 4 (1.3) 0 (0.0) 4 (1.0)
N00936: Bensham Hospital 13 (4.3) 1 (1.0) 14 (3.5)
N09829: Chorley and South Ribble hospital 23 (7.7) 3 (3.0) 26 (6.5)
N15868: Minerva Centre, Preston 3 (1.0) 2 (2.0) 5 (1.3)
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TABLE 84 Patient demographics
Patient demographics
In the follow-up
population (n= 299)
Not in the follow-up
population (n= 101)
Total: full analysis
set (N= 400)
Age, years
Mean (SD) 64.3 (12.8) 59.3 (14.2) 63.1 (13.3)
Median (IQR) 64.0 (56.0–74.0) 58.0 (49.0–72.0) 63.0 (54.0–73.0)
Range 28–99 26–91 26–99
Age at sampling (years, by median), n (%)a
≤ 63 years 146 (48.8) 62 (61.4) 208 (52.0)
> 63 years 153 (51.2) 39 (38.6) 192 (48.0)
Sex, n (%)
Male 233 (77.9) 83 (82.2) 316 (79.0)
Female 66 (22.1) 18 (17.8) 84 (21.0)
Ethnicity, n (%)
White 284 (95.0) 93 (92.1) 377 (94.3)
Other mixed background 1 (0.3) 0 (0.0) 1 (0.3)
Asian: Indian 2 (0.7) 1 (1.0) 3 (0.8)
Asian: Pakistani 8 (2.7) 3 (3.0) 11 (2.8)
Other Asian background 2 (0.7) 0 (0.0) 2 (0.5)
Black: Caribbean 1 (0.3) 2 (2.0) 3 (0.8)
Black: African 1 (0.3) 0 (0.0) 1 (0.3)
Other ethnic group 0 (0.0) 2 (2.0) 2 (0.5)
Site of recruitment
Hospital ward 38 (12.7) 15 (14.9) 53 (13.3)
Outpatient clinic 241 (80.6) 78 (77.2) 319 (79.8)
Community clinic 20 (6.7) 8 (7.9) 28 (7.0)
IQR, interquartile range; SD, standard deviation.
a Based on the median of the full CODIFI sample (median= 63 years).
TABLE 85 Diabetes details
Diabetes details
In the follow-up
population (N= 299)
Not in the follow-up
population (N= 101)
Total: full analysis
set (N= 400)
Diabetes type, n (%)
Type 1 40 (13.4) 18 (17.8) 58 (14.5)
Type 2 259 (86.6) 83 (82.2) 342 (85.5)
Duration of diabetes (years)a
Number of patients with missing data 2 1 3
Mean (SD) 17.2 (11.1) 15.5 (10.5) 16.8 (11.0)
Median (IQR) 15.0 (10.0–23.0) 14.5 (8.0–21.5) 15.0 (9.0–23.0)
Range 0–57 0–44 0–57
Duration of diabetes (split by median), n (%)b
< 15 years 136 (45.5) 50 (49.5) 186 (46.5)
≥ 15 years 161 (53.8) 50 (49.5) 211 (52.8)
Missing 2 (0.7) 1 (1.0) 3 (0.8)
APPENDIX 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
144
TABLE 85 Diabetes details (continued )
Diabetes details
In the follow-up
population (N= 299)
Not in the follow-up
population (N= 101)
Total: full analysis
set (N= 400)
Current diabetes treatment, n (%)
Yes 289 (96.7) 96 (95.0) 385 (96.3)
No 10 (3.3) 5 (5.0) 15 (3.8)
Diabetes treatment details, n (%)c
Oral hypoglycaemic agent 77 (26.6) 30 (31.3) 107 (27.8)
Insulin 126 (43.6) 42 (43.8) 168 (43.6)
Both, oral hypoglycaemic agent and insulin 85 (29.4) 24 (25.0) 109 (28.3)
Other 1 (0.3) 0 (0.0) 1 (0.3)
Total 289 (100.0) 96 (100.0) 385 (100.0)
HbA1C (%)
Number of patients 294 100 394
Number of patients with missing data 5 1 6
Mean (SD) 8.61 (2.24) 9.04 (2.40) 8.72 (2.29)
Median (IQR) 8.10 (7.00–9.90) 8.45 (6.95–10.70) 8.10 (7.00–10.20)
Range 4.6–17.2 5.4–17.1 4.6–17.2
IQR, interquartile range; SD, standard deviation.
a The minimum duration of diabetes was 2 weeks (displayed as 0 years).
b Based on the median of the full and follow-up CODIFI sample (median= 15 years).
c The other diabetes treatment was oral hypoglycaemic agent or insulin or both.
TABLE 86 Clinical assessment
Clinical assessment
In the follow-up
population (N= 299)
Not in the follow-up
population (N= 101)
Total: full analysis
set (N= 400)
Temperature (°C)
Number of patients with missing data 7 3 10
Mean (SD) 36.61 (0.62) 36.58 (0.61) 36.60 (0.62)
Median (IQR) 36.60 (36.20–37.00) 36.60 (36.20–37.00) 36.60 (36.20–37.00)
Range 35.0–39.5 35.1– 38.6 35.0–39.5
Heart rate (beats/minute)
Number of patients with missing data 3 1 4
Mean (SD) 80.8 (13.6) 83.0 (13.5) 81.4 (13.6)
Median (IQR) 80.0 (72.0–90.0) 81.5 (72.0–94.0) 80.0 (72.0–90.5)
Range 50–118 58–120 50–120
Respiratory rate (breaths/minute)
Number of patients with missing data 4 0 4
Mean (SD) 18.1 (4.5) 17.9 (3.5) 18.1 (4.3)
Median (IQR) 18.0 (15.0–20.0) 18.0 (15.0–20.0) 18.0 (15.0–20.0)
Range 9–40 10–28 9–40
IQR, interquartile range; SD, standard deviation.
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Missing data
Table 94 presents the level of missing data present for the long-term follow-up population, for the
outcome time to healing and baseline covariates. Table 95 presents summary statistics of the 10 imputed
healing times derived for each of the 12 patients with missing time to healing and overall. Compared with
the time of healing in patients where the healing date was known, imputed times were on average higher
(median 6.5 months).
Cumulative incidence curves
Plots of the cumulative incidence of healing, with 95% CIs, in the presence of the competing risks of
death and amputation by each of the factors found to be significant in the univariate analysis are
presented in Figures 22–31. Note that the actual cumulative incidence curves were obtained via estimation
of the cumulative incidence functions using non-parametric methods and are based on the first imputed
data set only.
Proportional hazards assumption
In order to test the assumption of proportional hazards, competing risks were treated as censored events
in order to generate log-cumulative hazards plots by the selected factor. Under the proportional hazards
assumption we would expect the lines to be parallel and not to cross for each level of the factor. The plots
presented were from the first imputed data set. To further investigate departures from the proportional
TABLE 87 Ulcer characteristics
Ulcer characteristics
In the follow-up
population (N= 299)
Not in the follow-up
population (N= 101)
Total: full analysis
set (N= 400)
Location of ulcer(s), n (%)
Ulcers on both right and left foot 50 (16.7) 10 (9.9) 60 (15.0)
Ulcer(s) on right foot only 125 (41.8) 48 (47.5) 173 (43.3)
Ulcer(s) on left foot only 124 (41.5) 43 (42.6) 167 (41.8)
Total number of ulcers, n (%)
1 194 (64.9) 74 (73.3) 268 (67.0)
2 60 (20.1) 18 (17.8) 78 (19.5)
3 36 (12.0) 7 (6.9) 43 (10.8)
4 4 (1.3) 2 (2.0) 6 (1.5)
5 1 (0.3) 0 (0.0) 1 (0.3)
6 3 (1.0) 0 (0.0) 3 (0.8)
7 1 (0.3) 0 (0.0) 1 (0.3)
Total number of ulcers
Mean (SD) 1.6 (1.0) 1.4 (0.7) 1.5 (0.9)
Median (IQR) 1.0 (1.0–2.0) 1.0 (1.0–2.0) 1.0 (1.0–2.0)
Range 1–7 1–4 1–7
IQR, interquartile range; SD, standard deviation.
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TABLE 88 Index ulcer characteristics
Index ulcer characteristics
In the follow-up
population (N= 299)
Not in the follow-up
population (N= 101)
Total: full analysis
set (N= 400)
Foot containing index ulcer, n (%)
Right foot 150 (50.2) 55 (54.5) 205 (51.3)
Left foot 149 (49.8) 46 (45.5) 195 (48.8)
Other ulcers on index foot, n (%)
Single index ulcer on index foot 222 (74.2) 82 (81.2) 304 (76.0)
> 1 ulcer on index foot 77 (25.8) 19 (18.8) 96 (24.0)
Index ulcer location, n (%)a
Apex 31 (10.4) 16 (15.8) 47 (11.8)
Interdigital 18 (6.0) 7 (6.9) 25 (6.3)
Plantar 133 (44.5) 39 (38.6) 172 (43.0)
Dorsum 38 (12.7) 18 (17.8) 56 (14.0)
Digital 70 (23.4) 20 (19.8) 90 (22.5)
Other 7 (2.3) 1 (1.0) 8 (2.0)
Missing 2 (0.7) 0 (0.0) 2 (0.5)
Duration of index ulcer (months)
Number of patients with missing data 4 0 4
Mean (SD) 4.80 (8.28) 7.86 (19.68) 5.58 (12.28)
Median (IQR) 1.84 (0.69–6.00) 1.84 (0.69–4.60) 1.84 (0.69–6.00)
Range 0.1–75.0 0.2–144.0 0.1–144.0
First or recurrent index ulcer, n (%)
Incident 206 (68.9) 82 (81.2) 288 (72.0)
Recurrent 91 (30.4) 19 (18.8) 110 (27.5)
Missing 2 (0.7) 0 (0.0) 2 (0.5)
Aetiology of index ulcer, n (%)
Any ischaemia (± neuropathy) 142 (47.5) 54 (53.5) 196 (49.0)
Neuropathic only 155 (51.8) 47 (46.5) 202 (50.5)
Missing 2 (0.7) 0 (0.0) 2 (0.5)
Antimicrobial dressing on the infected ulcer, n (%)
Yes 175 (58.5) 66 (65.3) 241 (60.3)
No 119 (39.8) 35 (34.7) 154 (38.5)
Missing 5 (1.7) 0 (0.0) 5 (1.3)
IQR, interquartile range; SD, standard deviation.
a The other locations of index ulcer are the dorsum and digital for two patients and the: apex/interdigital/plantar surface, lateral
surface, lateral outer aspect of the foot, left lateral malleolus, medial surface and medial malleolus of the remaining patients.
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hazards assumption, a time-dependent covariate was included in the univariate model for two
level factors.
The plots suggest that for the majority of factors the proportional hazards assumption holds. However,
there is some question over the assumption for CNS, although the violation of proportional hazards occurs
at a point at which there are very few healing events. For this two-level factor, the assumption of
proportional hazards was further investigated via the inclusion of a time-dependent covariate, which
suggested further evidence against the proportional hazards assumption for CNS with an increased
incidence of healing in patients without CNS prior to 1 month post sample, but an increased and
increasing incidence of healing in patients with CNS after 1 month (i.e. non-constant HR).
Furthermore, the proportional hazards assumption appears to be satisfied for the reference grade 1 of
both the depth/tissue loss classification and Wagner ulcer grade; however, lines do cross for grades 2 and
3 (Wagner grades 3/4/5) owing to the reduced differences observed in the cumulative incidence for these
levels. This suggests that grouping grades > 1, for both the depth/tissue loss classification and Wagner
ulcer grade, may not result in a substantial loss of information on the likely incidence of healing.
TABLE 89 Baseline antibiotic regimen
Antibiotic regimen
In the follow-up
population (N= 299)
Not in the follow-up
population (N= 101)
Total: full analysis
set (N= 400)
Currently on antibiotic regimen, n (%)
Yes 139 (46.5) 48 (47.5) 187 (46.8)
No 145 (48.5) 49 (48.5) 194 (48.5)
Missing 15 (5.0) 4 (4.0) 19 (4.8)
Days spent on current antibiotic regimen
Number of patients 138 48 186
Number of patients with missing data 1 0 1
Mean (SD) 15.2 (21.8) 13.2 (22.2) 14.6 (21.9)
Median (IQR) 7.0 (4.0–16.0) 5.5 (2.0–13.0) 7.0 (3.0–14.0)
Range 1–145 1–124 1–145
Proposed new antibiotic regimen, n (%)
Yes 198 (66.2) 50 (49.5) 248 (62.0)
No 91 (30.4) 42 (41.6) 133 (33.3)
Missing 10 (3.3) 9 (8.9) 19 (4.8)
Summary of patients pre and post sampling antibiotic regimen, n (%)
Not a pre-sampling antibiotic regimen with
initiation immediately post sampling
131 (43.8) 37 (36.6) 168 (42.0)
Not on a pre-sampling antibiotic regimen with
no initiation immediately post sampling
14 (4.7) 12 (11.9) 26 (6.5)
On a pre-sampling antibiotic regimen with or
without a change immediately post sampling
139 (46.5) 48 (47.5) 187 (46.8)
Unknown whether on a pre-sampling
antibiotic regimen but initiation/change
immediately post sampling
15 (5.0) 4 (4.0) 19 (4.8)
IQR, interquartile range; SD, standard deviation.
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TABLE 91 Perfusion, Extent/Size, Depth/Tissue loss, Infection, Sensation classification: extent/size
PEDIS classification
In the follow-up
population (N= 299)
Not in the follow-up
population (N= 101)
Total: full analysis
set (N= 400)
Ulcer debridement undertaken, n (%)
Yes 261 (87.3) 90 (89.1) 351 (87.8)
No 38 (12.7) 11 (10.9) 49 (12.3)
Estimated index ulcer area (cm)a
Number of patients 297 100 397
Number of patients with missing data 2 1 3
Mean (SD) 6.71 (15.37) 6.91 (14.57) 6.76 (15.16)
Median (IQR) 1.77 (0.63–5.50) 1.57 (0.79–6.73) 1.77 (0.63–6.15)
Range 0.0–138.2 0.0–94.2 0.0–138.2
IQR, interquartile range; SD, standard deviation.
a Calculated using Kundin:81 length ×width × 0.785.
TABLE 90 Perfusion, Extent/Size, Depth/Tissue loss, Infection, Sensation classification
PEDIS classification
In the follow-up
population (N= 299)
Not in the follow-up
population (N= 101)
Total: full analysis
set (N= 400)
Perfusion (PAD), n (%)
Grade 1 147 (49.2) 53 (52.5) 200 (50.0)
Grade 2 146 (48.8) 46 (45.5) 192 (48.0)
Grade 3 6 (2.0) 2 (2.0) 8 (2.0)
Depth/tissue loss, n (%)
Grade 1 96 (32.1) 35 (34.7) 131 (32.8)
Grade 2 100 (33.4) 34 (33.7) 134 (33.5)
Grade 3 103 (34.4) 32 (31.7) 135 (33.8)
Infection, n (%)
Grade 1 0 (0.0) 2 (2.0) 2 (0.5)
Grade 2 104 (34.8) 45 (44.6) 149 (37.3)
Grade 3 skin/subcutaneous tissue 185 (61.9) 52 (51.5) 237 (59.3)
Grade 4 10 (3.3) 2 (2.0) 12 (3.0)
Sensation, n (%)
Grade 1 20 (6.7) 7 (6.9) 27 (6.8)
Grade 2 279 (93.3) 94 (93.1) 373 (93.3)
DOI: 10.3310/hta20820 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 82
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Nelson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
149
TABLE 92 Clinical signs and symptoms classification
Clinical signs and symptoms
In the follow-up
population (N= 299)
Not in the follow-up
population (N= 101)
Total: full analysis
set (N= 400)
Wound odour, n (%)
Yes 93 (31.1) 34 (33.7) 127 (31.8)
No 206 (68.9) 67 (66.3) 273 (68.3)
Pocketing in wound, n (%)
Yes 127 (42.5) 43 (42.6) 170 (42.5)
No 172 (57.5) 58 (57.4) 230 (57.5)
Discoloured granulation tissue, n (%)
Yes 162 (54.2) 63 (62.4) 225 (56.3)
No 137 (45.8) 38 (37.6) 175 (43.8)
Friable granulation tissue, n (%)
Yes 146 (48.8) 58 (57.4) 204 (51.0)
No 153 (51.2) 43 (42.6) 196 (49.0)
Recent increase in pain, n (%)
Yes 95 (31.8) 30 (29.7) 125 (31.3)
No 203 (67.9) 71 (70.3) 274 (68.5)
Missing 1 (0.3) 0 (0.0) 1 (0.3)
Recent decrease in pain, n (%)
Yes 7 (2.3) 2 (2.0) 9 (2.3)
No 289 (96.7) 99 (98.0) 388 (97.0)
Missing 3 (1.0) 0 (0.0) 3 (0.8)
Recent increase in wound size, n (%)
Yes 186 (62.2) 60 (59.4) 246 (61.5)
No 113 (37.8) 40 (39.6) 153 (38.3)
Missing 0 (0.0) 1 (1.0) 1 (0.3)
Breakdown of epithelium, n (%)
Yes 94 (31.4) 32 (31.7) 126 (31.5)
No 204 (68.2) 69 (68.3) 273 (68.3)
Missing 1 (0.3) 0 (0.0) 1 (0.3)
TABLE 93 Wagner ulcer grade
Wagner grade
In the follow-up
population
(N= 299), n (%)
Not in the follow-up
population (N= 101),
n (%)
Total: full analysis
set (N= 400),
n (%)
Grade 1 104 (34.8) 32 (31.7) 136 (34.0)
Grade 2 93 (31.1) 41 (40.6) 134 (33.5)
Grade 3 sepsis 96 (32.1) 26 (25.7) 122 (30.5)
Grade 4 5 (1.7) 2 (2.0) 7 (1.8)
Grade 5 foot 1 (0.3) 0 (0.0) 1 (0.3)
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TABLE 94 Missing data summary
Missing dataa Total (N= 299), n (%)
Yes 43 (14.4)
Healing date 12 (4.0)
Diabetes duration 2 (0.7)
HbA1c 5 (1.7)
Extent of ulcer 2 (0.7)
Ulcer type 2 (0.7)
Recurrent ulcer 2 (0.7)
Ulcer duration 4 (1.3)
Previous antibiotic therapy 15 (5.0)
Antimicrobial dressing 3 (1.0)
No 256 (85.6)
a Three patients in the follow-up population were not in the evaluable main trial population owing to the loss or misuse of
study swab samples; however, these patients’ tissue sample results were available and were thus included in the
follow-up analysis, meaning that there were no missing baseline pathogen data.
TABLE 95 Summary statistics for the imputed time to healing estimates
Trial number
Number of
imputations Mean SD Median
Lower
quartile
Upper
quartile Minimum Maximum
1 10 7.0 2.60 6.2 5.02 9.07 4.1 11.3
43 10 8.8 2.39 8.8 6.49 10.10 6.4 13.9
57 10 9.3 2.94 8.8 6.77 10.86 5.6 15.2
82 10 2.8 2.53 2.1 0.72 4.61 0.5 7.7
104 10 4.4 2.73 4.5 3.07 5.20 0.3 9.5
108 10 5.4 4.04 4.4 1.85 8.48 0.7 13.0
113 10 4.8 1.91 4.6 3.09 6.03 2.2 7.8
117 10 7.8 3.43 8.8 5.31 10.30 2.1 12.7
158 10 5.0 3.37 4.4 1.59 6.66 1.2 11.2
222 10 5.7 2.39 5.0 4.14 7.33 3.0 10.3
331 10 10.1 3.53 10.0 7.87 12.91 5.4 16.2
386 10 8.3 2.20 8.1 6.67 9.55 4.9 12.4
All 12 patients 120 6.6 3.52 6.5 4.2 9.1 0.3 16.2
SD, standard deviation.
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FIGURE 22 Cumulative incidence of healing by perfusion grade.
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FIGURE 23 Cumulative incidence of healing by age group.
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FIGURE 24 Cumulative incidence of healing by the presence of more than one ulcer.
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FIGURE 25 Cumulative incidence of healing by presence of CNS.
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FIGURE 26 Cumulative incidence of healing by wound duration.
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FIGURE 27 Cumulative incidence of healing by PEDIS depth/tissue loss grade.
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FIGURE 28 Cumulative incidence of healing by PEDIS infection grade.
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FIGURE 29 Cumulative incidence of healing by Wagner ulcer grade.
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FIGURE 30 Cumulative incidence of healing by the presence of an antimicrobial dressing.
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Log-cumulative hazard plots
Figures 32–36 present the log-cumulative hazard plots of time to healing by perfusion, age, presence of
more than one ulcer, wound duration and CNS.
Figures 37–41 present the log-cumulative hazard plots of time to healing by depth/tissue loss, infection
grade, ulcer grade, presence of antimicrobial dressing and MRSA.
Time-dependent covariate
Table 96 shows that the interaction of the presence of CNS against time (having applied a log function)
is significant. The parameter estimate for the interaction term suggests that the likelihood of healing
increases over time for patients with CNS reported at baseline. However, the negative parameter estimate
for the presence of CNS suggests that prior to month 1, patients with no CNS reported were more likely to
heal than those in which it was reported. This relationship is demonstrated in Figure 42 which presents the
relative hazard of healing over time for a patient who had CNS reported at baseline relative to those who
did not.
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FIGURE 31 Cumulative incidence of healing by the presence of MRSA.
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FIGURE 32 Log-cumulative hazard plot of time to healing by perfusion. Proportional hazards assumption satisfied.
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FIGURE 33 Log-cumulative hazard plot of time to healing by age. Curves are very close and appear to cross early
on; however, this is after only very few healing events, hence proportional hazards assumption is satisfied.
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FIGURE 34 Log-cumulative hazard plot of time to healing by presence of more than one ulcer. Proportional
hazards assumption satisfied.
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FIGURE 35 Log-cumulative hazard plot of time to healing by wound duration. Proportional hazards
assumption satisfied.
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FIGURE 36 Log-cumulative hazard plot of time to healing by presence of CNS. Curves cross and, hence, the
proportional hazards assumption is questionable; however, there are few healing events in those with CNS, in
particular prior to the point at which lines cross.
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FIGURE 37 Log-cumulative hazard plot of time to healing by PEDIS depth/tissue loss grade. Proportional hazards
assumption satisfied for grade 1; however, lines do cross for grades 2 and 3.
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FIGURE 38 Log-cumulative hazard plot of time to healing by PEDIS infection grade. Proportional hazards
assumption satisfied.
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FIGURE 39 Log-cumulative hazard plot of time to healing by Wagner ulcer grade. Proportional hazards assumption
satisfied for grade 1; however, lines do cross for grades 2 and 3, 4, 5.
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FIGURE 40 Log-cumulative hazard plot of time to healing by presence of antimicrobial dressing. Proportional
hazards assumption satisfied.
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FIGURE 41 Log-cumulative hazard plot of time to healing by presence of MRSA. Proportional hazards
assumption satisfied.
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TABLE 96 Inclusion of a time-dependent covariate in the univariate proportional subdistribution hazards model to
test the proportional hazard assumption for presence of CNS
Model Parameter estimate p-value HR (95% CI)
CNS: With Time ×CNS interaction
CNS: Yes vs. No 0.204243 0.5833 1.23 (0.59 to 2.54)
Interaction: CNS × Time 0.059799 0.2945 1.06 (0.95 to 1.19)
CNS: With log(Time) × CNS interaction
CNS: Yes vs. No –0.180176 0.6739 0.84 (0.36 to 1.93)
Interaction: CNS × log(Time) 0.479331 0.0567 1.61 (0.99 to 2.64)
0
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3
FIGURE 42 Plot of the relative hazard of healing for a patient with CNS vs. a patient without, over time.
RH, relative hazard.
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Appendix 4 Centre differences
Questionnaire responses
TABLE 97 Responding sites
Responding sites
Bensham
Bradford
Chorley and South Ribble
Fairfields
Huddersfield Royal Infirmary
Manchester Diabetes Centre, CMFT NHS Trust
Minerva Centre
New Cross Hospital
Norfolk and Norwich University Hospital NHS Foundation Trust
North Manchester General Hospital
North Tees and Hartlepool Foundation Trust
Pinderfields Hospital
Queen Elizabeth Hospital King’s Lynn
Royal Oldham
Scarborough Hospital
St James’s University Hospital
Tameside NHS Foundation Trust
James Cook University Hospital
University Hospitals Coventry and Warwickshire NHS Trust
University Hospital Birmingham
University Hospital North Staffordshire
Weston General Hospital
Grand total n= 22
Clinical acquisition of samples
The majority of responding sites (20/21) used a scalpel to collect tissue samples, of which the majority
(16/20), used a cutting motion, whereas a minority (4/20) used a scraping motion.
TABLE 98 Which technique does your site use to collect the tissue samples from ulcers?
Technique Count
Dermal curette 1
Scalpel 20
Grand total 21
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TABLE 99 If you use a scalpel to collect the tissue samples, which phrase would best describe the technique
you use?
Technique Count
Not applicable 1
Use a cutting motion 16
Use a scraping motion 4
Grand total 21
Transport, analysis and reporting of samples by laboratory
Transport
There are no differences in the time it takes for swab and tissue samples to reach the laboratory. The
majority of laboratories report no clear difference in the time it takes from receipt of swab and tissue
samples to processing, with just 4 out of 17 reporting slightly more urgent/quicker time to processing for
tissue samples.
TABLE 100 Is this laboratory on the same hospital site as the clinic you recruit patients from?
Laboratory location Count
No 9
Path laboratory is at hospital site: clinics are held at both hospital site and community centres around the city.
Therefore, samples arrive quicker from clinics held at the hospital
1
Yes 11
Yes and no: recruitment takes place at both hospitals 1
Grand total 22
TABLE 101 On average, how long (hours) does it take a swab to arrive at the laboratory after collection from
the patient?
Time for swab to arrive at laboratory Count
≤ 1 hour 8
2–4 hours 7
If at North Tees within 1 hour of sampling at Hartlepool; if at Hartlepool within 2 hours 1
If sent from hospital site: immediately via airtube system in pods. 2 hours if sent from a community care clinic 1
≤ 24 hours 1
Unknown 2
Grand total 20
TABLE 102 Any difference in how long it takes samples to arrive at the laboratory?
Time differences Count
Same 19
Grand total 19
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TABLE 103 Are tissue samples refrigerated overnight before transit to the laboratory?
Refrigeration of samples Count
Samples are kept overnight but not refrigerated 3
Samples are never kept overnight before transit 16
Yes samples are refrigerated overnight before transit 1
Grand total 20
TABLE 104 Any difference in overnight refrigeration of samples before transit to the laboratory?
Differences in overnight refrigeration Count
Same 18
Same: however, slight difference in frequency from rarely (swab) to never (tissue) 1
Same: however, slight difference in frequency from rarely (tissue) to never (swab) 1
Grand total 20
Differences here probably attributable to reporting rather than actual differences.
TABLE 105 On average, how long (hours) does it take for a swab to start being processed after it has arrived at
the laboratory?
Time to swab processing Count
≤ 1 hour 7
1–2 hours 2
2–4 hours 3
6–12 hours 1
Between 20 minutes and 18 hours depending on time of day 1
Depends on the time of arrival to the laboratory. Swabs are processed within 1 hour until 16.00 and then
refrigerated overnight and processed within 16 hours
1
Same day 1
2 hours unless urgent 1
Unknown: setups done throughout the day but will not be done after 23.00 until 08.00 the next day 1
Unknown 1
Grand total 19
TABLE 106 Any difference in how long it takes for a sample to start being processed after it has arrived at
the laboratory?
Differences in time to swab processing Count
Same 13
Same (but tissue sample usually with more urgency) 1
Swab 2 hours vs. tissue 1 hour 1
Swab 2–4 hours vs. tissue 2 hours 1
Tissue processing continues later into the day (20.00 vs. 16.00) and if refrigerated are processed within 12 hours
vs. 16 hours
1
Grand total 17
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TABLE 107 Details of the transport medium used for the swab?
Swab transport medium Count
Amies (Amies Plain) 4
Amies CIR or Amies Charcoal 12
Amies CIR or Amies Charcoal/none received in sterile universal 1
Amies Liquid 1
Standard swab sample tube 1
Grand total 19
TABLE 108 Details of the transport medium used for the tissue sample?
Tissue sample transport medium Count
Amies (Amies Plain) 1
Amies CIR or Amies Charcoal 1
Dry pot (no medium) 2
Dry Universal with a few drops of sterile saline 1
In sterile sample pot (no medium) 1
No transport media used, sample placed in aseptic universal container with saline 1
None/no transport medium used 2
Plain sterile universal container 6
Sterile saline 1
Stuarts CIR or Stuarts Charcoal 1
Grand total 17
Analysis
Just 3 out of 19 laboratories report performing a Gram stain on both swab and tissue samples, whereas
9 out of 19 laboratories perform these only on tissue samples; the remaining 6 never perform one,
with 1 performing them only on request (Table 109).
Reporting
A combination of systems are used to report growth, with a slight majority (8/18) using combinations of
scanty/light/moderate/heavy, 4 out of 18 using combinations of +/++/+++/++++, and 4 out of 18 not
reporting growth (Table 110).
Isolates are reported to a variety of taxonomic ranks ranging from species, genus and other. It is reported that
16 out of 18 laboratories report to the same level for swab and tissue samples, whereas 1 out of 18 reports
that tissue isolates are provided to the species level and only significant organisms are provided in such detail
for the swab. However, differences are more apparent when considering whether or not all recovered isolates
are reported to the clinician, with only 8 out of 18 laboratories reporting that the same isolates are reported
from swab and tissue samples. In contrast, the remaining 10 laboratories report that all isolated are reported
from a tissue sample, whereas reporting of those from a swab sample depends on a mix of clinical details,
clinical significance, whether or not there is heavy pure growth, and whether or not those pathogens that are
not reported as enteric or skin flora are significant. In 16 out of 19 laboratories, it was reported that standard
procedures allow identification of the same isolates; however, 3 out of 16 laboratories said that standard
procedures would not allow this, of which 1 laboratory mentioned that the tissue samples are also put into a
broth (Tables 110–117).
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TABLE 111 At what taxonomic rank are isolates from a swab typically reported?
Taxonomic rank Count
Dependant on organism: we identify ‘significant pathogens’ (e.g. S. aureus, P. aeruginosa, etc.) 1
Genus 2
Genus/species 2
Genus/species/other 1
Other 2
Species 10
Grand total 18
TABLE 110 What system does the microbiology laboratory use to report bacterial growth?
System for reporting bacterial growth Count
+/++/+++ 3
+/++/+++ or +/++/+++/++++ 1
Both 1
Light/moderate/heavy 5
Scanty/light/moderate/heavy 2
Scanty/moderate/heavy 1
Scanty, profuse, mixed, a growth 1
My laboratory does not report amount bacterial growth 3
My laboratory does not report bacterial growth/+/++/+++ 1
Grand total 18
TABLE 109 Does the laboratory perform a Gram stain on each sample before primary isolation is initiated?
Gram staining Count
Never performs a Gram stain 6
Only on request 1
Only performs a Gram stain on tissue samples 9
Performs a Gram stain on both swabs and tissue samples 2
Performs a Gram stain on both swabs (deep sites) and tissue samples 1
Grand total 19
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TABLE 112 At what taxonomic rank are isolates from a tissue sample typically reported?
Taxonomic rank Count
Genus 2
Genus/species 2
Other 3
Species 11
Grand total 18
TABLE 113 Any difference in taxonomic rank isolates reported in samples?
Differences in taxonomic rank isolates Count
Insufficient tissue details but appears to reference subset of genus, whereas swab references genus/species/other 1
Only significant organisms reported in greater detail for swab. Tissue reported to species level 1
Same 16
Grand total 18
TABLE 114 Are all isolates that are recovered from a swab reported to the clinician?
Reported/not reported (with reasons) Count
No 15
Significant pathogens reported but others are grouped into enteric flora or skin flora, etc. 1
Biomedical science decides depending on clinical significance of Istalks 2
Clinically significant isolates are determined by national HPA guidelines or if indicated by the medical
microbiologist
1
Depends on clinical details given. Common pathogens such as S. aureus 1
Depends on type of sample and clinical details 1
Heavy pure growth 1
No: may be reported as mixed growth with no obvious pathogen or interpretive comment 1
Only if clinically necessary 1
Pathogens are reported. Others may be reported as normal skin flora 1
Skin flora 1
Skin flora not reported as individual isolate 1
Target organisms as per the HPA SMI 1
We report significant pathogens. Mixed skin flora for example does not get reported to species level 1
Yes 4
Grand total 19
SMI, Standards for Microbiology Investigations.
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TABLE 115 Are all isolates that are recovered from a tissue sample reported to the clinician?
Reporting Count
No 4
No: may be reported as mixed growth with no obvious pathogen other interpretive comment. Depends on
number/amount of growth and species isolated in conjunction with clinical data provided
1
Pathogens are reported. Others may be reported as normal skin flora 1
Target organisms as per HPA SMI 1
Type of sample and clinical diagnosis 1
Yes 14
Generally we report everything, but we might add a significance comment to an isolate of CNS 1
Grand total 18
SMI, Standards for Microbiology Investigations.
TABLE 116 Any difference in whether or not all isolates recovered from each sample is reported to the clinician?
Reporting of isolates Count
All reported tissue not swab 1
All reported tissue not swab (depends on clinical details) 1
All reported tissue not swab (only if clinically significant) 5
All reported tissue not swab (only if heavy pure growth) 1
All reported tissue not swab (significant pathogens reported but others grouped into enteric or skin flora) 1
All reported tissue not swab (skin flora) 1
Same 8
Grand total 18
TABLE 117 Do standard procedures allow identification of the same isolates in both the swab and tissue sample?
Identification of same isolates across samples Count
No 3
Not necessarily: the same pathogens would be identified but not skin flora 1
Tissue samples are put up in a broth culture as well 1
Yes 16
Grand total 19
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Reporting: antimicrobial resistance for S. aureus, coagulase-negative
Staphylococcus and enterococci
None of the responding 19 laboratories reported that they tested the antimicrobial sensitivity of S. aureus to
meticillin for swab or tissue samples. A total of 12 out of 13 laboratories reported that the same agents
were tested in swab and tissue samples, with 1 laboratory reporting additional agents for the tissue sample.
None of the responding 19 laboratories reported that they tested the antimicrobial sensitivity of CNS to
meticillin for swab or tissue samples; 4 out of 19 laboratories reported that they tested no agents for swab
samples; and 1 out of 17 laboratories reported that they tested no agents for tissue samples. In 10 out of
12 laboratories, the same agents (or lack of) were reported to be tested for in swab and tissue samples;
however, the remaining two laboratories do not test agents for swab samples but do for tissue samples.
When enterococci is isolated, antimicrobial sensitivity to vancomycin is reported to be tested for in
10 out of 19 laboratories for swab samples and 13 out of 17 laboratories for tissue samples. In 9 out of
12 laboratories, the same agents were reported to be tested for swab and tissue samples; however, the
remaining 3 laboratories reported that no agents are tested for swab samples, whereas numerous agents
are tested for in tissue samples (Tables 118–126).
TABLE 118 When testing antimicrobial sensitivity, please specify which agents you test against S. aureus from
a swab?
Agents Count
Flucloxacillin, erythromycin, clindamycin, trimethoprim, doxycycline, clarithromycin, fusidin, cefoxitin 1
Benzylpenicillin, chloramphenicol, ciprofloxacin, clindamycin, daptomycin, erythromycin, fuscidic acid,
nitrofurantoin, oxacillin, rifampicin, gentamicin, linezolid, mupirocin, teicoplanin, tetracycline, tgercycline,
vancomycin, trimethoprim
2
Beta-lactams, macrolides 1
Cefoxitin as marker for flucloxacillin, erythromycin, clindamycin, doxycycline, co-trimoxazole, rifampicin,
vancomycin, linezolid, mupirocin
1
Cefoxitin, oxacillin, vancomycin, erythromycin, fusidic acid, tetracycline, mupirocin 1
Chloramphenicol, ciprofloxacin, clindamycin, daptomycin, erythromycin, flucloxacillin, fusidic acid, gent,
mupirocin, lizenzolid, pencillin, rifampicin, teicoplanin, tetracycline, tigecycline, trimethoprim, vancomycion
(VITEK card)
1
Ciprofloxacin, tetracycline, gentamicin, erythromycin, flucloxacillin, fusidic acid 1
Clindamycin, gentamicin, mupirocin, oxacillin, tetracycline 1
E, doxycycline, W5, CN, FD, FOX, neomycin, C10 1
Flucloxacillin, cefoxatin, erythromycin, pencillin, fusidic acid, chloramphenicol, ciprofloxacin, erythromycin,
clindamycin, daptomycin, gentomycin, linezolid, muprirocin, teicoplanin, tetracycline, tigecycline, vancomycin
1
Flucloxacillin, erythromycin, fusidic acid, rifampicin, gentamicin, tetracycline, clindamycin, cefradine,
chloramphenicol, daptomycin, linezolid, penicillin, tigecycline, vancomycion, teicoplanin, trimethoprim
1
Pencillin, erythromycin, clindamycin, ciprofloxacin, co-amoxiclav, fusidic acid, gentamycin, rifampicin, mupricollin,
linezolid, tetracycline
1
Penicillin, cefoxitin, erythromycin, clindamycin, tetracycline, vancomycin, ciprofloxacin, neomycin, fusidic acid,
mupirocin, rifampacin, gentamycin
1
Penicillin, erythromycin, clindamycin, flucloxacillin, gentamicin, vancomycin, fusidic acid, rifampicin, ciprofloxacin,
linezolid, daptomycin
1
Penicillin, erythromycin, clindamycin, tetracycline, rifampicin, cefotaxine, vancomycin, mupirocin 1
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TABLE 119 When testing antimicrobial sensitivity, please specify which agents you test against S. aureus from a
tissue sample?
Agents Count
Beta-lactams, macrolides 1
Cefoxitin as marker for flucloxacillin, erythromycin, clindamycin, doxycycline, co-trimoxazole, rifampicin,
vancomycin, linezolid, mupirocin
1
Cefoxitin, oxacillin, vancomycin, erythromycin, fusidic acid, tetracycline, mupirocin 1
Chloramphenicol, ciprofloxacin, clindamycin, daptomycin, erythromycin, flucloxacillin, fusidic acid, gentamicin,
mupirocin, lizenzolid, penicillin, rifampicin, teicoplanin, tetracycline, tigecycline, trimethoprim, vancomycin
(VITEK card)
1
Ciprofloxacin, tetracycline, gentamicin, erythromycin, flucloxacillin, fusidic acid 1
Clindamycin, gentamicin, mupirocin, oxacillin, tetracycline 1
E, doxycycline, W5, CN, FD, FOX, neomycin, C10 1
Flucloxacillin, erythromycin, clindamycin, trimethoprim, doxycycline, clarithromycin, fusidin, rifampicin, cefoxitin,
gentamicin, vancomycin, teicoplanin, linezolid, daptomycin
1
Flucloxacillin, cefoxatin, erythromycin, pencillin, fusidic acid, chloramphenicol, ciprofloxacin, erythromycin,
clindamycin, daptomycin, gentomycin, linezolid, muprirocin, teicoplanin, tetracycline, tigecycline, vancomycin
1
Flucloxacillin, erythromycin, fusidic acid, rifampicin, gentamicin, tetracycline, clindamycin, cefradine,
chloramphenicol, daptomycin, linezolid, penicillin, tigecycline, vancomycion, teicoplanin, trimethoprim
1
Penicillin, erythromycin, clindamycin, ciprofloxacin, co-amoxiclav, fusidic acid, gentamycin, rifampicin, mupricollin,
linezolid, tetracycline
1
Penicillin, cefoxitin, erythromycin, clindamycin, tetracycline, vancomycin, ciprofloxacin, neomycin, fusidic acid,
mupirocin, rifampacin, gentamycin
1
Penicillin, erythromycin, clindamycin, tetracycline, rifampicin, cefotaxine, vancomycin, mupirocin 1
Penicillin, erythromycin, flucloxacillin, tetracycline, rifampicin, trimethoprim, linezolid, vancomycin, mupirocin,
gentamicin, ciprofloxacin, fusidic acid
1
Penicillin, erythromycin, clindamycin, flucloxacillin, gentamicin, vancomycin, fusidic acid, rifampicin, ciprofloxacin,
linezolid, daptomycin
1
Sensitivities on these isolates are performed on the Biomeriuex Vitek2 system with a P620 card which has
22 antibiotics
1
Grand total 16
FOX, cefoxitin.
No meticillin listed: MRSA.
TABLE 118 When testing antimicrobial sensitivity, please specify which agents you test against S. aureus from
a swab? (continued )
Agents Count
Penicillin, erythromycin, flucloxacillin, tetracycline, rifampicin, trimethoprim, linezolid, vancomycin, mupirocin,
gentamicin, ciprofloxacin, fusidic acid
1
Sensitivities on these isolates are performed on Biomeriuex Vitek2 system with a P620 card which has
22 antibiotics
1
Grand total 18
FOX, cefoxitin.
No meticillin listed: MRSA.
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TABLE 120 Derived: any difference in agents tested against for S. aureus?
Difference in agents tested against for S. aureus Count
Same 12
Tissue tests additional (rifampicin, gentamicin, vancomycin, teicoplanin, linezolid, daptomycin) 1
Grand total 13
TABLE 121 When testing antimicrobial sensitivity, please specify which agents you test against CNS from a swab?
Agents Count
As above 1
Benzylpenicillin, chloramphenicol, ciprofloxacin, clindamycin, daptomycin, erythromycin, fuscidic acid,
nitrofurantoin, oxacillin, rifampicin, gentamicin, linezolid, mupirocin, teicoplanin, tetracycline, tigecycline,
vancomycin, trimethoprim
2
Beta-lactams, macrolides 1
Cefoxitin, oxacillin, vancomycin, erythromycin, fusidic acid, tetracycline, mupirocin 1
Chloramphenicol, ciprofloxacin, clindamycin, daptomycin, erythromycin, flucloxacillin, fusidic acid, gentamicin,
mupirocin, lizenzolid, penicillin, rifampicin, teicoplanin, tetracycline, tigecycline, trimethoprim, vancomycin
(VITEK card)
1
Clindamycin, gentamicin, mupirocin, oxacillin, tetracycline 1
E, doxycycline, W5, CN, FD, FOX, neomycin, C11 1
Flucloxacillin, erythromycin, fusidic acid, rifampicin, gentamicin, tetracycline, clindamycin, cefradine,
chloramphenicol, daptomycin, linezolid, penicillin, tigecycline, vancomycion, teicoplanin, trimethoprim
1
N/A 1
Nil 1
None 1
Pencillin, erythromycin, clindamycin, ciprofloxacin, co-amoxiclav, fusidic acid, gentamycin, rifampicin, mupricollin,
linezolid, tetracycline
1
Penicillin, cefoxitin, erythromycin, clindamycin, tetracycline, vancomycin, ciprofloxacin, neomycin, fusidic acid,
mupirocin, rifampacin, gentamycin
1
Penicillin, erythromycin, clindamycin, tetracycline, rifampicin, cefotaxine, vancomycin, mupirocin 1
Penicillin, erythromycin, flucloxacillin, tetracycline, rifampicin, trimethoprim, linezolid, vancomycin, mupirocin,
gentamicin, ciprofloxacin, fusidic acid
1
Probably none 1
Sensitivities on these isolates are performed on the Biomeriuex Vitek2 system with P620 card which has
22 antibiotics
1
Ticked 1
Grand total 19
FOX, cefoxitin; N/A, not applicable.
No meticillin listed.
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TABLE 122 When testing antimicrobial sensitivity, please specify which agents you test against CNS from a
tissue sample?
Agents Count
As above 1
As for S. aureus 1
Beta-lactams, macrolides 1
Cefoxitin, oxacillin, vancomycin, erythromycin, fusidic acid, tetracycline, mupirocin 1
Chloramphenicol, ciprofloxacin, clindamycin, dapto, erythromycin, flucloxacillin, fusidic acid, gentamycin,
mupirocin, lizenzolid, penicillin, rifampicin, teicoplanin, tetracycline, tigecycline, trimethoprim, vancomycion
(VITEK card)
1
Clindamycin, gentamicin, oxacillin, tetracycline 1
E, doxycycline, W5, CN, FD, FOX, neomycin, C11 1
Flucloxacillin, erythromycin, clindamycin, trimethoprim, doxycycline, clarithromycin, fusidin, rifampicin, cefoxitin,
gentamicin, vancomycin, teicoplanin, linezolid, daptomycin
1
Flucloxacillin, erythromycin, fusidic acid, rifampicin, gentamicin, tetracycline, clindamycin, cefradine,
chloramphenicol, daptomycin, linezolid, penicillin, tigecycline, vancomycion, teicoplanin, trimethoprim
1
N/A 1
Pencillin, erythromycin, clindamycin, ciprofloxacin, co-amoxiclav, fusidic acid, gentamycin, rifampicin, mupricollin,
linezolid, tetracycline
1
Penicillin, cefoxitin, erythromycin, clindamycin, tetracycline, vancomycin, ciprofloxacin, neomycin, fusidic acid,
mupirocin, rifampacin, gentamycin
1
Penicillin, erythromycin, clindamycin, flucloxacillin, gentamicin, vancomycin, fusidic acid, rifampicin, ciprofloxacin,
linezolid, daptomycin
1
Penicillin, erythromycin, clindamycin, tetracycline, rifampicin, cefotaxine, vancomycin, mupirocin 1
Penicillin, erythromycin, flucloxacillin, tetracycline, rifampicin, trimethoprim, linezolid, vancomycin, mupirocin,
gentamicin, ciprofloxacin, fusidic acid
1
Sensitivities on these isolates are performed on the Biomeriuex Vitek2 system with P620 card which has
22 antibiotics
1
Ticked 1
Grand total 17
FOX, cefoxitin.
N/A, not applicable.
No meticillin listed.
TABLE 123 Derived: any difference in agents tested against for CNS?
Difference in agents tested against Count
Same 9
Same (N/A) 1
Tissue tests numerous, swab tests none 1
Tissue tests numerous, swab tests none 1
Grand total 12
N/A, not applicable.
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TABLE 124 When testing antimicrobial sensitivity, please specify which agents you test against enterococci from a swab?
Agents Count
Amoxicillin, co-amoxicillin, imipenem, linezolid, vancomycin, teicoplanin, tetracycline 1
Amoxicillin, vancomycin, tetracycline 1
Ampicillin, linezolid, vancomycin, gentamicin, teicoplanin 1
Ampicillin, clindamycin, erythromycin, high-level gentomycin, linezolid, penicillin, quinupristin/dalfopristin,
teicoplanin, tetracycline, tigecycline, vancomycin
1
Ampicillin, vancomycin 1
Chloramphenicol, ciprofloxacin, clindamycin, daptomycin, erythromycin, linezolid, teicoplanin, tetracycline,
trimethoprim, vancomycin
2
Glycopeptides, beta-lactams 1
N/A 1
None 2
P, AML, TE, TEC, vancomycin, linezolid 1
Pencillin, ampicillin, vancomycin, teicoplanin, linezolid, dalfopristin/quinupristin, high-level gentamycin 1
Pencillin, erythromycin, clindamycin, ciprofloxacin, co-amoxiclav, fusidic acid, gentamycin, rifampicin, mupricollin,
linezolid, tetracycline
1
Probably none 1
Sensitivities on these isolates are performed on the Biomeriuex Vitek2 system with P607 card which has
20 antibiotics
1
Ticked 1
Vancomycin, amoxicillin 1
Vancomycin, amoxicillin, gentamycin 1
Grand total 19
N/A, not applicable.
Vancomycin tested for 10/19 responding centres.
TABLE 125 When testing antimicrobial sensitivity, please specify which agents you test against enterococci from a
tissue sample?
Agents Count
Amoxicillin, vancomycin, teicoplanin, gentamicin (high level), linezolid, syndercid 1
Amoxicillin, co-amoxicillin, imipenem, linezolid, vancomycin, teicoplanin, tetracycline 1
Amoxicillin, vancomycin, linezolid 1
Amoxicillin, vancomycin, tetracycline 1
Ampicillin, linezolid, vancomycin, gentamicin, teicoplanin 1
Ampicillin, clindamycin, erythromycin, high-level gentomycin, linezolid, penicillin, quinupristin/dalfopristin,
teicoplanin, tetracycline, tigecycline, vancomycin
1
Ampicillin, vancomycin 1
Ampicillin, vancomycin, linezolid, co-trimoxazole 1
Glycopeptides, beta-lactams 1
Pencillin, amoxicillin, teicoplanin, tetracycline, vancomycin, linezolid 1
Pencillin, ampicillin, vancomycin, teicoplanin, linezolid, dalfopristin/quinupristin, high-level gentomycin 1
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TABLE 125 When testing antimicrobial sensitivity, please specify which agents you test against enterococci from a
tissue sample? (continued )
Agents Count
Pencillin, erythromycin, clindamycin, ciprofloxacin, co-amoxiclav, fusidic acid, gentamycin, rifampicin, mupricollin,
linezolid, tetracycline
1
Sensitivities on these isolates are performed on the Biomeriuex Vitek2 system (BioMérieux, Inc., Durham,
NC, USA) with P607 card which has 20 antibiotics
1
Ticked 1
Vancomycin, amoxicillin 1
Vancomycin, amoxicillin, gentamycin 1
When reported ampicillin, gentamicin, teicoplanin, vancomycin, linezolid 1
Grand total 17
Vancomycin tested for 13/17 responding centres.
Local antibiotic protocols
Questions asked:
l Local antibiotic protocol for infected DFUs, including specific antibiotics, dose, inclusions and
contradictions, in:
¢ outpatients
¢ inpatients.
l Local antibiotic protocol for patients with infected DFUs and osteomyelitis if different from the above.
l Any other antibiotic protocols you have.
Responses to these questions were provided via free text, with a wide range of in-depth detail provided;
for example, at least one site has attached their full protocol/documentation. As such quantitative analysis
is not practical here, paper copies of each site’s responses are available for qualitative review if necessary.
TABLE 126 Derived: any difference in agents tested against for entercocci?
Difference in agents tested against Count
Same 9
Tissue tests numerous, swab tests none 1
Tissue tests numerous, swab tests none 1
Tissue tests numerous, swab tests none (N/A) 1
Grand total 12
N/A, not applicable.
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Appendix 5 Case report forms
O riginal forms, questionnaires and trial documentation are included as separate files:
1. screening log
2. eligibility checklist
3. baseline assessment
4. sample collection
5. additional sample collection
6. registration
7. swab sample microbiology
8. swab sample microbiology continuation
9. curettage sample microbiology
10. curettage sample microbiology continuation
11. clinical review
12. RUSAE-related medical history
13. RUSAE
14. withdrawal
15. long-term follow-up
16. protocol violation.
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